Biotech RadarJobs updated

Raises and deals from press releases

314 raises and 106 partnership or acquisition deals at 326 companies, from releases on the companies’ own websites. Every row links to its release and quotes it. This list is partial. Below them, 332 more raises come from SEC Form D filings.

Raises (314)

CompanyWhat was announcedDateSource
ZAP SurgicalUndisclosed round · $36M · announced Oct 19, 2026
Source quote
  • Oct 19, 2026 · Company release ↗
    “SAN CARLOS, Calif. , October 19, 2026 – ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced it has secured $36 million in financing led by Catalio Capital Management”
Oct 19, 2026Company release ↗
Dogwood TherapeuticsPrivate placement · $5M · announced Oct 19, 2026
Source quote
  • Oct 19, 2026 · Company release ↗
    “Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.”
Oct 19, 2026Company release ↗
SensydiaUndisclosed round · more than $6M · announced Oct 13, 2026
Source quote
  • Oct 13, 2026 · Company release ↗
    “Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion of Sensydia’s ongoing ACOUSTIC‑1 study for the Cardiac Performance System (CPS™) and preparation for commercial launch LOS ANGELES, October 13, 2026 /PRNewswire/ -- Sensydia,”
Oct 13, 2026Company release ↗
Multiply LabsSeries B · $75M · announced Oct 6, 2026
Source quote
  • Oct 6, 2026 · Company release ↗
    “SAN FRANCISCO, OCTOBER 6, 2026 — Multiply Labs, the physical AI company automating some of the most complex manufacturing processes in medicine, today announced a $75 million Series B , bringing its total capital raised to over $100 million since its founding in 2016.”
Oct 6, 2026Company release ↗
Consano Bio, Inc.Undisclosed round · more than $15M · announced Oct 5, 2026
Source quote
  • Oct 5, 2026 · Company release ↗
    “Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)”
Oct 5, 2026Company release ↗
KallyopeUndisclosed round · $94M · announced Oct 1, 2026
Source quote
  • Oct 1, 2026 · Company release ↗
    “TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine”
Oct 1, 2026Company release ↗
Brightline Interactive LLCStrategic · amount not disclosed · announced Oct 1, 2026
Source quote
  • Oct 1, 2026 · Company release ↗
    “Brightline Interactive Closes Strategic Investment Led by Drone Executive Allan Evans”
Oct 1, 2026Company release ↗
BiotiaUndisclosed round · $9M · announced Oct 1, 2026
Source quote
  • Oct 1, 2026 · Company release ↗
    “New York, NY – October 1, 2026 — Biotia , the clinical metagenomics company whose BIOTIA-ID Urine Test identifies the cause of recurrent and complicated urinary tract infections (UTIs) with 97% sensitivity and 99% specificity, today announced an oversubscribed $9 million financing”
Oct 1, 2026Company release ↗
Astrocyte Pharmaceuticals Inc.Series B · $9.5M · announced Sep 30, 2026
Source quote
  • Sep 30, 2026 · Company release ↗
    “– Astrocyte Pharmaceuticals Inc. , a pioneering clinical-stage biotechnology company developing first-in-class cerebroprotective therapies for concussion, traumatic brain injury (TBI) and stroke, today announced the completion of a $9.5 million Series B financing round”
Sep 30, 2026Company release ↗
Aqua MedicalSeries B · amount not disclosed · announced Sep 24, 2026
Source quote
  • Sep 24, 2026 · Company release ↗
    “PLEASANTON, Calif., [September 24, 2026] — Aqua Medical, Inc., a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration for the treatment of Type 2 diabetes, today announced the closing of a Series B financing led by Nashville”
Sep 24, 2026Company release ↗
Brightline Interactive LLCStrategic · amount not disclosed · announced Sep 24, 2026
Source quote
  • Sep 24, 2026 · Company release ↗
    “Brightline Interactive Regains Compliance with Nasdaq Minimum Bid Price Requirement Brightline Interactive to Attend the 2026 Maxim Growth Summit Brightline Interactive Closes Strategic Investment Led by Drone Executive Allan Evans”
  • Oct 1, 2026 · Company release ↗
    “Brightline Interactive Regains Compliance with Nasdaq Minimum Bid Price Requirement Brightline Interactive to Attend the 2026 Maxim Growth Summit Brightline Interactive Secures Strategic Investment Led by Drone Executive Allan Evans”
Sep 24, 2026Company release ↗
Enveda BiosciencesSeries E · $311M · announced Sep 23, 2026
Source quote
  • Sep 23, 2026 · Company release ↗
    “BOULDER, Colo. — ( BUSINESS WIRE ) — September 23, 2026: Enveda, a clinical-stage biotechnology company that uses AI to discover medicines from life’s chemistry, today announced the close of a $311 million Series E financing led by Catalio Capital Management”
Sep 23, 2026Company release ↗
BioSapienPre-Series A · more than $8M · announced Sep 22, 2026
Source quote
  • Sep 22, 2026 · Company release ↗
    “UAE’s BioSapien Extends Pre-Series A to Over USD 8M Backed by Globivest”
Sep 22, 2026Company release ↗
Teal Health, Inc.Series A · $22M · announced Sep 22, 2026 SEC Form D Equity · Form D reports $21.26M sold · first sale Aug 5, 2026 · SEC Form D ↗
Source quote
  • Sep 22, 2026 · Company release ↗
    “SAN FRANCISCO - September 22, 2026 – Teal Health , creators of the Teal Wand TM , the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, today announced $22 million in Series A”
Sep 22, 2026Company release ↗
Primrose BioGrowth · amount not disclosed · announced Sep 22, 2026
Source quote
  • Sep 22, 2026 · Company release ↗
    “Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners”
Sep 22, 2026Company release ↗
HighLifeUndisclosed round · $80M (converted from EUR) · announced Sep 22, 2026
Source quote
  • Sep 22, 2026 · Company release ↗
    “Paris, France, September 22 – HighLife SAS, a MedTech company focused on transcatheter solutions for structural heart disease, today announced the successful completion of a $90+ Million (€80 Million) financing round”
Sep 22, 2026Company release ↗
Axio BioPharmaUndisclosed round · $2.4M · announced Sep 21, 2026
Source quote
  • Sep 21, 2026 · Company release ↗
    “Axio BioPharma Raises $2.4 Million to Connect Manufacturing Data Across Companies”
Sep 21, 2026Company release ↗
Sling TherapeuticsSeries C · $123M · announced Sep 16, 2026
Source quote
  • Sep 16, 2026 · Company release ↗
    “– Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the close of a $123 million Series C financing”
Sep 16, 2026Company release ↗
Circle PharmaSeries E · $92.5M · announced Sep 16, 2026
Source quote
  • Sep 16, 2026 · Company release ↗
    “Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development”
Sep 16, 2026Company release ↗
RegCellUndisclosed round · $66M · announced Sep 15, 2026
Source quote
  • Sep 15, 2026 · Company release ↗
    “RegCell Secures $66 Million of Additional Funding to Bring Nobel-Winning Immune Tolerance Science to the Clinic”
  • Sep 17, 2026 · Company release ↗
    “Regcell Inc. has raised $66 million in new financing and Japanese government support to move its Nobel-linked regulatory T-cell (Treg) platform toward the clinic”
Sep 15, 2026Company release ↗
GlucotrackUndisclosed round · $11.5M · announced Sep 11, 2026
Source quote
  • Sep 11, 2026 · Company release ↗
    “(NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over”
Sep 11, 2026Company release ↗
Encoded TherapeuticsSeries F · $275M · announced Sep 9, 2026
Source quote
  • Sep 9, 2026 · Company release ↗
    “Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline – Co led by GV and another healthcare fund”
Sep 9, 2026Company release ↗
Moonwalk BiosciencesSeries B · $70M · announced Sep 8, 2026 SEC Form D Equity · Form D reports $60M sold · first sale Aug 26, 2026 · SEC Form D ↗
Source quote
  • Sep 8, 2026 · Company release ↗
    “)- Moonwalk Biosciences , a biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing”
Sep 8, 2026Company release ↗
BrainChild BioSeries A · $116M · announced Sep 8, 2026
Source quote
Sep 8, 2026Company release ↗
CytoDynUndisclosed round · $16.5M · announced Sep 1, 2026
Source quote
  • Sep 1, 2026 · Company release ↗
    “CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab :: CytoDyn Inc. (CYDY)”
Sep 1, 2026Company release ↗
EIT PharmaSeries A · $35M · announced Aug 31, 2026
Source quote
  • Aug 31, 2026 · Company release ↗
    “(“EIT Pharma” or the “Company”), a biotechnology company focused on developing therapies for infectious diseases, today announced the successful close of an oversubscribed $35 million Series A financing round.”
Aug 31, 2026Company release ↗
Airway TherapeuticsSeries E · $24M · announced Aug 25, 2026 SEC Form D Equity · Form D reports $43.5M sold · first sale Aug 10, 2026 · SEC Form D ↗
Source quote
  • Aug 25, 2026 · Company release ↗
    “The E-round consists of $26 million previously raised through a SAFE financing and $24 million through the Company’s Series E-2 round.”
Aug 25, 2026Company release ↗
AbcuroSeries D · $66M · announced Aug 18, 2026
Source quote
  • Aug 18, 2026 · Company release ↗
    “– Abcuro … Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participatio”
Aug 18, 2026Company release ↗
Leal TherapeuticsSeries A · $30M · announced Aug 17, 2026
Source quote
  • Aug 17, 2026 · Company release ↗
    “Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia”
Aug 17, 2026Company release ↗
Trinity BiotechUndisclosed round · $7M · announced Aug 14, 2026
Source quote
  • Aug 14, 2026 · Company release ↗
    “Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement”
Aug 14, 2026Company release ↗
InduPro, Inc.Series B · $77M · announced Aug 12, 2026
Source quote
  • Aug 12, 2026 · Company release ↗
    “— InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B”
Aug 12, 2026Company release ↗
AmplificaSeries B · $26M · announced Aug 12, 2026
Source quote
  • Aug 12, 2026 · Company release ↗
    “Amplifica Completes $26 Million Series B Financing to Advance Injectable Pipeline for Hair Growth”
Aug 12, 2026Company release ↗
Epicrispr BiotechnologiesSeries C · $90M · announced Aug 11, 2026
Source quote
  • Aug 11, 2026 · Company release ↗
    “– Epicrispr Biotechnologies , a clinical-stage biotechnology company pioneering programmable epigenetic medicines, today announced the closing of a $90 million oversubscribed Series C financing co-led by Octagon Capital and Janus Henderson Investors”
Aug 11, 2026Company release ↗
Vedanta Biosciences, Inc.Undisclosed round · $60M · announced Aug 6, 2026
Source quote
  • Aug 6, 2026 · Company release ↗
    “– Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding”
Aug 6, 2026Company release ↗
GlucotrackUndisclosed round · about $5.5M · announced Aug 5, 2026
Source quote
  • Aug 5, 2026 · Company release ↗
    “(NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors”
Aug 5, 2026Company release ↗
Grace TherapeuticsPrivate placement · about $10M · announced Aug 4, 2026
Source quote
  • Aug 4, 2026 · Company release ↗
    “The financing is expected to result in aggregate gross proceeds to the Company of approximately $10 million, before deducting placement agent fees and other offering expenses”
Aug 4, 2026Company release ↗
Crystalys TherapeuticsSeries B · $130M · announced Jul 27, 2026
Source quote
  • Jul 27, 2026 · Company release ↗
    “Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing”
Jul 27, 2026Company release ↗
MagnendoSeries A · $18M · announced Jul 24, 2026 SEC Form D Equity · Form D reports $18M sold · first sale Jul 17, 2026 · SEC Form D ↗
Source quote
  • Jul 24, 2026 · Company release ↗
    “NEWTON, Mass., July 24, 2026 ( GLOBE NEWSWIRE ) — Magnendo Corp., an MIT spinout developing magnetic robotic navigation technology for neuro-endovascular intervention, today announced the closing of an $18 million Series A financing led by Penumbra”
Jul 24, 2026Company release ↗
Estrigenix Therapeutics, Inc.Seed · $2M · announced Jul 21, 2026
Source quote
  • Jul 21, 2026 · Company release ↗
    “MILWAUKEE (July 21, 2026) — Estrigenix Therapeutics today announced the first closing of its $2M Series Seed financing, led by Talents Fund I.”
Jul 21, 2026Company release ↗
ROSE DiagnosticsUndisclosed round · $2.7M · announced Jul 17, 2026 SEC Form D Equity · Form D reports $2.21M sold · first sale Jul 10, 2026 · SEC Form D ↗
Source quote
  • Jul 17, 2026 · Company release ↗
    “ROSE Diagnostics Inc., a pioneer in rapid, point-of-care cancer diagnostics, today announced it has raised $2.7 million in its latest round of financing”
Jul 17, 2026Company release ↗
Cagent VascularSeries D · $41M · announced Jul 15, 2026
Source quote
  • Jul 15, 2026 · Company release ↗
    “)--Cagent Vascular, Inc., a leader in endovascular technologies, today announced two milestones: the successful completion of first human-use cases with the SONIC Intravascular Lithotripsy (IVL) System and the closing of a $41 million Series D financing round”
Jul 15, 2026Company release ↗
Allotera Therapeutics (Formerly Wugen)Undisclosed round · $35M · announced Jul 8, 2026
Source quote
  • Jul 8, 2026 · Company release ↗
    “Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers”
Jul 8, 2026Company release ↗
Fore BiotherapeuticsSeries D · $67.4M · announced Jul 7, 2026
Source quote
  • Jul 7, 2026 · Company release ↗
    “FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements”
Jul 7, 2026Company release ↗
PluristyxSeries A · amount not disclosed · announced Jul 6, 2026 SEC Form D Equity · Form D reports $9.76M sold · first sale Jul 1, 2026 · SEC Form D ↗
Source quote
  • Jul 6, 2026 · Company release ↗
    “SEATTLE, WA – July 6, 2026 – Pluristyx Inc., the leader in advanced induced pluripotent stem cell (iPSC) technologies, announces today the Initial Close of their Series A financing led by a global Fortune 500 company along with participation from existing investors”
Jul 6, 2026Company release ↗
Celea TherapeuticsUndisclosed round · $180M · announced Jul 2, 2026
Source quote
  • Jul 2, 2026 · Company release ↗
    “Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)”
Jul 2, 2026Company release ↗
Oryzon GenomicsUndisclosed round · $12M (converted from EUR) · announced Jul 1, 2026
Source quote
  • Jul 1, 2026 · Company release ↗
    “(ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced the successful completion of a €12 million gross capital increase through the issuance of 4,444,445 new ordinary shares, at a subscription price of €2.70 per share.”
Jul 1, 2026Company release ↗
Flare TherapeuticsSeries C · $85M · announced Jun 30, 2026
Source quote
  • Jun 30, 2026 · Company release ↗
    “Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer”
Jun 30, 2026Company release ↗
Oblenio BioSeries B · $62M · announced Jun 25, 2026
Source quote
  • Jun 25, 2026 · Company release ↗
    “Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development -- Round led by Pfizer Ventures”
Jun 25, 2026Company release ↗
Lycia TherapeuticsSeries D · $75M · announced Jun 25, 2026 SEC Form D Equity · Form D reports $75M sold · first sale Jun 10, 2026 · SEC Form D ↗
Source quote
  • Jun 25, 2026 · Company release ↗
    “– Lycia … company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the completion of an oversubscribed $75 million Series D”
Jun 25, 2026Company release ↗
Nura BioSeries B · $73.8M · announced Jun 22, 2026
Source quote
  • Jun 22, 2026 · Company release ↗
    “(Nura Bio), a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, today announced the completion of a $73.8M Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs”
Jun 22, 2026Company release ↗
Triveni BioSeries C · $65M · announced Jun 17, 2026
Source quote
  • Jun 17, 2026 · Company release ↗
    “– Triveni … Bio Inc., a clinical-stage biotechnology company advancing novel antibody treatments for immunological and inflammatory (I&I) disorders, today announced a $65 million Series C financing round to support pipeline expansion and continued corporate growth.”
Jun 17, 2026Company release ↗
SonoTheraSeries B · $125M · announced Jun 10, 2026 SEC Form D Equity · Form D reports $125.45M sold · first sale Jun 8, 2026 · SEC Form D ↗
Source quote
  • Jun 10, 2026 · Company release ↗
    “SonoThera , a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B”
Jun 10, 2026Company release ↗
CeQurSeries E · $100M · announced Jun 9, 2026
Source quote
  • Jun 9, 2026 · Company release ↗
    “CeQur ® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity ™ Series E Financing Reflects Sustained Investor Confidence in CeQur’s Commercial Trajectory”
Jun 9, 2026Company release ↗
Rejuvenate Bio Inc.Undisclosed round · $6M · announced Jun 8, 2026
Source quote
  • Jun 8, 2026 · Company release ↗
    “Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health”
Jun 8, 2026Company release ↗
CereVascSeries C · $85M · announced Jun 4, 2026
Source quote
  • Jun 4, 2026 · Company release ↗
    “Series C investors BOSTON, June 4, 2026 — CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing of an $85 million Series C financing”
Jun 4, 2026Company release ↗
MammogenSeries A · up to $30M · announced Jun 3, 2026
Source quote
  • Jun 3, 2026 · Company release ↗
    “Mammogen has announced the successful completion of a Series A financing round of up to $30 million, marking a significant milestone in the company's mission to transform breast cancer detection through innovative blood-based diagnostics”
Jun 3, 2026Company release ↗
ClearNote HealthSeries D · $52M · announced May 27, 2026
Source quote
  • May 27, 2026 · Company release ↗
    “— ClearNote Health , a company dedicated to improving early detection for some of the deadliest cancers, today announced the close of $52 million in Series D financing”
May 27, 2026Company release ↗
ProEncia BiotechnologyPre-seed · amount not disclosed · announced May 19, 2026
Source quote
  • May 19, 2026 · Company release ↗
    “MINNEAPOLIS--( BUSINESS WIRE )--Twin Cities-based ProEncia Biotechnology, a biopharma startup, today announced the company has closed significant pre-seed funding to advance its next-generation periodontal disease treatment”
May 19, 2026Company release ↗
Isomorphic LabsSeries B · $2.1B · announced May 12, 2026
Source quote
  • May 12, 2026 · Company release ↗
    “Isomorphic Labs announces it has raised $2.1 Billion in Series B funding”
May 12, 2026Company release ↗
LTZ TherapeuticsUndisclosed round · $38M · announced May 6, 2026
Source quote
  • May 6, 2026 · Company release ↗
    “– LTZ Therapeutics , a clinical-stage, immunotherapy-focused biotechnology company, today announced the completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager (U-MCE TM )-based immunotherapy pipeline”
May 6, 2026Company release ↗
PumpkinseedSeries A · $20M · announced May 5, 2026
Source quote
  • May 5, 2026 · Company release ↗
    “PALO ALTO, CA — May 5, 2026 — Pumpkinseed , The Biology Mining Company, today announced a $20 million Series A funding round to scale its protein sequencing platform”
May 5, 2026Company release ↗
Sapho BioSeed · more than $5M · announced Apr 20, 2026
Source quote
  • Apr 20, 2026 · Company release ↗
    “Sapho Bio, a biotechnology company developing a rapid microbiology release platform for precision medicine, announces over $5M in secured funding in an oversubscribed seed round”
Apr 20, 2026Company release ↗
Alloy TherapeuticsSeries E · $40M · announced Apr 15, 2026 SEC Form D Equity · Form D reports $30.02M sold · first sale Mar 31, 2026 · SEC Form D ↗
Source quote
  • Apr 15, 2026 · Company release ↗
    “Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure”
Apr 15, 2026Company release ↗
Terremoto BiosciencesSeries C · $108M · announced Apr 15, 2026 SEC Form D Equity · Form D reports $40.73M sold · first sale Apr 10, 2026 · SEC Form D ↗
Source quote
  • Apr 15, 2026 · Company release ↗
    “– Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round”
Apr 15, 2026Company release ↗
NeomorphSeries B · $100M · announced Apr 13, 2026
Source quote
  • Apr 13, 2026 · Company release ↗
    “Neomorph Announces Closing of $100 Million Series B Financing”
Apr 13, 2026Company release ↗
Bone Health TechnologiesUndisclosed round · $8M · announced Apr 9, 2026
Source quote
  • Apr 9, 2026 · Company release ↗
    “Osteoboost Secures $8M to Expand Access to its FDA-Cleared Prescription Wearable for Bone Health”
Apr 9, 2026Company release ↗
Incyclix BioSeries B · $5M · announced Apr 8, 2026
Source quote
  • Apr 8, 2026 · Company release ↗
    “Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX- 315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors Additional $5 million from Hatteras Venture Partners supports advancement of Phase 1/2 clinical”
Apr 8, 2026Company release ↗
Sidewinder TherapeuticsSeries B · $137M · announced Apr 8, 2026
Source quote
  • Apr 8, 2026 · Company release ↗
    “– Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer, today announced the closing of an oversubscribed $137 million Series B financing”
Apr 8, 2026Company release ↗
Route 92 MedicalGrowth · $50M · announced Apr 7, 2026
Source quote
  • Apr 7, 2026 · Company release ↗
    “growth financing round to support acceleration of commercial growth WEST JORDAN, Utah— Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced a $50 million growth financing”
Apr 7, 2026Company release ↗
Beacon BiosignalsSeries B · more than $97M · announced Apr 6, 2026
Source quote
  • Apr 6, 2026 · Company release ↗
    “Beacon Biosignals Upsizes Series B Financing to Over $97 Million”
Apr 6, 2026Company release ↗
Terrestrial BioSeries C · $50M · announced Mar 26, 2026 SEC Form D Equity · Form D reports $57.3M sold · first sale Mar 4, 2026 · SEC Form D ↗
Source quote
  • Mar 26, 2026 · Company release ↗
    “Announces $50M Series C and Rebrands from Vaxess Technologies BIOTECH COMPANY DEVELOPING MICROARRAY PATCH PLATFORM FOR THERAPEUTICS WILL ESTABLISH NEW HEADQUARTERS AND MANUFACTURING FACILITY IN BOSTON BOSTON, March 26, 2026 — Terrestrial Bio, Inc., formerly Vaxess Technologies, Inc., today”
Mar 26, 2026Company release ↗
RyboDynSeed · $10M · announced Mar 24, 2026
Source quote
  • Mar 24, 2026 · Company release ↗
    “RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed financing from a syndicate of new and existing investors”
Mar 24, 2026Company release ↗
Virchow MedicalSeed · $4M · announced Mar 24, 2026 SEC Form D Equity · Form D reports $4.12M sold · first sale Mar 19, 2026 · SEC Form D ↗
Source quote
  • Mar 24, 2026 · Company release ↗
    “— Virchow Medical, Inc., manufacturer of the Crow’s Nest® Biopsy Catchment System and operator of the Virchow Vault ™ Liquid Specimen Biorepository, today announced it has completed a $4 million seed financing led by Cerberus Ventures”
Mar 24, 2026Company release ↗
Avation MedicalSeries D · amount not disclosed · announced Mar 20, 2026
Source quote
  • Mar 20, 2026 · Company release ↗
    “VALENCIA, CA, UNITED STATES, March 20, 2026 / EINPresswire.com / — Avation Medical , a global leader in treating bladder conditions with its innovative non-invasive neuromodulation technology, is pleased to announce a successful closing of Series D financing and is excited to appoint Manish Vaishya”
Mar 20, 2026Company release ↗
CarecubesSeries A · $6.5M · announced Mar 19, 2026
Source quote
  • Mar 19, 2026 · Company release ↗
    “— Carecubes, which is transforming infectious disease response through its FDA 510(k)-cleared isolation unit built for rapid deployment wherever care is needed, today announced the close of its $6.5 million Series A funding round”
Mar 19, 2026Company release ↗
Imperative CareConvertible note · $100M · announced Mar 17, 2026 SEC Form D Debt / note · Form D reports $111.27M sold · first sale Mar 13, 2026 · SEC Form D/A ↗
Source quote
  • Mar 17, 2026 · Company release ↗
    “Imperative Care , Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the closing of an oversubscribed $100 million convertible note financing”
Mar 17, 2026Company release ↗
Mestag Therapeutics LimitedUndisclosed round · $40M · announced Mar 17, 2026
Source quote
  • Mar 17, 2026 · Company release ↗
    “Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic”
Mar 17, 2026Company release ↗
AvisiSeries A · $10.7M · announced Mar 12, 2026
Source quote
  • Mar 12, 2026 · Company release ↗
    “Avisi raises $10.7M to advance study on VisiPlate glaucoma device”
  • Round · Company release ↗
    “announced it has secured $10.7 million in a recent Series A financing round to support the SAPPHIRE pivotal clinical trial”
Mar 12, 2026Company release ↗
Vima TherapeuticsSeries A · $40M · announced Mar 11, 2026
Source quote
Mar 11, 2026Company release ↗
4TEEN4 Pharmaceuticals GmbHSeries C · more than $64M (converted from EUR) · announced Mar 10, 2026
Source quote
  • Mar 10, 2026 · Company release ↗
    “4TEEN4 Successfully Closes Series C Financing Round at Over €64 Million”
Mar 10, 2026Company release ↗
CytoDynUndisclosed round · $17.5M · announced Mar 5, 2026 SEC Form D Equity · Form D reports $18.6M sold · first sale Jan 30, 2026 · SEC Form D ↗
Source quote
  • Mar 5, 2026 · Company release ↗
    “CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab :: CytoDyn Inc. (CYDY)”
Mar 5, 2026Company release ↗
ScienceSeries C · $230M · announced Mar 5, 2026 SEC Form D Equity · Form D reports $230.05M sold · first sale Feb 26, 2026 · SEC Form D ↗
Source quote
  • Mar 5, 2026 · Company release ↗
    “We’ve closed a $230 million Series C financing with participation from Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital, all pre-existing investors in Science, among others”
Mar 5, 2026Company release ↗
BrainCheck, Inc.Undisclosed round · $13M · announced Feb 26, 2026
Source quote
  • Feb 26, 2026 · Company release ↗
    “BrainCheck Raises $13 Million to Expand AI-Enabled Cognitive Care Platform”
Feb 26, 2026Company release ↗
Blue ArborUndisclosed round · $5M · announced Feb 26, 2026
Source quote
  • Feb 26, 2026 · Company release ↗
    “Blue Arbor Technologies Announces Strategic Partnership with Ottobock and $5 Million Investment to Advance RESTORE™ Neuromuscular Interface System”
Feb 26, 2026Company release ↗
BreezeBioSeries B · amount not disclosed · announced Feb 25, 2026
Source quote
  • Feb 25, 2026 · Company release ↗
    “The Series B financing is led by new investors, Yuanta Investment and DSC Investment, with participation from SV investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, and others.”
Feb 25, 2026Company release ↗
Alveus TherapeuticsSeries A · $197M · announced Feb 24, 2026
Source quote
  • Feb 24, 2026 · Company release ↗
    “Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases”
Feb 24, 2026Company release ↗
Centauri Therapeutics LimitedSeries A · $30M (converted from GBP) · announced Feb 24, 2026
Source quote
  • Feb 24, 2026 · Company release ↗
    “Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate”
Feb 24, 2026Company release ↗
BrainStorm Cell TherapeuticsUndisclosed round · $1M · announced Feb 20, 2026
Source quote
  • Feb 20, 2026 · Company release ↗
    “Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market”
Feb 20, 2026Company release ↗
Sift BiosciencesPre-seed · $3.7M · announced Feb 17, 2026
Source quote
  • Feb 17, 2026 · Company release ↗
    “— Sift … Biosciences, a UC Berkeley spinout developing a next-generation peptide immunotherapy platform that integrates AI, metagenomics, and high-throughput immune profiling today announced the closing of a $3.7M Pre-Seed financing, co-led by Freeflow Ventures and Lifespan Vision Ventures, with pa”
Feb 17, 2026Company release ↗
Pharaoh NeuroSeries A · $20M · announced Feb 11, 2026
Source quote
  • Feb 11, 2026 · Company release ↗
    “Pharaoh Neuro Secures $20 Million Series A and Appoints CEO and CMO to Advance Neurapheresis™ Platform A medical device company developing innovative solutions for neurocritical care — advancing active CSF management after aneurysmal subarachnoid hemorrhage”
Feb 11, 2026Company release ↗
Stratus MedicalSeries B · $10M · announced Feb 4, 2026
Source quote
  • Feb 4, 2026 · Company release ↗
    “MAGNOLIA, Texas, Feb. 4, 2026 /PRNewswire/ -- Stratus® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing”
Feb 4, 2026Company release ↗
Third Arc BioSeries A · $52M · announced Feb 4, 2026
Source quote
  • Feb 4, 2026 · Company release ↗
    “$52M equity adds to previously announced $165M Series A New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn.”
Feb 4, 2026Company release ↗
Ecovia Renewables Inc.Series B · amount not disclosed · announced Feb 3, 2026
Source quote
  • Feb 3, 2026 · Company release ↗
    “Ecovia Bio Closes Series B Funding Round Led by Pointe Angels to Expand Manufacturing Capacity GROSSE POINTE, MI – February 3, 2026 – Ecovia Bio, an advanced biotechnology company specializing in sustainable, high-performance biopolymer ingredients, today announced the closing of a Series B”
Feb 3, 2026Company release ↗
Primmune TherapeuticsSeries B · $8.6M · announced Jan 26, 2026
Source quote
  • Jan 26, 2026 · Company release ↗
    “SAN DIEGO, January 26, 2026 – Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital.”
Jan 26, 2026Company release ↗
Coating PlaceGrowth · amount not disclosed · announced Jan 14, 2026
Source quote
  • Jan 14, 2026 · Company release ↗
    “VERONA, Wis. — Jan. 14, 2026 — Coating Place, a leading U.S.-based contract development and manufacturing organization (CDMO), has secured a strategic, growth investment from 1315 Capital”
Jan 14, 2026Company release ↗
Inquis MedicalSeries C · $75M · announced Jan 12, 2026
Source quote
  • Jan 12, 2026 · Company release ↗
    “MENLO PARK, Calif.–( BUSINESS WIRE )– Inquis Medical, Inc. , a privately held medical technology company dedicated to advancing mechanical thrombectomy for venous thromboembolic disease (“VTE”), today announced the closing of a $75 million Series C financing round”
Jan 12, 2026Company release ↗
Nanochon, Inc.Seed · $4.1M · announced Jan 12, 2026
Source quote
Jan 12, 2026Company release ↗
Avenue BiosciencesSeed extension · $5.7M · announced Jan 12, 2026
Source quote
  • Jan 12, 2026 · Company release ↗
    “Palo Alto, California, USA (January 12, 2026) – Avenue Biosciences, a protein engineering technology company, today announced $5.7M in seed extension funding round co-led by Balnord”
Jan 12, 2026Company release ↗
Kinaset TherapeuticsSeries B · $103M · announced Jan 10, 2026
Source quote
  • Jan 10, 2026 · Company release ↗
    “Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel”
Jan 10, 2026Company release ↗
Orca BioSeries F · amount not disclosed · announced Jan 9, 2026
Source quote
  • Jan 9, 2026 · Company release ↗
    “MENLO PARK, CA, Jan. 9, 2026 – Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the completion of a Series F financing round in December 2025 led by Lightspeed Venture Partners”
Jan 9, 2026Company release ↗
EpiBiologicsSeries B · $107M · announced Jan 8, 2026
Source quote
  • Jan 8, 2026 · Company release ↗
    “— EpiBiologics , a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson”
Jan 8, 2026Company release ↗
Beacon TherapeuticsSeries C · more than $75M · announced Jan 8, 2026
Source quote
  • Jan 8, 2026 · Company release ↗
    “Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million”
Jan 8, 2026Company release ↗
NeuroBionicsSeed · $10M · announced Dec 16, 2025
Source quote
  • Dec 16, 2025 · Company release ↗
    “NeuroBionics Announces Oversubscribed $10M Seed Round with Second Close Led by Future Ventures”
Dec 16, 2025Company release ↗
Alphyn BiologicsSeries B · $25M · announced Dec 12, 2025
Source quote
  • Dec 12, 2025 · Company release ↗
    “Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline”
Dec 12, 2025Company release ↗
Cayuga BiotechSeed · $8M · announced Dec 11, 2025
Source quote
Dec 11, 2025Company release ↗
InduPro, Inc.Strategic · amount not disclosed · announced Dec 10, 2025
Source quote
  • Dec 10, 2025 · Company release ↗
    “SEATTLE, WA and CAMBRIDGE, MA— December 10, 2025 — InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a strategic equity investment and research collaboration with”
Dec 10, 2025Company release ↗
Impulse DynamicsUndisclosed round · $158M · announced Dec 10, 2025
Source quote
Dec 10, 2025Company release ↗
RxMP TherapeuticsBridge · $2M · announced Dec 9, 2025
Source quote
  • Dec 9, 2025 · Company release ↗
    “RxMP Therapeutics Announces Opening of $2 Million Bridge Financing Round”
Dec 9, 2025Company release ↗
SanegeneBioSeries B · more than $110M · announced Dec 8, 2025
Source quote
  • Dec 8, 2025 · Company release ↗
    “BOSTON, SHANGHAI, and SUZHOU — December 8, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced the closing of Series B financing round, raising over $110 million.”
Dec 8, 2025Company release ↗
SciNeuro PharmaceuticalsUndisclosed round · $53M · announced Dec 4, 2025
Source quote
  • Dec 4, 2025 · Company release ↗
    “SciNeuro Pharmaceuticals (“ SciNeuro ”), a biotech company pioneering the development of novel treatments for neurodegenerative diseases, today announced the completion of a total of $53 million in equity financing”
Dec 4, 2025Company release ↗
Auxilius PharmaSeries A · $4M · announced Dec 3, 2025
Source quote
  • Dec 3, 2025 · Company release ↗
    “Auxilius Pharma Announces USD 4 Million Series A Financing Round to Advance Development of AUX-001 for Chronic Stable Angina Auxilius Pharma today announced the signing of a USD 4 million Series A financing round that will accelerate the company’s research”
Dec 3, 2025Company release ↗
Curi Bio, Inc.Series B · $10M · announced Dec 2, 2025
Source quote
  • Dec 2, 2025 · Company release ↗
    “SEATTLE, WA – December 2, 2025 [ Originally posted on BusinessWire ] – Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round”
Dec 2, 2025Company release ↗
Metri BioPre-seed · $5M · announced Dec 2, 2025
Source quote
  • Dec 2, 2025 · Company release ↗
    “Metri Bio has raised $5 million in an oversubscribed pre-seed financing round led by Pillar VC”
Dec 2, 2025Company release ↗
Circular GenomicsSeries A · $15M · announced Dec 1, 2025
Source quote
  • Dec 1, 2025 · Company release ↗
    “SAN DIEGO, Dec. 1, 2025 -- Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and psychiatry, today announced the successful closure of a $15 million Series A financing round”
Dec 1, 2025Company release ↗
Zetagen Therapeutics, Inc.Series B · $12.91M · announced Nov 25, 2025
Source quote
  • Nov 25, 2025 · Company release ↗
    “— Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, today announced the successful closure of its Series B1 financing round of $12,908,000.”
Nov 25, 2025Company release ↗
VerImmuneUndisclosed round · $500K · announced Nov 24, 2025
Source quote
  • Nov 24, 2025 · Company release ↗
    “COLUMBIA, Md., (November 24, 2025) — TEDCO , Maryland’s economic engine for technology companies, announced a recent $500,000 Maryland Equity Investment Fund (MEIF) investment in VerImmune, Inc”
Nov 24, 2025Company release ↗
Aspen NeuroscienceSeries C · $115M · announced Nov 20, 2025
Source quote
  • Nov 20, 2025 · Company release ↗
    “SAN DIEGO, Nov. 20, 2025 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round”
Nov 20, 2025Company release ↗
AI ProteinsSeries A · $41.5M · announced Nov 19, 2025
Source quote
  • Nov 19, 2025 · Company release ↗
    “BOSTON--( BUSINESS WIRE )--AI Proteins, a biotech company pioneering a new class of de novo medicines built from the ground up using artificial intelligence, today announced the closing of a $41.5 million Series A financing”
Nov 19, 2025Company release ↗
Pattern BioscienceSeries D · $43M · announced Nov 18, 2025
Source quote
  • Nov 18, 2025 · Company release ↗
    “November 18, 2025 • Press Releases • Kyle Fieleke Pattern Bioscience Raises $43 Million in Series D Financing to Pursue FDA Clearance for Its Rapid Pneumonia Diagnostic Funding led by AMR Action Fund”
Nov 18, 2025Company release ↗
Imbria PharmaceuticalsSeries B · amount not disclosed · announced Nov 17, 2025
Source quote
  • Nov 17, 2025 · Company release ↗
    “(“Imbria”), a clinical-stage company developing transformational cardiovascular disease therapeutics, today announced the participation of AXA IM Alts in an upsized Series B financing, advancing the company’s mission to develop breakthrough solutions that address the world’s most urgent”
Nov 17, 2025Company release ↗
TandemAISeries A · $22M · announced Nov 14, 2025
Source quote
  • Nov 14, 2025 · Company release ↗
    “TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery”
Nov 14, 2025Company release ↗
Angiex, Inc.Undisclosed round · $31M · announced Nov 14, 2025
Source quote
  • Nov 14, 2025 · Company release ↗
    “Angiex Completes Financings Totaling $31M to Support the Phase 1 Clinical Development of AGX101 in Patients with Advanced Solid Tumors CAMBRIDGE”
Nov 14, 2025Company release ↗
Beacon BiosignalsSeries B · $86M · announced Nov 13, 2025
Source quote
  • Nov 13, 2025 · Company release ↗
    “BOSTON, MA – November 13, 2025 – Beacon Biosignals, a leading neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, today announced an oversubscribed $86 million Series B”
  • Apr 6, 2026 · Company release ↗
    “Boston, MA — April 6, 2026 — Beacon Biosignals today announced an extension to its Series B financing, bringing the funding round to $97 million and the company’s cumulative funding to over $132 million”
Nov 13, 2025Company release ↗
Gate BioscienceSeries B · $65M · announced Nov 13, 2025
Source quote
  • Nov 13, 2025 · Company release ↗
    “Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic”
Nov 13, 2025Company release ↗
Ladder BioSeed · $5.5M · announced Nov 12, 2025
Source quote
  • Nov 12, 2025 · Company release ↗
    “ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer”
Nov 12, 2025Company release ↗
Inquis MedicalSeries B · $40M · announced Oct 28, 2025
Source quote
  • Oct 28, 2025 · Company release ↗
    “MENLO PARK, Calif.–( BUSINESS WIRE )– Inquis Medical , a pioneering medical technology company specializing in advanced thrombectomy systems, today announced the successful closure of its $40 million Series B financing round”
Oct 28, 2025Company release ↗
VitriVaxSeries B · $17.25M · announced Oct 22, 2025
Source quote
  • Oct 22, 2025 · Company release ↗
    “BOULDER, COLORADO – October 22, 2025 – VitriVax, Inc ., a vaccine formulation technology company, today announced it raised a total of $17.25 million in Series B financing”
Oct 22, 2025Company release ↗
Electra TherapeuticsSeries C · $183M · announced Oct 22, 2025
Source quote
  • Oct 22, 2025 · Company release ↗
    “Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer Proceeds will fund a global pivotal trial of lead product candidate”
Oct 22, 2025Company release ↗
Catalyst OrthoScienceGrowth · $15M · announced Oct 22, 2025
Source quote
  • Oct 22, 2025 · Company release ↗
    “CATALYST ORTHOSCIENCE Secures $15.0 Million in Growth Financing”
Oct 22, 2025Company release ↗
GreenJay TherapeuticsSeries A · $1M · announced Oct 21, 2025
Source quote
  • Oct 21, 2025 · Company release ↗
    “GreenJay Therapeutics Successfully Closes $1 Million in its Series A Preferred Round of Financing”
Oct 21, 2025Company release ↗
PleoPharmaSeries B · $36M · announced Oct 21, 2025
Source quote
  • Oct 21, 2025 · Company release ↗
    “PleoPharma, Inc. Closes $36 Million Series B Financing Round”
Oct 21, 2025Company release ↗
Valink TherapeuticsUndisclosed round · $11.8M · announced Oct 20, 2025
Source quote
  • Oct 20, 2025 · Company release ↗
    “Valink Therapeutics Closes $11.8 Million Pre-A Financing Round to Advance Oncology Pipeline Funding accelerates development of novel therapeutics to improve outcomes for patients with cancer October 20”
Oct 20, 2025Company release ↗
PeptilogicsUndisclosed round · $78M · announced Oct 16, 2025
Source quote
  • Oct 16, 2025 · Company release ↗
    “Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial”
Oct 16, 2025Company release ↗
Pelage PharmaceuticalsSeries B · $120M · announced Oct 15, 2025 SEC Form D Equity · Form D reports $120M sold · first sale Sep 18, 2025 · SEC Form D ↗
Source quote
  • Oct 15, 2025 · Company release ↗
    “— Pelage Pharmaceuticals , a clinical-stage regenerative medicine biotechnology company, today announced the close of a $120 million Series B financing co-led by ARCH Venture Partners and GV (Google Ventures)”
Oct 15, 2025Company release ↗
BexorgUndisclosed round · $42.5M · announced Oct 15, 2025
Source quote
  • Oct 15, 2025 · Company release ↗
    “Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform”
Oct 15, 2025Company release ↗
Lila SciencesSeries A · $350M · announced Oct 10, 2025
Source quote
  • Oct 10, 2025 · Company release ↗
    “Today we’re announcing the close of our $350M Series A, bringing Lila’s total capital raised to $550M.”
Oct 10, 2025Company release ↗
Lumen BioscienceSeries C · $30M · announced Oct 8, 2025
Source quote
Oct 8, 2025Company release ↗
Epion TherapeuticsUndisclosed round · $18.5M · announced Oct 7, 2025
Source quote
  • Oct 7, 2025 · Company release ↗
    “(Epion), a late-stage biotechnology company developing a minimally-invasive, epithelium-on treatment for keratoconus, announced the closing of a $18.5M financing round led by OCULUS Optikgeräte GmbH (“OCULUS”) GmbH”
Oct 7, 2025Company release ↗
OncoC4Series B · about $50M · announced Oct 2, 2025
Source quote
  • Oct 2, 2025 · Company release ↗
    “ROCKVILLE, Md., Oct. 02, 2025 — OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million.”
Oct 2, 2025Company release ↗
Crystalys TherapeuticsSeries A · $205M · announced Oct 1, 2025
Source quote
  • Oct 1, 2025 · Company release ↗
    “Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing”
Oct 1, 2025Company release ↗
AiM Medical RoboticsSeries A · $8.1M · announced Sep 30, 2025
Source quote
  • Sep 30, 2025 · Company release ↗
    “AiM Medical Robotics Secures $8.1 Million Series A Financing to Transform Neurosurgery with MRI-Compatible Surgical Robotics”
Sep 30, 2025Company release ↗
Star TherapeuticsSeries D · $125M · announced Sep 30, 2025
Source quote
  • Sep 30, 2025 · Company release ↗
    “Star Therapeutics Announces Oversubscribed $125 Million Series D Financing Proceeds to support continued clinical advancement of lead program”
Sep 30, 2025Company release ↗
ReCode TherapeuticsUndisclosed round · more than $29M · announced Sep 29, 2025 SEC Form D Debt / note · Form D reports $29.44M sold · first sale Sep 23, 2025 · SEC Form D ↗
Source quote
Sep 29, 2025Company release ↗
FYR BioUndisclosed round · $8M · announced Sep 24, 2025
Source quote
  • Sep 24, 2025 · Company release ↗
    “— FYR Bio , a biotechnology company leveraging extracellular vesicles (EVs) to create an end-to-end solution for new precision medicine tools, today announced it has closed a new $8 million round of funding”
Sep 24, 2025Company release ↗
Sparrow PharmaceuticalsSeries B · $95M · announced Sep 24, 2025
Source quote
  • Sep 24, 2025 · Company release ↗
    “— Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the close of a $95 million Series B financing”
Sep 24, 2025Company release ↗
Seed TherapeuticsSeries A · $30M · announced Sep 23, 2025
Source quote
  • Sep 23, 2025 · Company release ↗
    “SEED Therapeutics Completes $30 Million Series A-3 Financing King of Prussia, PA – September 23, 2025 – SEED Therapeutics, Inc.”
Sep 23, 2025Company release ↗
EnsomaUndisclosed round · $53M · announced Sep 22, 2025
Source quote
  • Sep 22, 2025 · Company release ↗
    “Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON”
Sep 22, 2025Company release ↗
Avenzo TherapeuticsSeries B · $60M · announced Sep 22, 2025
Source quote
  • Sep 22, 2025 · Company release ↗
    “Avenzo Therapeutics Announces $60 Million Series B Financing”
Sep 22, 2025Company release ↗
AllRock BioSeries A · $50M · announced Sep 16, 2025
Source quote
  • Sep 16, 2025 · Company release ↗
    “AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients Topline data from ROC-101 Phase 1 study demonstrate favorable safety and tolerability, and”
Sep 16, 2025Company release ↗
Reunion NeuroscienceSeries A · amount not disclosed · announced Sep 16, 2025
Source quote
  • Sep 16, 2025 · Company release ↗
    “16 Sep Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD) — Upsized Series A Financing Brings Total Amount Raised to $133 Million — — GAD Affects 3.1% of U.S.”
Sep 16, 2025Company release ↗
Actuate TherapeuticsPublic offering · $17.25M · announced Sep 11, 2025
Source quote
  • Sep 11, 2025 · Company release ↗
    “(“Actuate” … kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option”
Sep 11, 2025Company release ↗
Seneca TherapeuticsSeries B · $3.9M · announced Sep 5, 2025
Source quote
  • Sep 5, 2025 · Company release ↗
    “Seneca Therapeutics Announces the Closing of $3.9 million Series B Extension Round”
Sep 5, 2025Company release ↗
Enveda BiosciencesSeries D · $150M · announced Sep 4, 2025
Source quote
  • Sep 4, 2025 · Company release ↗
    “Enveda Raises $150M Series D Funding to Reach Unicorn Status”
Sep 4, 2025Company release ↗
Cognition TherapeuticsUndisclosed round · $30M · announced Sep 2, 2025
Source quote
  • Sep 2, 2025 · Company release ↗
    “Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)”
Sep 2, 2025Company release ↗
Leal TherapeuticsSeries A · $30M · announced Aug 27, 2025
Source quote
  • Aug 27, 2025 · Company release ↗
    “Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need”
Aug 27, 2025Company release ↗
Frontier Medicines CorporationSeries C · $20M · announced Aug 27, 2025
Source quote
  • Aug 27, 2025 · Company release ↗
    “Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension -Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO) -Company adds $20 million to close”
Aug 27, 2025Company release ↗
Allotera Therapeutics (Formerly Wugen)Equity financing · $115M · announced Aug 27, 2025
Source quote
  • Aug 27, 2025 · Company release ↗
    “today announced the closing of $115 million equity financing led by Fidelity Management & Research Company”
Aug 27, 2025Company release ↗
Incyclix BioSeries B · $11.25M · announced Aug 25, 2025
Source quote
  • Aug 25, 2025 · Company release ↗
    “Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in”
Aug 25, 2025Company release ↗
Cellular Intelligence (Formerly Somite)Strategic · amount not disclosed · announced Aug 20, 2025
Source quote
  • Aug 20, 2025 · Company release ↗
    “Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures, following Somite's $47M Series A closing led by Khosla Ventures in May”
Aug 20, 2025Company release ↗
Mission BioEquity financing · amount not disclosed · announced Aug 5, 2025
Source quote
  • Aug 5, 2025 · Company release ↗
    “Cato Joining as CCO SOUTH SAN FRANCISCO, Calif., August 5, 2025 – Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, today announced the successful completion of equity financing led by Ally Bridge Group”
Aug 5, 2025Company release ↗
Maxwell BiosciencesUndisclosed round · $20M · announced Aug 5, 2025
Source quote
  • Aug 5, 2025 · Company release ↗
    “– Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today announced the closing of its $20 million financing round”
Aug 5, 2025Company release ↗
RyghtSeed · $3M · announced Jul 28, 2025
Source quote
  • Jul 28, 2025 · Company release ↗
    “Ryght AI, a startup using agentic AI to automate clinical trials, raised a $3 million seed round”
Jul 28, 2025Company release ↗
Neuros MedicalSeries D · $56M · announced Jul 14, 2025
Source quote
  • Jul 14, 2025 · Company release ↗
    “— Neuros Medical, Inc., the maker of the Altius® Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain, today announced the closing of an oversubscribed $56 million Series D financing round”
Jul 14, 2025Company release ↗
Titan PharmaceuticalsPrivate placement · $600K · announced Jun 27, 2025
Source quote
  • Jun 27, 2025 · Company release ↗
    “Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock”
Jun 27, 2025Company release ↗
Neuron23Series D · $96.5M · announced Jun 24, 2025
Source quote
  • Jun 24, 2025 · Company release ↗
    “– Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of a $96.5 million Series D financing round led by a healthcare investor”
Jun 24, 2025Company release ↗
GeneCentric TherapeuticsSeries C · $8M · announced Jun 18, 2025
Source quote
  • Jun 18, 2025 · Company release ↗
    “– GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing”
Jun 18, 2025Company release ↗
DASI SimulationsUndisclosed round · $5M · announced Jun 17, 2025
Source quote
  • Jun 17, 2025 · Company release ↗
    “DASI Simulations Closes Third Funding Round of $5 Million; Finalizes 11 Commercial Agreements for Its AI-Powered Predictive Modeling Products for Structural Heart Care Company expands sales force”
Jun 17, 2025Company release ↗
Corvia MedicalUndisclosed round · $55M · announced Jun 17, 2025
Source quote
  • Jun 17, 2025 · Company release ↗
    “– Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company’s existing investment syndicate of Third Rock Ventures”
Jun 17, 2025Company release ↗
NanoCell TherapeuticsSeed · amount not disclosed · announced Jun 16, 2025
Source quote
  • Jun 16, 2025 · Company release ↗
    “(“NanoCell”), a biotechnology company developing a non-viral, DNA-based in vivo gene therapy platform, today announced the successful closing of a seed-extension financing round, with participation from The Institute for Follicular Lymphoma Innovation (“IFLI”), a leading non-profit organization”
Jun 16, 2025Company release ↗
Elicio TherapeuticsUndisclosed round · $10M · announced Jun 4, 2025
Source quote
Jun 4, 2025Company release ↗
Estrella ImmunopharmaUndisclosed round · about $3.35M · announced Jun 3, 2025
Source quote
  • Jun 3, 2025 · Company release ↗
    “Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing Emeryville, California, June 3, 2025 – Estrella Immunopharma, Inc.”
Jun 3, 2025Company release ↗
CellCentricSeries C · $120M · announced May 19, 2025
Source quote
  • May 19, 2025 · Company release ↗
    “Cambridge, UK and Boston, MA – May 19, 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma, today announced the completion of a $120 million Series C funding round”
May 19, 2025Company release ↗
Pathos AISeries D · $365M · announced May 15, 2025
Source quote
  • May 15, 2025 · Company release ↗
    “Where the Future of Drug Development Begins Where the Future of Drug Development Begins Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI New York”
May 15, 2025Company release ↗
Alpheus MedicalSeries B · $52M · announced May 15, 2025
Source quote
  • May 15, 2025 · Company release ↗
    “CHANHASSEN, Minn., May 15, 2025 — Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round”
May 15, 2025Company release ↗
ROSE DiagnosticsUndisclosed round · $2.3M · announced May 14, 2025
Source quote
  • May 14, 2025 · Company release ↗
    “ROSE Diagnostics Inc., an innovative leader in rapid cancer diagnostics, today announced the successful completion of its second financing round, securing $2.3 million.”
May 14, 2025Company release ↗
Therini BioSeries A · $39M · announced May 14, 2025
Source quote
  • May 14, 2025 · Company release ↗
    “Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline”
May 14, 2025Company release ↗
Remedy Plan TherapeuticsUndisclosed round · more than $18M · announced May 13, 2025
Source quote
  • May 13, 2025 · Company release ↗
    “-- Remedy Plan Therapeutics (Remedy Plan), a privately-held, clinical-stage pharmaceutical company developing novel, hyperbolic NAMPT inhibitors, today announced the company has raised over $18 million in an oversubscribed insider financing round”
May 13, 2025Company release ↗
Cellular Intelligence (Formerly Somite)Series A · more than $47M · announced May 13, 2025
Source quote
  • May 13, 2025 · Company release ↗
    “We’ve just raised over $47M in Series A funding led by Khosla Ventures to accelerate development of DeltaStem”
May 13, 2025Company release ↗
Path Ex, Inc.Undisclosed round · $5M · announced May 8, 2025
Source quote
  • May 8, 2025 · Company release ↗
    “PATH EX, Inc., a medical device company located in the Texas Medical Center Innovation Factory, is excited to announce the successful completion of a $5 million financing round”
May 8, 2025Company release ↗
Trailhead BiosystemsUndisclosed round · $20M · announced May 6, 2025
Source quote
  • May 6, 2025 · Company release ↗
    “Trailhead Biosystems Secures $20 Million to Drive Innovation and Accelerate Growth”
May 6, 2025Company release ↗
Noveome BiotherapeuticsSeries E · $51M · announced Apr 23, 2025
Source quote
  • Apr 23, 2025 · Company release ↗
    “Noveome Biotherapeutics, Inc. Completes $51 million Series E Financing to Support Clinical Trials in NEC”
Apr 23, 2025Company release ↗
Biolinq Inc.Series C · $100M · announced Apr 22, 2025
Source quote
  • Apr 22, 2025 · Company release ↗
    “Biolinq Announces Close of $100M Series C Financing to Advance Its Biowearable Platform for Metabolic Health”
Apr 22, 2025Company release ↗
GenrAbPrivate placement · $5.6M · announced Apr 22, 2025
Source quote
  • Apr 22, 2025 · Company release ↗
    “GenrAb … lead therapy into the clinic Growing pipeline of novel partnerable neurotherapeutic antibodies Dallas, TX – April 22, 2025 – GenrAb, Inc., a developer of first-in-class neuroprotective therapies, today announced completion of a private placement with aggregate gross proceeds of $5.6 million”
Apr 22, 2025Company release ↗
GlycomineSeries C · $115M · announced Apr 16, 2025
Source quote
  • Apr 16, 2025 · Company release ↗
    “Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate”
Apr 16, 2025Company release ↗
Titan PharmaceuticalsPrivate placement · $1M · announced Apr 11, 2025
Source quote
  • Apr 11, 2025 · Company release ↗
    “Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock”
Apr 11, 2025Company release ↗
Terrestrial BioUndisclosed round · $9M · announced Apr 9, 2025
Source quote
  • Apr 9, 2025 · Company release ↗
    “Vaxess Announces $9M in Funding for Microarray Drug Delivery Platform VAXESS ANNOUNCES $9M IN FUNDING FOR MICROARRAY DRUG DELIVERY PLATFORM WOBURN, Mass., April 9, 2025 — Vaxess Technologies, Inc.”
Apr 9, 2025Company release ↗
SoteriusSeries A · amount not disclosed · announced Apr 8, 2025
Source quote
  • Apr 8, 2025 · Company release ↗
    “Soterius and Celegence are pleased to announce that as a part of Soterius’ Series A financing round”
Apr 8, 2025Company release ↗
Atsena Therapeutics, Inc.Series C · $150M · announced Apr 2, 2025
Source quote
  • Apr 2, 2025 · Company release ↗
    “Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs”
Apr 2, 2025Company release ↗
Evident VascularSeries B · amount not disclosed · announced Mar 25, 2025
Source quote
  • Mar 25, 2025 · Company release ↗
    “– Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B”
Mar 25, 2025Company release ↗
SurrozenPrivate placement · $175M · announced Mar 24, 2025
Source quote
  • Mar 24, 2025 · Company release ↗
    “Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases”
Mar 24, 2025Company release ↗
Wheeler BioSeries A · $35M · announced Mar 20, 2025
Source quote
  • Mar 20, 2025 · Company release ↗
    “The $35 million round was led by Alloy Therapeutics and Echo Investment Capital (Echo), with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.”
Mar 20, 2025Company release ↗
Ampersand BiomedicinesSeries B · $65M · announced Mar 19, 2025
Source quote
  • Mar 19, 2025 · Company release ↗
    “– Ampersand Biomedicines … a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced it has secured $65 million in Series B funding from investors including Ampersand’s founder, Flagship Pioneering, Eli Lilly & Comp”
Mar 19, 2025Company release ↗
RegCellSeed · amount not disclosed · announced Mar 18, 2025
Source quote
  • Mar 18, 2025 · Company release ↗
    “— RegCell, Inc., a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T-cells (Tregs), today announced the closing of an oversubscribed seed”
Mar 18, 2025Company release ↗
Arbor BiotechnologiesSeries C · $73.9M · announced Mar 18, 2025
Source quote
  • Mar 18, 2025 · Company release ↗
    “Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics”
Mar 18, 2025Company release ↗
ElegenSeries B · $35M · announced Mar 9, 2025
Source quote
  • Mar 9, 2025 · Company release ↗
    “Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing Elegen announced a Series B financing of $35 million led by Triatomic Capital”
Mar 9, 2025Company release ↗
Eikon TherapeuticsSeries D · $350.7M · announced Feb 26, 2025
Source quote
  • Feb 26, 2025 · Company release ↗
    “– Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today announced the initial closing of a $350.7 million Series D financing”
Feb 26, 2025Company release ↗
AbcuroSeries C · $200M · announced Feb 12, 2025
Source quote
  • Feb 12, 2025 · Company release ↗
    “– Abcuro … Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the closing of a $200 million Series C financing led by New Enterprise Associates (NEA) with Foresite Ca”
Feb 12, 2025Company release ↗
iVeena Delivery Systems, Inc.Series B · $3M · announced Feb 5, 2025
Source quote
  • Feb 5, 2025 · Company release ↗
    “(“iVeena”) , a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million.”
Feb 5, 2025Company release ↗
Auron TherapeuticsSeries B · $27M · announced Feb 4, 2025
Source quote
  • Feb 4, 2025 · Company release ↗
    “– Auron … Therapeutics , a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced progress for its lead KAT2A/B program and clinical candidate, AUTX-703, and the completion of a $27 million Series B fina”
Feb 4, 2025Company release ↗
ImvaxUndisclosed round · $29M · announced Jan 29, 2025
Source quote
  • Jan 29, 2025 · Company release ↗
    “— Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the closing of a $29 million financing round from existing investors”
Jan 29, 2025Company release ↗
PinkDxSeries A · $45M · announced Jan 23, 2025
Source quote
  • Jan 23, 2025 · Company release ↗
    “This brings the total raised in the upsized round to $45 million.”
Jan 23, 2025Company release ↗
NeuroBionicsSeed · $5M · announced Jan 21, 2025 SEC Form D Equity · Form D reports $4.25M sold · first sale Nov 25, 2025 · SEC Form D ↗
Source quote
  • Jan 21, 2025 · Company release ↗
    “by NeuroBionics | Jan 21, 2025 | News , Press NeuroBionics , a neurotech company revolutionizing neuromodulation therapy with minimally invasive implantable devices, today announced the successful close of its $5 million Seed Round”
  • Dec 16, 2025 · Company release ↗
    “NeuroBionics Announces Oversubscribed $10M Seed Round with Second Close Led by Future Ventures”
Jan 21, 2025Company release ↗
Hinge Bio, Inc.Series A · $30M · announced Jan 15, 2025
Source quote
Jan 15, 2025Company release ↗
VisiRoseSeed · $3M · announced Jan 14, 2025
Source quote
  • Jan 14, 2025 · Company release ↗
    “(“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.”
  • Jan 14, 2025 · Company release ↗
    “VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics”
Jan 14, 2025Company release ↗
Tune TherapeuticsSeries B · more than $175M · announced Jan 13, 2025
Source quote
  • Jan 13, 2025 · Company release ↗
    “Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs”
Jan 13, 2025Company release ↗
NormunitySeries B · $75M · announced Jan 13, 2025
Source quote
  • Jan 13, 2025 · Company release ↗
    “Normunity closes $75 million Series B financing to advance lead drug program into the clinic and broaden pipeline of novel anti-cancer therapies targeting untapped drug mechanisms Financing co-led by Samsara Biocapital and Enavate Sciences, with participation from Pfizer Ventures and Regeneron”
Jan 13, 2025Company release ↗
Curadel PharmaSeries A · $10.5M · announced Jan 13, 2025
Source quote
  • Jan 13, 2025 · Company release ↗
    “Curadel Pharma secures $10.5M in series A2 funding to propel novel Zwitterionic Radiotherapy Platform”
Jan 13, 2025Company release ↗
ImmunisSeries A · $25M · announced Jan 11, 2025
Source quote
Jan 11, 2025Company release ↗
A2 BiotherapeuticsSeries C · $80M · announced Jan 9, 2025
Source quote
  • Jan 9, 2025 · Company release ↗
    “(A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column”
Jan 9, 2025Company release ↗
RyboDynPre-seed · $4M · announced Jan 9, 2025
Source quote
  • Jan 9, 2025 · Company release ↗
    “Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- RyboDyn, Inc., has announced the discovery of a new proteome and the successful closing of a $4 million”
Jan 9, 2025Company release ↗
ZetoSeries B · $31M · announced Jan 8, 2025
Source quote
  • Jan 8, 2025 · Company release ↗
    “Zeto, Inc., Secures $31 Million In Series B Funding To Redefine The Future Of EEG Brain Monitoring”
Jan 8, 2025Company release ↗
GeneoscopySeries C · $105M · announced Jan 8, 2025
Source quote
  • Jan 8, 2025 · Company release ↗
    “LOUIS & HERCULES, Calif. – Jan. 8, 2025 – Geneoscopy, Inc ., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the closing of a Series C funding round raising $105 million.”
Jan 8, 2025Company release ↗
CeQurUndisclosed round · $120M · announced Jan 7, 2025
Source quote
  • Jan 7, 2025 · Company release ↗
    “CeQur ® , a medical device company dedicated to simplifying insulin delivery for individuals on multiple daily injections, today announced the successful close of a $120 million financing round”
Jan 7, 2025Company release ↗
Peptinovo BiopharmaSeries A · $1.4M · announced Dec 19, 2024
Source quote
  • Dec 19, 2024 · Company release ↗
    “Biotech firm’s nanotechnology aims to enhance cancer treatment efficacy, reduce side effects Dec. 19, 2024, Ann Arbor, Michigan [Press Release] Peptinovo Biopharma, an Ann Arbor-based biopharma company, has successfully closed $1.4 million in funding as part of its Series A round”
Dec 19, 2024Company release ↗
Alessa Therapeutics, Inc.Seed · $15M · announced Dec 12, 2024
Source quote
  • Dec 12, 2024 · Company release ↗
    “Alessa Therapeutics Announces Closing $15M Seed Financing”
Dec 12, 2024Company release ↗
OkogenUndisclosed round · $3.3M · announced Dec 11, 2024
Source quote
  • Dec 11, 2024 · Company release ↗
    “Plano, TX – December 11, 2024 – Okogen Inc. , a company specializing in innovative eyecare solutions, today announced the successful completion of $3.3 million in financing”
Dec 11, 2024Company release ↗
Noema Pharma AGSeries B · $147M (converted from CHF) · announced Dec 11, 2024
Source quote
  • Dec 11, 2024 · Company release ↗
    “Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)”
Dec 11, 2024Company release ↗
Nuvig TherapeuticsSeries B · $161M · announced Dec 5, 2024
Source quote
  • Dec 5, 2024 · Company release ↗
    “Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel”
Dec 5, 2024Company release ↗
ViTToria BiotherapeuticsUndisclosed round · $25M · announced Nov 22, 2024
Source quote
  • Nov 22, 2024 · Company release ↗
    “Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates Funding to support clinical proof-of-concept for the lead program”
Nov 22, 2024Company release ↗
Enveda BiosciencesSeries C · $130M · announced Nov 21, 2024
Source quote
  • Nov 21, 2024 · Company release ↗
    “Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates Enveda”
Nov 21, 2024Company release ↗
Synapticure Inc.Series A · $25M · announced Nov 19, 2024
Source quote
  • Nov 19, 2024 · Company release ↗
    “- Synapticure , a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with Alzheimer’s and related dementias, Parkinson’s, and other neurodegenerative diseases, today announced the successful close of its $25 million Series A funding round”
Nov 19, 2024Company release ↗
NOWDiagnostics, Inc.Series B · $22.5M · announced Nov 19, 2024
Source quote
  • Nov 19, 2024 · Company release ↗
    “NOWDiagnostics Secures $22.5 Million in Series B Funding”
Nov 19, 2024Company release ↗
Avenzo TherapeuticsSeries A · amount not disclosed · announced Nov 18, 2024
Source quote
  • Nov 18, 2024 · Company release ↗
    “In addition, Avenzo has closed the final tranche of an oversubscribed Series A/A-1 financing, adding three new investors.”
Nov 18, 2024Company release ↗
Tiziana Life Sciences LTDUndisclosed round · up to about $10M · announced Oct 31, 2024
Source quote
  • Oct 31, 2024 · Company release ↗
    “Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million”
Oct 31, 2024Company release ↗
Leal TherapeuticsUndisclosed round · $45M · announced Oct 30, 2024
Source quote
  • Oct 30, 2024 · Company release ↗
    “-- Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), today announced a $45 million financing”
Oct 30, 2024Company release ↗
Axonis TherapeuticsSeries A · $115M · announced Oct 30, 2024
Source quote
  • Oct 30, 2024 · Company release ↗
    “– Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing”
Oct 30, 2024Company release ↗
CytoTronicsSeed · $13.5M · announced Oct 25, 2024
Source quote
  • Oct 25, 2024 · Company release ↗
    “CytoTronics Secures $13.5M Series Seed 2 Financing to Speed Market Entry of Pixel System for Breakthroughs in Cell Biology”
Oct 25, 2024Company release ↗
ViTToria BiotherapeuticsUndisclosed round · more than $15M · announced Oct 12, 2024
Source quote
  • Oct 12, 2024 · Company release ↗
    “Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies Funds to support advancement of lead candidate”
Oct 12, 2024Company release ↗
Arda TherapeuticsSeries A · $43M · announced Oct 9, 2024
Source quote
  • Oct 9, 2024 · Company release ↗
    “Arda as chief scientific officer October 09, 2024 08:00 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, today announced the successful completion of a $43 million Series A financing round”
Oct 9, 2024Company release ↗
Cellipont BioservicesUndisclosed round · amount not disclosed · announced Oct 7, 2024
Source quote
  • Oct 7, 2024 · Company release ↗
    “Head’s CEO role, Cellipont today announces a minority growth equity investment from HealthQuest Capital, a leading growth investor partnering with transformative healthcare companies.”
Oct 7, 2024Company release ↗
Triveni BioSeries B · $115M · announced Oct 2, 2024
Source quote
  • Oct 2, 2024 · Company release ↗
    “– Triveni … Bio Inc., a biotech company advancing novel antibody treatments for I&I disorders, today announced a $115 million Series B to support pipeline expansion.”
Oct 2, 2024Company release ↗
858 TherapeuticsSeries B · $50M · announced Sep 26, 2024
Source quote
  • Sep 26, 2024 · Company release ↗
    “The latest company announcements, milestones, publications, and presentations 858 Therapeutics Announces $50 Million Series B Financing — Round led by Avidity Partners with participation from Insight Capital”
Sep 26, 2024Company release ↗
VerImmunePre-Series A · $4.5M · announced Sep 23, 2024
Source quote
  • Sep 23, 2024 · Company release ↗
    “-- VerImmune Inc., ("VerImmune"), a venture-backed biotechnology company developing a groundbreaking Virus-inspired Particle (ViP™) platform technology, today announced the successful first closing of $4.5 million in its Pre-Series A financing round”
Sep 23, 2024Company release ↗
ARZEDA Corp.Undisclosed round · $38M · announced Sep 17, 2024
Source quote
  • Sep 17, 2024 · Company release ↗
    “Arzeda closes a $38M oversubscribed funding round with new investors Sofinnova Partners”
Sep 17, 2024Company release ↗
Nura BioSeries A · $68M · announced Sep 17, 2024
Source quote
  • Sep 17, 2024 · Company release ↗
    “Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million”
Sep 17, 2024Company release ↗
ONL TherapeuticsSeries D · $65M · announced Sep 13, 2024
Source quote
  • Sep 13, 2024 · Company release ↗
    “ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN”
Sep 13, 2024Company release ↗
Catalyst OrthoScienceUndisclosed round · $20M · announced Sep 10, 2024
Source quote
  • Sep 10, 2024 · Company release ↗
    “Catalyst OrthoScience Surpasses 10,000 Total Shoulder Arthroplasty (TSA) Procedures and Announces $20 Million Financing”
Sep 10, 2024Company release ↗
Toi Labs, Inc.Strategic · amount not disclosed · announced Sep 10, 2024
Source quote
  • Sep 10, 2024 · Company release ↗
    “Toi Labs Announces Strategic Investment from TOTO September 10, 2024 – San Francisco, CA – Toi Labs, Inc., a pioneering technology company advancing at-home health monitoring through innovative bathroom solutions, today announced a strategic investment from TOTO Ltd.”
Sep 10, 2024Company release ↗
Harmonia Holding Group, LLCStrategic · amount not disclosed · announced Sep 9, 2024
Source quote
  • Sep 9, 2024 · Company release ↗
    “Strategic Investment in Harmonia Holdings Group; Industry Veteran Damon Griggs joins Harmonia as CEO and Chairman MDP investment to accelerate Harmonia’s strategy to become a leading digital transformation provider for the U.S”
Sep 9, 2024Company release ↗
CSA MedicalSeries D · $53M · announced Sep 9, 2024
Source quote
  • Sep 9, 2024 · Company release ↗
    “— CSA Medical Inc., developer of The RejuvenAir® System, a Breakthrough Medical Device advancing the power of liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis, today announced the completion of an oversubscribed $53 million Series D preferred stock equity financing”
Sep 9, 2024Company release ↗
Arsenal BiosciencesSeries C · $325M · announced Sep 4, 2024
Source quote
  • Sep 4, 2024 · Company release ↗
    “(ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round.”
Sep 4, 2024Company release ↗
Navigator MedicinesSeries A · $100M · announced Aug 27, 2024
Source quote
  • Aug 27, 2024 · Company release ↗
    “In connection with the transaction, Navigator has closed a $100M Series A financing, co-led by RA Capital Management and Forbion.”
Aug 27, 2024Company release ↗
Diakonos OncologySeed · $11.4M · announced Aug 26, 2024
Source quote
  • Aug 26, 2024 · Company release ↗
    “Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance Its Highly Differentiated Dendritic Cell Vaccine (DOC1021) into a Phase 2 Clinical Trial”
Aug 26, 2024Company release ↗
Nammi TherapeuticsSeries B · $30M · announced Aug 7, 2024
Source quote
  • Aug 7, 2024 · Company release ↗
    “Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of our lead program”
Aug 7, 2024Company release ↗
SpineologySeries AA · $25M · announced Aug 6, 2024
Source quote
  • Aug 6, 2024 · Company release ↗
    “Spineology, the medical technology company pioneering Conform and Expand™ technology, today announced that it has raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing investor, RC Capital.”
Aug 6, 2024Company release ↗
Seed TherapeuticsSeries A · $24M · announced Aug 6, 2024
Source quote
  • Aug 6, 2024 · Company release ↗
    “Concurrently, SEED has launched Series A-3 financing with a first close of $24 million from investors”
Aug 6, 2024Company release ↗
Outpace BioSeries B · $144M · announced Aug 1, 2024
Source quote
  • Aug 1, 2024 · Company release ↗
    “With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies”
Aug 1, 2024Company release ↗
MinderaConvertible note · $14M · announced Jul 31, 2024
Source quote
  • Jul 31, 2024 · Company release ↗
    “San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE ) — Mindera Health Inc. announces the closing of a $14M convertible note financing”
Jul 31, 2024Company release ↗
LTZ TherapeuticsSeries A · more than $20M · announced Jul 30, 2024
Source quote
  • Jul 30, 2024 · Company release ↗
    “– LTZ Therapeutics , an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases”
Jul 30, 2024Company release ↗
Imperative CareSeries E · up to $150M · announced Jul 25, 2024
Source quote
  • Jul 25, 2024 · Company release ↗
    “Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors”
Jul 25, 2024Company release ↗
Autobahn TherapeuticsSeries C · $100M · announced Jul 24, 2024
Source quote
  • Jul 24, 2024 · Company release ↗
    “– Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the closing of an oversubscribed $100 million Series C financing led by Newpath Partners”
Jul 24, 2024Company release ↗
Brenig TherapeuticsSeries A · $65M · announced Jul 23, 2024
Source quote
  • Jul 23, 2024 · Company release ↗
    “Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson’s Disease Pipeline”
Jul 23, 2024Company release ↗
Cardurion PharmaceuticalsSeries B · $260M · announced Jul 17, 2024
Source quote
  • Jul 17, 2024 · Company release ↗
    “Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases”
Jul 17, 2024Company release ↗
Beacon TherapeuticsSeries B · $170M · announced Jul 3, 2024
Source quote
  • Jul 3, 2024 · Company release ↗
    “Beacon … Mass., July 3, 2024 – Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced it has raised $170 million in Series B”
Jul 3, 2024Company release ↗
ROSE DiagnosticsSeed · $1M · announced Jun 27, 2024
Source quote
  • Jun 27, 2024 · Company release ↗
    “Carlsbad, California – June 27th 2024 ROSE Diagnostics, an innovative leader in rapid cancer diagnostics, today announced the successful completion of its seed round, securing $1 million through a Reg D financing”
Jun 27, 2024Company release ↗
InsightecUndisclosed round · $150M · announced Jun 18, 2024
Source quote
  • Jun 18, 2024 · Company release ↗
    “Bridge Group Co-Lead Robust Investor Syndicate HAIFA, Israel and MIAMI , June 18, 2024 — Insightec , a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced it has raised $150 million in equity financing”
Jun 18, 2024Company release ↗
Enveda BiosciencesSeries B · $55M · announced Jun 14, 2024
Source quote
  • Jun 14, 2024 · Company release ↗
    “Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials BOULDER, Colo.–( BUSINESS WIRE )–Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new financing round”
Jun 14, 2024Company release ↗
AlzheonSeries E · $100M · announced Jun 12, 2024
Source quote
  • Jun 12, 2024 · Company release ↗
    “Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease”
Jun 12, 2024Company release ↗
Envisagenics Inc.Series B · amount not disclosed · announced Jun 5, 2024
Source quote
  • Jun 5, 2024 · Company release ↗
    “New York, NY (June 5, 2024) – Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire”
Jun 5, 2024Company release ↗
Osteal TherapeuticsSeries D · $50M · announced Jun 5, 2024
Source quote
  • Jun 5, 2024 · Company release ↗
    “Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate Financing led by Zimmer Biomet with participation from existing investors Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners, and HM Capital.”
Jun 5, 2024Company release ↗
SofieGrowth · amount not disclosed · announced Jun 4, 2024
Source quote
  • Jun 4, 2024 · Company release ↗
    “NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity firm, announced today that it has made a substantial growth investment in SOFIE Biosciences (“SOFIE” or the “Company”)”
Jun 4, 2024Company release ↗
CinRx PharmaUndisclosed round · $73M · announced May 30, 2024
Source quote
  • May 30, 2024 · Company release ↗
    “CinRx Pharma Announces Additional $73 Million Financing”
May 30, 2024Company release ↗
Fuse DiagnosticsSeed · $1.6M (converted from GBP) · announced May 29, 2024
Source quote
  • May 29, 2024 · Company release ↗
    “Fuse Diagnostics has today announced that it has completed an oversubscribed seed investment round – raising a total of £1.6 million from a syndicate of angel investors and innovation agency Innovate UK.”
May 29, 2024Company release ↗
NeuraNova (Formerly StrokeDx)Seed · $5M · announced May 23, 2024
Source quote
  • May 23, 2024 · Company release ↗
    “May 23, 2024 - StrokeDx , a pioneer in next-generation stroke technology, today announced the successful closing of $5 million in Series Seed Prime funding”
May 23, 2024Company release ↗
Vaxess Technologies Inc.Undisclosed round · $12M · announced May 22, 2024
Source quote
May 22, 2024Company release ↗
PolarityBioUndisclosed round · $12.5M · announced May 20, 2024
Source quote
  • May 20, 2024 · Company release ↗
    “SALT LAKE CITY, May 20th, 2024 – PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in equity financing from institutional investors and current shareholders.”
May 20, 2024Company release ↗
CinDome PharmaSeries B extension · $40M · announced May 16, 2024
Source quote
  • May 16, 2024 · Company release ↗
    “CINCINNATI – May 16, 2024 – CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension”
May 16, 2024Company release ↗
CENTOGENEUndisclosed round · $20M · announced May 15, 2024
Source quote
  • May 15, 2024 · Company release ↗
    “CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position”
May 15, 2024Company release ↗
CereVascSeries B · $70M · announced May 13, 2024
Source quote
  • May 13, 2024 · Company release ↗
    “— CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced today it has successfully completed the initial closing of a $70 Million Series B financing”
May 13, 2024Company release ↗
Lycia TherapeuticsSeries C · $106.6M · announced May 13, 2024
Source quote
  • May 13, 2024 · Company release ↗
    “Lycia … from financing to progress its lead programs into the clinic for autoimmune and inflammatory diseases SOUTH SAN FRANCISCO, CA, May 13, 2024 – Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the completion of an oversubscribed $106.6 million Series C”
May 13, 2024Company release ↗
Zenas BioPharmaSeries C · $200M · announced May 7, 2024
Source quote
  • May 7, 2024 · Company release ↗
    “Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and”
May 7, 2024Company release ↗
Reunion NeuroscienceSeries A · $103M · announced May 2, 2024
Source quote
  • May 2, 2024 · Company release ↗
    “Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with underserved”
May 2, 2024Company release ↗
AdaptilensSeries A · $17.5M · announced Apr 29, 2024
Source quote
  • Apr 29, 2024 · Company release ↗
    “BOSTON, April 29, 2024 /PRNewswire/ — Adaptilens, Inc., a pre-clinical company dedicated to transforming the standard of care for cataract surgery, today announced the closing of a Series A financing round of $17.5 million led by Perceptive Xontogeny Venture Funds (PXV Funds)”
Apr 29, 2024Company release ↗
Endeavor BioMedicinesSeries C · $132.5M · announced Apr 24, 2024
Source quote
  • Apr 24, 2024 · Company release ↗
    “Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines – Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis”
Apr 24, 2024Company release ↗
Asher BiotherapeuticsSeries C · $55M · announced Apr 16, 2024
Source quote
  • Apr 16, 2024 · Company release ↗
    “Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials – Proceeds will fund further development of AB248”
Apr 16, 2024Company release ↗
Nectero TherapeuticsSeries D · $96M · announced Apr 11, 2024
Source quote
  • Apr 11, 2024 · Company release ↗
    “TEMPE, Ariz.–( BUSINESS WIRE )– Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round.”
Apr 11, 2024Company release ↗
NKGEN BiotechUndisclosed round · $5M · announced Apr 11, 2024
Source quote
  • Apr 11, 2024 · Company release ↗
    “(Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has closed $5 million in second lien convertible loan”
Apr 11, 2024Company release ↗
RenalytixUndisclosed round · up to $4M · announced Apr 8, 2024
Source quote
  • Apr 8, 2024 · Company release ↗
    “Renalytix Announces Financing with Expected Size of up to $4 Million”
Apr 8, 2024Company release ↗
MedcuraUndisclosed round · $22.4M · announced Apr 3, 2024
Source quote
  • Apr 3, 2024 · Company release ↗
    “Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio”
Apr 3, 2024Company release ↗
Avenzo TherapeuticsSeries A · $150M · announced Mar 26, 2024
Source quote
  • Mar 26, 2024 · Company release ↗
    “Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline”
Mar 26, 2024Company release ↗
X-ThermaSeries B · $22.4M · announced Mar 13, 2024
Source quote
  • Mar 13, 2024 · Company release ↗
    “SAN FRANCISCO, March 13, 2024 /PRNewswire/ — X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has completed an oversubscribed $22.4 million Series B funding round”
Mar 13, 2024Company release ↗
Vescent Technologies Inc.Seed · $5M · announced Mar 7, 2024
Source quote
  • Mar 7, 2024 · Company release ↗
    “Vescent Announces $5M in Series Seed Funding Led by Corporate Fuel”
Mar 7, 2024Company release ↗
BrainCheck, Inc.Undisclosed round · $15M · announced Mar 6, 2024
Source quote
  • Mar 6, 2024 · Company release ↗
    “AUSTIN, Texas, March 6, 2024 – BrainCheck, Inc. , a digital health innovator delivering first-of-its-kind technology into the growing digital cognitive assessment market, today announced a $15 million new financing round”
Mar 6, 2024Company release ↗
Shape Memory MedicalUndisclosed round · $38M · announced Mar 5, 2024
Source quote
  • Mar 5, 2024 · Company release ↗
    “Shape Memory Medical Completes $38 Million in Financing to Advance Endovascular Embolization”
Mar 5, 2024Company release ↗
Bone Health TechnologiesUndisclosed round · $5M · announced Mar 4, 2024
Source quote
  • Mar 4, 2024 · Company release ↗
    “Redwood City, CA, March 4, 2024 – Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a new $5 million funding round from leading investment firms”
Mar 4, 2024Company release ↗
Nocion TherapeuticsSeries B · $62M · announced Mar 4, 2024
Source quote
  • Mar 4, 2024 · Company release ↗
    “Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development Financing led by new investors Arkin Bio Capital and Monograph Capital Participation from additional new and existing investors and a strategic Financing will support a global”
Mar 4, 2024Company release ↗
Pelage PharmaceuticalsSeries A · $16.75M · announced Feb 27, 2024
Source quote
  • Feb 27, 2024 · Company release ↗
    “Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss”
Feb 27, 2024Company release ↗
Frontier Medicines CorporationSeries C · $80M · announced Feb 22, 2024
Source quote
  • Feb 22, 2024 · Company release ↗
    “Frontier Medicines Announces Oversubscribed $80 Million Series C”
Feb 22, 2024Company release ↗
Cagent VascularSeries C · more than $30M · announced Feb 19, 2024
Source quote
  • Feb 19, 2024 · Company release ↗
    “Funds will be used to accelerate US market adoption and to expand the product portfolio of the first and only Serration Angioplasty Technology (Wayne, PA) Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M.”
Feb 19, 2024Company release ↗
Sudo BiosciencesSeries B (second close) · $30M · announced Feb 13, 2024
Source quote
  • Feb 13, 2024 · Company release ↗
    “today announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million”
Feb 13, 2024Company release ↗
Neurona TherapeuticsUndisclosed round · $120M · announced Feb 8, 2024
Source quote
  • Feb 8, 2024 · Company release ↗
    “Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders – The financing”
Feb 8, 2024Company release ↗
AttralusUndisclosed round · $56M · announced Feb 6, 2024
Source quote
Feb 6, 2024Company release ↗
HumabiologicsSeed · $1M · announced Feb 5, 2024
Source quote
  • Feb 5, 2024 · Company release ↗
    “A $1 million seed funding is taking Humabiologics, Inc. closer to the market with its unique biomedical product.”
Feb 5, 2024Company release ↗
ProcyrionSeries E · $57.7M · announced Feb 5, 2024
Source quote
Feb 5, 2024Company release ↗
Adipo TherapeuticsSeed · $1.9M · announced Feb 1, 2024
Source quote
  • Feb 1, 2024 · Company release ↗
    “Adipo Therapeutics completes $1.9M seed funding bridge to advance obesity treatment”
Feb 1, 2024Company release ↗
Basking BiosciencesUndisclosed round · $55M · announced Jan 30, 2024
Source quote
  • Jan 30, 2024 · Company release ↗
    “Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing”
Jan 30, 2024Company release ↗
Circular GenomicsSeries A · $8.3M · announced Jan 24, 2024
Source quote
  • Jan 24, 2024 · Company release ↗
    “Albuquerque, New Mexico, January 24, 2024 - Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the closing of an $8.3 Million Series A investment round”
Jan 24, 2024Company release ↗
BreezeBioSeries A · $24M · announced Jan 23, 2024
Source quote
  • Jan 23, 2024 · Company release ↗
    “SOUTH SAN FRANCISCO, Calif., January 23, 2024 – GenEdit, Inc. , a developer of genetic medicines that leverage its NanoGalaxy ® platform for tissue-selective delivery, today announced that it has raised $24 million in a Series A1 financing.”
Jan 23, 2024Company release ↗
Cyrano TherapeuticsSeries B · $9M · announced Jan 16, 2024
Source quote
  • Jan 16, 2024 · Company release ↗
    “Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss”
Jan 16, 2024Company release ↗
OnCusp TherapeuticsSeries A · $100M · announced Jan 4, 2024
Source quote
  • Jan 4, 2024 · Company release ↗
    “OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients”
Jan 4, 2024Company release ↗
Radionetics OncologySeries A · $52.5M · announced Jan 3, 2024
Source quote
  • Jan 3, 2024 · Company release ↗
    “Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader”
Jan 3, 2024Company release ↗
Sudo BiosciencesSeries B · $116M · announced Dec 20, 2023
Source quote
  • Dec 20, 2023 · Company release ↗
    “CARMEL, IN – December 20, 2023: Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which”
Dec 20, 2023Company release ↗
Lassen TherapeuticsSeries B · $85M · announced Dec 19, 2023
Source quote
  • Dec 19, 2023 · Company release ↗
    “19 December 2023 | Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B”
Dec 19, 2023Company release ↗
Cadenza BioSeed · $2.44M · announced Dec 14, 2023
Source quote
  • Dec 14, 2023 · Company release ↗
    “(Cadenza), a privately-held biotechnology company focused on developing novel small molecule compounds for demyelinating and inflammatory diseases, has announced the initial closing of an oversubscribed $2.44M Series Seed financing”
Dec 14, 2023Company release ↗
Zepto Life TechnologySeries A · amount not disclosed · announced Dec 14, 2023
Source quote
  • Dec 14, 2023 · Company release ↗
    “Zepto Life Technology (“Zepto”) is thrilled to announce the successful closing of its oversubscribed Series A funding round from Huimei Healthcare”
Dec 14, 2023Company release ↗
Diasome PharmaceuticalsSeries C · amount not disclosed · announced Dec 7, 2023
Source quote
  • Dec 7, 2023 · Company release ↗
    “-- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell targeting platform to develop innovative therapies for diabetes, obesity, and other metabolic disorders, has announced the first closing of its Series C financing today”
Dec 7, 2023Company release ↗
Seismic TherapeuticSeries B · $121M · announced Dec 4, 2023
Source quote
  • Dec 4, 2023 · Company release ↗
    “Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform”
Dec 4, 2023Company release ↗
GelSana TherapeuticsSeed · amount not disclosed · announced Nov 30, 2023
Source quote
  • Nov 30, 2023 · Company release ↗
    “GelSana Announces Initial Close on Second Seed Priced Round”
Nov 30, 2023Company release ↗
Aro BiotherapeuticsSeries B · $41.5M · announced Nov 28, 2023
Source quote
  • Nov 28, 2023 · Company release ↗
    “Philadelphia, PA, November 28, 2023 --- Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round”
Nov 28, 2023Company release ↗
Nature's ToolboxSeries B · $47.5M · announced Nov 16, 2023
Source quote
  • Nov 16, 2023 · Company release ↗
    “Nature’s Toolbox Raises $47.5 M in Series B Funding to Advance Next Generation Biomanufacturing”
Nov 16, 2023Company release ↗
ProJenXSeries A · $15M · announced Nov 2, 2023
Source quote
  • Nov 2, 2023 · Company release ↗
    “ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors NEW YORK”
Nov 2, 2023Company release ↗
Terremoto BiosciencesSeries B · $175M · announced Nov 2, 2023
Source quote
  • Nov 2, 2023 · Company release ↗
    “– Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round”
Nov 2, 2023Company release ↗
Forward TherapeuticsSeries A · $50M · announced Oct 31, 2023
Source quote
  • Oct 31, 2023 · Company release ↗
    “Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Forward Therapeutics”
Oct 31, 2023Company release ↗
Terremoto BiosciencesSeries B · $175M · announced Oct 31, 2023
Source quote
  • Oct 31, 2023 · Company release ↗
    “Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round”
  • Nov 2, 2023 · Company release ↗
    “– Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round”
Oct 31, 2023Company release ↗

Deals (106)

CompanyWhat was announcedDateSource
insitroAstraZeneca deal · $40M upfront · announced Oct 15, 2026
Source quote
  • Oct 15, 2026 · Company release ↗
    “Collaboration applies insitro’s Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical need insitro to receive $40 million upfront and up to approximately $1.46 billion in potential discovery”
Oct 15, 2026Company release ↗
Chai DiscoveryGSK deal · amount not disclosed · announced Oct 9, 2026
Source quote
  • Oct 9, 2026 · Company release ↗
    “Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with biopharma company GSK following a successful technology evaluation”
Oct 9, 2026Company release ↗
Gate BioscienceDeal · up to $870M total · announced Oct 5, 2026
Source quote
  • Oct 5, 2026 · Company release ↗
    “The total potential value of the agreement could exceed $870 million, contingent on the achievement of milestones.”
Oct 5, 2026Company release ↗
Dualitas TherapeuticsRoche deal · amount not disclosed · announced Sep 17, 2026
Source quote
  • Sep 17, 2026 · Company release ↗
    “South San Francisco, CA – September 17, 2026 – Dualitas Therapeutics, Inc. , a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammation (“I&I”) indications, today announced a research collaboration”
Sep 17, 2026Company release ↗
OwkinServier deal · amount not disclosed · announced Sep 11, 2026
Source quote
  • Sep 11, 2026 · Company release ↗
    “NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier”
Sep 11, 2026Company release ↗
OwkinBoehringer Ingelheim deal · amount not disclosed · announced Sep 2, 2026
Source quote
  • Sep 2, 2026 · Company release ↗
    “NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro”
Sep 2, 2026Company release ↗
Weave BioTakeda deal · amount not disclosed · announced Sep 1, 2026
Source quote
  • Sep 1, 2026 · Company release ↗
    “Weave Bio announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets”
Sep 1, 2026Company release ↗
TevaDeal · $57.5M · announced Aug 28, 2026
Source quote
  • Aug 28, 2026 · Company release ↗
    “Under the terms of the Agreement, Teva would acquire worldwide rights to the assets including dexmedetomidine sublingual film for an upfront payment of $57.5 million and up to an additional $67.5 million in contingent payments.”
Aug 28, 2026Company release ↗
DeepcellGilead deal · amount not disclosed · announced Aug 20, 2026
Source quote
  • Aug 20, 2026 · Company release ↗
    “Deepcell, a pioneer in AI-powered, label-free single-cell morphology analysis company, today announced a collaboration with Gilead Sciences”
Aug 20, 2026Company release ↗
Chai DiscoveryBristol Myers Squibb deal · amount not disclosed · announced Aug 20, 2026
Source quote
  • Aug 20, 2026 · Company release ↗
    “Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence”
Aug 20, 2026Company release ↗
Actio BiosciencesJazz Pharmaceuticals deal · $820M upfront · announced Aug 10, 2026
Source quote
  • Aug 10, 2026 · Company release ↗
    “Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration”
Aug 10, 2026Company release ↗
GenprexRoche deal · amount not disclosed · announced Aug 3, 2026
Source quote
  • Aug 3, 2026 · Company release ↗
    “Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies”
Aug 3, 2026Company release ↗
Relation TherapeuticsGSK deal · amount not disclosed · announced Jul 30, 2026
Source quote
Jul 30, 2026Company release ↗
Phanes TherapeuticsDeal · amount not disclosed · announced Jul 21, 2026
Source quote
  • Jul 21, 2026 · Company release ↗
    “Phanes Therapeutics announces expansion of clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for”
Jul 21, 2026Company release ↗
Halozyme TherapeuticsIncyte deal · amount not disclosed · announced Jul 20, 2026
Source quote
  • Jul 20, 2026 · Company release ↗
    “Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology”
Jul 20, 2026Company release ↗
Chai DiscoveryNovartis deal · amount not disclosed · announced Jul 13, 2026
Source quote
  • Jul 13, 2026 · Company release ↗
    “Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Novartis to advance the discovery of therapeutic antibodies using artificial intelligence”
Jul 13, 2026Company release ↗
TevaDeal · amount not disclosed · announced Jul 9, 2026
Source quote
  • Jul 9, 2026 · Company release ↗
    “Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis”
Jul 9, 2026Company release ↗
NovartisDeal · $1.1B · announced Jul 6, 2026
Source quote
  • Jul 6, 2026 · Company release ↗
    “Transaction Details Under the terms of the agreement, Novartis will pay USD 1.1bn upfront, with up to USD 400m in potential milestone payments to acquire Myricx Bio.”
Jul 6, 2026Company release ↗
CilcareDeal · amount not disclosed · announced Jun 23, 2026
Source quote
  • Jun 23, 2026 · Company release ↗
    “Montpellier, France, Paris, France and Boston, USA – June 23, 2026 – Cilcare, a biotechnology company focused on developing novel therapies for hearing disorders, announces an update of its license agreement covering its two lead programs, CIL001 and CIL003, on improved financial terms, alongside”
Jun 23, 2026Company release ↗
OtsukaDeal · $700M · announced Jun 12, 2026
Source quote
  • Jun 12, 2026 · Company release ↗
    “Under the terms of the agreement, Otsuka paid $700 million to Transcend shareholders at closing, with up to $525 million in additional contingent consideration based on future sales related to assets in development.”
Jun 12, 2026Company release ↗
OwkinSanofi deal · amount not disclosed · announced Jun 5, 2026
Source quote
  • Jun 5, 2026 · Company release ↗
    “NEW YORK & PARIS - 5th June, 2026 - Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents”
Jun 5, 2026Company release ↗
OwkinAstraZeneca deal · amount not disclosed · announced May 13, 2026
Source quote
  • May 13, 2026 · Company release ↗
    “Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement”
May 13, 2026Company release ↗
Cellular Intelligence (Formerly Somite)Novo Nordisk deal · amount not disclosed · announced May 11, 2026
Source quote
  • May 11, 2026 · Company release ↗
    “We have entered into an agreement with Novo Nordisk to acquire STEM-PD”
May 11, 2026Company release ↗
TevaDeal · $700M · announced Apr 29, 2026
Source quote
  • Apr 29, 2026 · Company release ↗
    “Upon closing, Teva will pay $700 million, and Emalex’s shareholders will be eligible to receive up to $200 million based on future commercial milestones as well as royalties on global net sales of ecopipam, subject to regulatory approval.”
Apr 29, 2026Company release ↗
Imagene AIDaiichi Sankyo deal · amount not disclosed · announced Apr 9, 2026
Source quote
  • Apr 9, 2026 · Company release ↗
    “Imagene AI , a pioneer in multimodal AI for precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) to advance biomarker discovery and response prediction in oncology drug development”
Apr 9, 2026Company release ↗
Dyno TherapeuticsDeal · $15M · announced Apr 8, 2026
Source quote
  • Apr 8, 2026 · Company release ↗
    “Under the terms of the 2021 collaboration agreement, Astellas will pay Dyno a $15 million license fee and will be responsible for preclinical, clinical, and commercialization activities for gene therapy candidates using the licensed capsid.”
Apr 8, 2026Company release ↗
Alloy TherapeuticsBiogen deal · amount not disclosed · announced Apr 7, 2026
Source quote
  • Apr 7, 2026 · Company release ↗
    “Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform”
Apr 7, 2026Company release ↗
Quotient TherapeuticsMerck deal · amount not disclosed · announced Mar 24, 2026
Source quote
  • Mar 24, 2026 · Company release ↗
    “CAMBRIDGE , Mass., March 24 , 2026 – Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck”
Mar 24, 2026Company release ↗
insitroBristol Myers Squibb deal · amount not disclosed · announced Mar 23, 2026
Source quote
  • Mar 23, 2026 · Company release ↗
    “– – insitro … the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS).”
Mar 23, 2026Company release ↗
Ouro MedicinesGilead deal · $1.68B · announced Mar 23, 2026
Source quote
  • Mar 23, 2026 · Company release ↗
    “Under the terms of the agreement Gilead will acquire all of the outstanding equity of Ouro Medicines for a total of $1,675 million in upfront cash consideration”
Mar 23, 2026Company release ↗
Synnovation TherapeuticsNovartis deal · $2B upfront · announced Mar 20, 2026
Source quote
  • Mar 20, 2026 · Company release ↗
    “Novartis to acquire Synnovation Therapeutics’s pan-mutant selective PI3Kα inhibitor program - Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 billion in development”
Mar 20, 2026Company release ↗
Mirecule Inc.Sanofi deal · amount not disclosed · announced Mar 18, 2026
Source quote
  • Mar 18, 2026 · Company release ↗
    “GAITHERSBURG, Md.–( BUSINESS WIRE )–Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi”
Mar 18, 2026Company release ↗
LeveragenDaiichi Sankyo deal · amount not disclosed · announced Mar 18, 2026
Source quote
  • Mar 18, 2026 · Company release ↗
    “BOSTON, Mass. – March 18, 2026 — Leveragen , a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today announced a collaboration agreement with Daiichi Sankyo (TSE: 4568) to support research efforts in advanced biologics”
Mar 18, 2026Company release ↗
Sinopia BiosciencesOno Pharmaceutical deal · amount not disclosed · announced Mar 3, 2026
Source quote
  • Mar 3, 2026 · Company release ↗
    “SAN DIEGO, March 03, 2026 - Sinopia Biosciences, Inc. , a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced a target discovery collaboration with Ono Pharmaceutical Co.”
Mar 3, 2026Company release ↗
SynthekineMerck deal · amount not disclosed · announced Feb 26, 2026
Source quote
  • Feb 26, 2026 · Company release ↗
    “MENLO PARK, CA – February 26, 2026 – Synthekine Inc ., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada)”
Feb 26, 2026Company release ↗
EvinovaBristol Myers Squibb deal · amount not disclosed · announced Feb 9, 2026
Source quote
  • Feb 9, 2026 · Company release ↗
    “Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency BAAR, Switzerland, [9 February 2026] – Evinova”
Feb 9, 2026Company release ↗
Iambic TherapeuticsTakeda deal · amount not disclosed · announced Feb 9, 2026
Source quote
  • Feb 9, 2026 · Company release ↗
    “San Diego, CA and Cambridge, MA – February 9, 2026 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration”
Feb 9, 2026Company release ↗
SanegeneBioGenentech deal · amount not disclosed · announced Feb 2, 2026
Source quote
  • Feb 2, 2026 · Company release ↗
    “BOSTON, SHANGHAI, and SUZHOU – February 2, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global licensing agreement with Genentech”
Feb 2, 2026Company release ↗
Origami Therapeutics, Inc.Ipsen deal · amount not disclosed · announced Jan 30, 2026
Source quote
  • Jan 30, 2026 · Company release ↗
    “– Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases SAN DIEGO–( BUSINESS WIRE )– Origami Therapeutics”
Jan 30, 2026Company release ↗
Repertoire Immune MedicinesLilly deal · amount not disclosed · announced Jan 29, 2026
Source quote
  • Jan 29, 2026 · Company release ↗
    “Collaboration unites Repertoire’s DECODE ™ platform to develop T cell targeted immune medicines with Lilly’s commitment to bringing transformative medicines to patients with unmet need CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines,”
Jan 29, 2026Company release ↗
Isomorphic LabsJohnson & Johnson deal · amount not disclosed · announced Jan 20, 2026
Source quote
  • Jan 20, 2026 · Company release ↗
    “Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson”
Jan 20, 2026Company release ↗
AbelZeta PharmaAstraZeneca deal · amount not disclosed · announced Jan 19, 2026
Source quote
  • Jan 19, 2026 · Company release ↗
    “AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca”
Jan 19, 2026Company release ↗
AttralusBayer deal · amount not disclosed · announced Jan 12, 2026
Source quote
  • Jan 12, 2026 · Company release ↗
    “(Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m)”
Jan 12, 2026Company release ↗
SciNeuro PharmaceuticalsNovartis deal · amount not disclosed · announced Jan 12, 2026
Source quote
  • Jan 12, 2026 · Company release ↗
    “SciNeuro grants Novartis an exclusive worldwide license to develop SciNeuro’s novel antibody program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer’s Disease SciNeuro and Novartis will collaborate during early development”
Jan 12, 2026Company release ↗
InduPro, Inc.Lilly deal · amount not disclosed · announced Jan 7, 2026
Source quote
  • Jan 7, 2026 · Company release ↗
    “SEATTLE and CAMBRIDGE, MA— January 7, 2026 — InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement”
Jan 7, 2026Company release ↗
HelixGSK deal · amount not disclosed · announced Jan 7, 2026
Source quote
  • Jan 7, 2026 · Company release ↗
    “> Helix Announces Multi Year Strategic Collaboration With Gsk To Drive Precision Medicine Development SAN MATEO”
Jan 7, 2026Company release ↗
Nimbus TherapeuticsLilly deal · amount not disclosed · announced Jan 6, 2026
Source quote
  • Jan 6, 2026 · Company release ↗
    “Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment — New collaboration follows previous Lilly and Nimbus AMPK research collaboration in cardiometabolic disease — BOSTON”
Jan 6, 2026Company release ↗
OncoNano MedicineGilead deal · amount not disclosed · announced Jan 6, 2026
Source quote
  • Jan 6, 2026 · Company release ↗
    “OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate”
Jan 6, 2026Company release ↗
Valo HealthMerck deal · amount not disclosed · announced Nov 20, 2025
Source quote
  • Nov 20, 2025 · Company release ↗
    “Valo Health Announces Collaboration with Merck KGaA, Darmstadt,…”
Nov 20, 2025Company release ↗
Quotient TherapeuticsDeal · amount not disclosed · announced Nov 20, 2025
Source quote
  • Nov 20, 2025 · Company release ↗
    “First feasibility agreements under Flagship and GSK framework collaboration Agreements will utilize ProFound’s and Quotient’s platform technologies to discover and validate novel treatments for respiratory and liver diseases Cambridge, Mass.”
Nov 20, 2025Company release ↗
ProFound TherapeuticsDeal · amount not disclosed · announced Nov 20, 2025
Source quote
  • Nov 20, 2025 · Company release ↗
    “Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK”
Nov 20, 2025Company release ↗
Beacon BiosignalsTakeda deal · amount not disclosed · announced Nov 19, 2025
Source quote
  • Nov 19, 2025 · Company release ↗
    “Boston, MA – November 19, 2025 – Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda”
Nov 19, 2025Company release ↗
LTZ TherapeuticsGSK deal · amount not disclosed · announced Nov 19, 2025
Source quote
  • Nov 19, 2025 · Company release ↗
    “LTZ … Therapeutics (LTZ), an immunotherapy-focused biotechnology company based in Redwood City, California, today announced a strategic research collaboration to advance the development of novel myeloid cell engagers (MCEs) to address significant unmet need in oncology.”
Nov 19, 2025Company release ↗
Octant Inc.Bristol Myers Squibb deal · amount not disclosed · announced Nov 12, 2025
Source quote
  • Nov 12, 2025 · Company release ↗
    “Octant Enters Research Collaboration with Bristol Myers Squibb to Discover Novel Small Molecules for Neurodegenerative Diseases”
Nov 12, 2025Company release ↗
General ProximityDaiichi Sankyo deal · amount not disclosed · announced Nov 12, 2025
Source quote
  • Nov 12, 2025 · Company release ↗
    “San Francisco, CA – Nov. 12, 2025 – General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, today announced a strategic multi-target collaboration”
Nov 12, 2025Company release ↗
Manifold BioRoche deal · amount not disclosed · announced Nov 3, 2025
Source quote
  • Nov 3, 2025 · Company release ↗
    “Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases”
Nov 3, 2025Company release ↗
ModeX TherapeuticsRegeneron deal · up to $1B total · announced Oct 29, 2025
Source quote
  • Oct 29, 2025 · Company release ↗
    “Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — ModeX Therapeutics Inc.”
Oct 29, 2025Company release ↗
Ventus TherapeuticsDeal · amount not disclosed · announced Oct 21, 2025
Source quote
  • Oct 21, 2025 · Company release ↗
    “Ventus will receive an upfront payment and is eligible for further preclinical, development and commercial milestones exceeding $460 million plus tiered royalties on net sales.”
Oct 21, 2025Company release ↗
Arrowhead PharmaceuticalsNovartis deal · amount not disclosed · announced Oct 21, 2025
Source quote
  • Oct 21, 2025 · Company release ↗
    “Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis PASADENA”
Oct 21, 2025Company release ↗
Flare TherapeuticsMerck deal · amount not disclosed · announced Oct 21, 2025
Source quote
  • Oct 21, 2025 · Company release ↗
    “Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA ® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer”
Oct 21, 2025Company release ↗
insitroBristol Myers Squibb deal · amount not disclosed · announced Oct 14, 2025
Source quote
  • Oct 14, 2025 · Company release ↗
    “— insitro … a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE: BMY), today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS).”
Oct 14, 2025Company release ↗
Palatin TechnologiesBoehringer Ingelheim deal · amount not disclosed · announced Sep 22, 2025
Source quote
  • Sep 22, 2025 · Company release ↗
    “About the Collaboration On August 18, 2025 , Palatin entered into a strategic partnership with Boehringer Ingelheim to develop potential first-in-class melanocortin receptor–targeted treatments for patients with retinal diseases”
Sep 22, 2025Company release ↗
insitroLilly deal · amount not disclosed · announced Sep 9, 2025
Source quote
  • Sep 9, 2025 · Company release ↗
    “– insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules”
Sep 9, 2025Company release ↗
Arrowhead PharmaceuticalsNovartis deal · $200M · announced Sep 2, 2025
Source quote
  • Sep 2, 2025 · Company release ↗
    “Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA”
Sep 2, 2025Company release ↗
Kumquat BiosciencesBayer deal · amount not disclosed · announced Aug 12, 2025
Source quote
  • Aug 12, 2025 · Company release ↗
    “Berlin, Germany and San Diego, USA – Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor”
Aug 12, 2025Company release ↗
LTZ TherapeuticsEli Lilly deal · amount not disclosed · announced Jul 29, 2025
Source quote
  • Jul 29, 2025 · Company release ↗
    “Collaboration combines LTZ’s first-in-class Myeloid Engager Platform with Lilly’s world-class expertise in research, development and commercialization REDWOOD CITY, California and SHENZHEN, China – July 29, 2025 – LTZ Therapeutics ("LTZ")”
Jul 29, 2025Company release ↗
Gate BioscienceLilly deal · amount not disclosed · announced Jul 24, 2025
Source quote
  • Jul 24, 2025 · Company release ↗
    “Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company (“Lilly”) to discover”
Jul 24, 2025Company release ↗
ProFound TherapeuticsNovartis deal · amount not disclosed · announced Jun 26, 2025
Source quote
  • Jun 26, 2025 · Company release ↗
    “ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease”
Jun 26, 2025Company release ↗
Deep Apple TherapeuticsNovo Nordisk deal · up to $812M total · announced Jun 11, 2025
Source quote
  • Jun 11, 2025 · Company release ↗
    “Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases Deep Apple is eligible to receive up to $812 million, including an upfront payment”
Jun 11, 2025Company release ↗
Viz.aiNovartis deal · amount not disclosed · announced Jun 2, 2025
Source quote
  • Jun 2, 2025 · Company release ↗
    “Multi-year collaboration with Novartis to develop AI-powered workflows for prostate and breast cancer, helping to reach patients eligible to benefit from guideline-based precision treatments Marks strategic expansion for Viz.ai into oncology”
Jun 2, 2025Company release ↗
Telesis BioRegeneron deal · amount not disclosed · announced May 28, 2025
Source quote
  • May 28, 2025 · Company release ↗
    “Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis New technology has potential to accelerate timelines for therapeutic research and drug development SAN DIEGO–(BUSINESS WIRE)–May 28”
May 28, 2025Company release ↗
Viz.aiSanofi deal · amount not disclosed · announced May 20, 2025
Source quote
  • May 20, 2025 · Company release ↗
    “Companies will collaborate on an AI-powered care improvement solution for patients with high-risk COPD SAN FRANCISCO – May 20, 2025 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY)”
May 20, 2025Company release ↗
Creyon BioDeal · $13M · announced Apr 29, 2025
Source quote
  • Apr 29, 2025 · Company release ↗
    “Under the terms of the agreement, Creyon will receive a $13 million upfront payment, which includes cash and the purchase of Creyon equity, and Creyon is also eligible to receive over $1 billion in development and commercialization payments provided certain milestones are achieved.”
Apr 29, 2025Company release ↗
Circular GenomicsLilly deal · amount not disclosed · announced Mar 17, 2025
Source quote
  • Mar 17, 2025 · Company release ↗
    “Circular Genomics' move to the Lilly Gateway Labs community will enhance scientific collaboration and innovation to foster the development of its Alzheimer's disease diagnostic and prognostic blood tests SAN DIEGO”
Mar 17, 2025Company release ↗
ElegenGSK deal · amount not disclosed · announced Mar 9, 2025
Source quote
  • Mar 9, 2025 · Company release ↗
    “Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology GSK has signed a collaboration & licensing agreement to leverage Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines & medicines”
Mar 9, 2025Company release ↗
Stemline TherapeuticsMenarini deal · amount not disclosed · announced Feb 20, 2025
Source quote
  • Feb 20, 2025 · Company release ↗
    “Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next”
Feb 20, 2025Company release ↗
Alloy TherapeuticsDeal · amount not disclosed · announced Feb 11, 2025
Source quote
  • Feb 11, 2025 · Company release ↗
    “Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform”
Feb 11, 2025Company release ↗
NeomorphAbbVie deal · up to $1.64B total · announced Jan 23, 2025
Source quote
  • Jan 23, 2025 · Company release ↗
    “Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones”
Jan 23, 2025Company release ↗
Arsenal BiosciencesDeal · amount not disclosed · announced Jan 13, 2025
Source quote
  • Jan 13, 2025 · Company release ↗
    “Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs”
Jan 13, 2025Company release ↗
Stemline TherapeuticsDeal · $20M · announced Jan 10, 2025
Source quote
  • Jan 10, 2025 · Company release ↗
    “Under the terms of the agreement, Stemline will provide a $20 million upfront payment to Insilico.”
Jan 10, 2025Company release ↗
Mediar TherapeuticsLilly deal · $99M (upfront + near-term milestones) · announced Jan 10, 2025
Source quote
  • Jan 10, 2025 · Company release ↗
    “Under the terms of the agreement Mediar will receive a combined $99 million, which is inclusive of an upfront payment and near-term milestones”
Jan 10, 2025Company release ↗
Light Horse TherapeuticsNovartis deal · amount not disclosed · announced Jan 9, 2025
Source quote
  • Jan 9, 2025 · Company release ↗
    “SAN DIEGO–( BUSINESS WIRE )–Light Horse Therapeutics ® Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class therapeutics using the biotech’s platform”
Jan 9, 2025Company release ↗
Link Cell TherapiesJohnson & Johnson deal · amount not disclosed · announced Jan 9, 2025
Source quote
  • Jan 9, 2025 · Company release ↗
    “SOUTH SAN FRANCISCO, CA, January 9, 2025 — Link Cell Therapies (“Link”), an oncology cell therapy company, today announced a strategic collaboration with Johnson & Johnson* to develop novel logic-gated LINK CAR T therapies”
Jan 9, 2025Company release ↗
Capsida BiotherapeuticsAbbVie deal · up to $40M total · announced Jan 7, 2025
Source quote
  • Jan 7, 2025 · Company release ↗
    “Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties THOUSAND OAKS”
Jan 7, 2025Company release ↗
Alloy TherapeuticsSanofi deal · amount not disclosed · announced Jan 7, 2025
Source quote
  • Jan 7, 2025 · Company release ↗
    “Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi”
Jan 7, 2025Company release ↗
Photys TherapeuticsDeal · up to $186M total · announced Dec 18, 2024
Source quote
  • Dec 18, 2024 · Company release ↗
    “Under the terms of the agreement, Photys is eligible to receive up to $186M in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales.”
Dec 18, 2024Company release ↗
AI ProteinsBristol Myers Squibb deal · up to $400M total · announced Dec 3, 2024
Source quote
  • Dec 3, 2024 · Company release ↗
    “AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M”
Dec 3, 2024Company release ↗
Incyclix BioLilly deal · amount not disclosed · announced Nov 18, 2024
Source quote
  • Nov 18, 2024 · Company release ↗
    “Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio ® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer INX-315”
Nov 18, 2024Company release ↗
Flare TherapeuticsRoche deal · $70M upfront · announced Nov 12, 2024
Source quote
  • Nov 12, 2024 · Company release ↗
    “Flare Therapeutics to receive US $70 million upfront, and potential milestone payments exceeding US$1”
Nov 12, 2024Company release ↗
AitiaDeal · amount not disclosed · announced Oct 30, 2024
Source quote
  • Oct 30, 2024 · Company release ↗
    “Somerville, MA, Oct. 30, 2024: Aitia, a biotech company pioneering the use of causal AI and Digital Twins in drug discovery and development, is expanding its collaboration with Servier, a global and independent pharmaceutical company, to tackle gliomas, a broad group of brain cancers.”
Oct 30, 2024Company release ↗
NeomorphBiogen deal · amount not disclosed · announced Oct 29, 2024
Source quote
  • Oct 29, 2024 · Company release ↗
    “(Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s”
Oct 29, 2024Company release ↗
Mestag Therapeutics LimitedMSD deal · amount not disclosed · announced Oct 8, 2024
Source quote
  • Oct 8, 2024 · Company release ↗
    “– Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has entered into a license and collaboration agreement with MSD (tradename of Merck & Co.”
Oct 8, 2024Company release ↗
Avenzo TherapeuticsGilead deal · amount not disclosed · announced Sep 3, 2024
Source quote
  • Sep 3, 2024 · Company release ↗
    “Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer”
Sep 3, 2024Company release ↗
LeveragenModerna deal · amount not disclosed · announced Jul 31, 2024
Source quote
  • Jul 31, 2024 · Company release ↗
    “Leveragen and Moderna have entered a research, option and licence agreement to advance the development of various therapeutics”
Jul 31, 2024Company release ↗
Belharra TherapeuticsSanofi deal · up to $40M total · announced Jun 18, 2024
Source quote
  • Jun 18, 2024 · Company release ↗
    “Belharra … is eligible to receive up to $40 million in upfront and near-term milestone payments, and up to nearly $700 million in aggregate research, development and commercial milestone payments and royalties on net sales SAN MATEO AND SAN DIEGO, CA, June 18, 2024 — Belharra Therapeutics, a next-g”
Jun 18, 2024Company release ↗
ALZpath, Inc.Roche deal · amount not disclosed · announced Jun 10, 2024
Source quote
  • Jun 10, 2024 · Company release ↗
    “(ALZpath), a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced a strategic license”
Jun 10, 2024Company release ↗
Aulos BioscienceMerck deal · amount not disclosed · announced May 15, 2024
Source quote
  • May 15, 2024 · Company release ↗
    “Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA”
May 15, 2024Company release ↗
Kumquat BiosciencesTakeda deal · up to $130M total · announced Apr 16, 2024
Source quote
  • Apr 16, 2024 · Company release ↗
    “Kumquat will receive up to $130 million in near-term payments and potentially more than $1.2 billion if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement”
Apr 16, 2024Company release ↗
NeomorphNovo Nordisk deal · up to $1.46B total · announced Feb 26, 2024
Source quote
  • Feb 26, 2024 · Company release ↗
    “Collaboration leverages Neomorph’s leading molecular glue discovery platform and Novo Nordisk’s extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 26, 2024 /PRNewswire/ — Neomorph, Inc”
Feb 26, 2024Company release ↗
Tentarix BiotherapeuticsAbbVie deal · $64M · announced Feb 22, 2024
Source quote
  • Feb 22, 2024 · Company release ↗
    “Under the terms of the agreements, Tentarix will receive upfront option payments, totaling $64 million from AbbVie”
Feb 22, 2024Company release ↗
Blacksmith MedicinesZoetis deal · amount not disclosed · announced Feb 14, 2024
Source quote
  • Feb 14, 2024 · Company release ↗
    “Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics”
Feb 14, 2024Company release ↗
SynthekineSanofi deal · $40M upfront · announced Jan 29, 2024
Source quote
  • Jan 29, 2024 · Company release ↗
    “Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on net sales MENLO PARK, CA – Jan. 29, 2024 – Synthekine Inc ., an engineered cytokine therapeutics company, today announced a worldwide collaboration”
Jan 29, 2024Company release ↗
BreezeBioDeal · $15M · announced Jan 23, 2024
Source quote
  • Jan 23, 2024 · Company release ↗
    “GenEdit will receive an upfront payment of $15 million and is eligible to receive up to $629 million in near-term, preclinical and clinical development, commercial, and net sales milestone payments over the course of the collaboration as well as tiered royalties on global net sales for resulting”
Jan 23, 2024Company release ↗
AitiaDeal · amount not disclosed · announced Jan 8, 2024
Source quote
  • Jan 8, 2024 · Company release ↗
    “Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI”
Jan 8, 2024Company release ↗
HiberCellMerck deal · amount not disclosed · announced Dec 5, 2023
Source quote
  • Dec 5, 2023 · Company release ↗
    “Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) NEW YORK, Dec. 05, 2023 — HiberCell, Inc.”
Dec 5, 2023Company release ↗
Improved PharmaDeal · amount not disclosed · announced Nov 9, 2023
Source quote
  • Nov 9, 2023 · Company release ↗
    “Joint research collaboration between Merck, Purdue University, Argonne National Laboratory, and Improved Pharma”
Nov 9, 2023Company release ↗

Raises from SEC Form D filings (332)

These come from SEC Form D filings made Oct 20, 2025 to Oct 16, 2026 (12 months). The press-release lists above reach back 36 months. A Form D reports the amount sold when it was filed; the round may be larger or still open. The date shown is the date of first sale. Where a press release covers the same round, it is listed above instead. Form D amounts are not added to company totals.

CompanyWhat the filing reportsFirst saleSource
Gradient Health, Inc.SEC Form D Equity · Form D reports $2.13M sold
Source quote
  • Filed Oct 7, 2026 · SEC Form D ↗
    “Name of Issuer: Gradient Health, Inc.; CIK: 1914365; Address: Durham, NC; Submission type: D; Filing date: 2026-10-07; Industry Group: Other Health Care; Date of First Sale: 2026-10-06; Types of Securities Offered: Equity, Other (Shares of Issuer preferred stock and the issuer capital stock into which such preferred stock may convert.); Business combination transaction: false; Total Offering Amount: 2132720; Total Amount Sold: 2132720; Federal exemptions: 06b”
Oct 6, 2026SEC Form D ↗
Ensho TherapeuticsSEC Form D Equity · Form D reports $7.28M sold of $15.6M offered
Source quote
  • Filed Oct 15, 2026 · SEC Form D ↗
    “Name of Issuer: Ensho Therapeutics, Inc.; CIK: 2032849; Address: Woodcliff Lake, NJ; Submission type: D; Filing date: 2026-10-15; Industry Group: Biotechnology; Date of First Sale: 2026-10-02; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 15604179; Total Amount Sold: 7281948; Federal exemptions: 06b”
Oct 2, 2026SEC Form D ↗
Lungpacer MedicalSEC Form D Debt / note · Form D reports $7.83M sold of $30M offered
Source quote
  • Filed Oct 14, 2026 · SEC Form D ↗
    “Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D; Filing date: 2026-10-14; Industry Group: Other Health Care; Date of First Sale: 2026-09-30; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 7833333; Federal exemptions: 06b”
Sep 30, 2026SEC Form D ↗
J3 BioscienceSEC Form D Debt / note · Form D reports $50K sold
Source quote
  • Filed Oct 16, 2026 · SEC Form D ↗
    “Name of Issuer: J3 BIOSCIENCE, INC.; CIK: 1408012; Address: Salt Lake City, UT; Submission type: D; Filing date: 2026-10-16; Industry Group: Other Health Care; Date of First Sale: 2026-09-30; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 50000; Total Amount Sold: 50000; Federal exemptions: 06b”
Sep 30, 2026SEC Form D ↗
BioStem TechnologiesSEC Form D Equity · Form D reports $3M sold
Source quote
  • Filed Oct 9, 2026 · SEC Form D ↗
    “Name of Issuer: BioStem Technologies, Inc.; CIK: 1658678; Address: Pompano Beach, FL; Submission type: D; Filing date: 2026-10-09; Industry Group: Biotechnology; Date of First Sale: 2026-09-29; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b”
Sep 29, 2026SEC Form D ↗
BioVentrixSEC Form D Debt / note · Form D reports $1.2M sold of $3M offered
Source quote
  • Filed Oct 8, 2026 · SEC Form D ↗
    “Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D; Filing date: 2026-10-08; Industry Group: Biotechnology; Date of First Sale: 2026-09-29; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1200000; Federal exemptions: 06b”
Sep 29, 2026SEC Form D ↗
CoeurativeSEC Form D Equity · Form D reports $100K sold of $2M offered
Source quote
  • Filed Oct 13, 2026 · SEC Form D ↗
    “Name of Issuer: Coeurative, Inc.; CIK: 1577355; Address: Roanoke, VA; Submission type: D; Filing date: 2026-10-13; Industry Group: Other Health Care; Date of First Sale: 2026-09-27; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 100000; Federal exemptions: 06b”
Sep 27, 2026SEC Form D ↗
EpiVario Inc.SEC Form D Debt / note · Form D reports $185K sold of $500K offered
Source quote
  • Filed Oct 13, 2026 · SEC Form D ↗
    “Name of Issuer: EpiVario Inc.; CIK: 1753351; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-25; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 185000; Federal exemptions: 06b”
Sep 25, 2026SEC Form D ↗
OncoNano MedicineSEC Form D Equity · Form D reports $10.05M sold of $15M offered
Source quote
  • Filed Oct 8, 2026 · SEC Form D ↗
    “Name of Issuer: OncoNano Medicine, Inc.; CIK: 1735726; Address: Dallas, TX; Submission type: D; Filing date: 2026-10-08; Industry Group: Biotechnology; Date of First Sale: 2026-09-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 10051615; Federal exemptions: 06b”
Sep 23, 2026SEC Form D ↗
PreciseDxSEC Form D Equity · Form D reports $3.7M sold
Source quote
  • Filed Oct 7, 2026 · SEC Form D ↗
    “Name of Issuer: PreciseDx, Inc.; CIK: 2013833; Address: New York, NY; Submission type: D; Filing date: 2026-10-07; Industry Group: Other Health Care; Date of First Sale: 2026-09-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3699998; Total Amount Sold: 3699998; Federal exemptions: 06b”
Sep 23, 2026SEC Form D ↗
Anvion Bio, Inc.SEC Form D Equity · Form D reports $100K sold of $1M offered
Source quote
  • Filed Oct 7, 2026 · SEC Form D ↗
    “Name of Issuer: Anvion Bio, Inc.; CIK: 2158000; Address: San Diego, CA; Submission type: D; Filing date: 2026-10-07; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 100000; Federal exemptions: 06b”
Sep 22, 2026SEC Form D ↗
Pace Pharmaceuticals, Inc.SEC Form D SAFE · Form D reports $50K sold (offering size open-ended)
Source quote
  • Filed Sep 28, 2026 · SEC Form D ↗
    “Name of Issuer: Pace Pharmaceuticals, Inc.; CIK: 2157304; Address: Cupertino, CA; Submission type: D; Filing date: 2026-09-28; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 50000; Federal exemptions: 06c”
Sep 18, 2026SEC Form D ↗
Navigator MedicinesSEC Form D Equity · Form D reports $10M sold of $40M offered
Source quote
  • Filed Sep 25, 2026 · SEC Form D ↗
    “Name of Issuer: Navigator Medicines, Inc.; CIK: 2035715; Address: San Mateo, CA; Submission type: D; Filing date: 2026-09-25; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 10000000; Federal exemptions: 06b”
Sep 18, 2026SEC Form D ↗
Virtual IncisionSEC Form D Equity · Form D reports $35.14M sold of $80.14M offered
Source quote
  • Filed Oct 5, 2026 · SEC Form D ↗
    “Name of Issuer: Virtual Incision Corp; CIK: 1380771; Address: Lincoln, NE; Submission type: D; Filing date: 2026-10-05; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 80140041; Total Amount Sold: 35140060; Federal exemptions: 06b”
Sep 18, 2026SEC Form D ↗
Vetmab Biosciences, Inc.SEC Form D Equity · Form D reports $11.44M sold of $11.94M offered
Source quote
  • Filed Sep 29, 2026 · SEC Form D ↗
    “Name of Issuer: Vetmab Biosciences, Inc.; CIK: 1932050; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11944990; Total Amount Sold: 11439990; Federal exemptions: 06b”
Sep 17, 2026SEC Form D ↗
Altay Therapeutics, Inc.SEC Form D Equity · Form D reports $15.74M sold of $45.07M offered
Source quote
  • Filed Oct 2, 2026 · SEC Form D ↗
    “Name of Issuer: Altay Therapeutics, Inc.; CIK: 2157551; Address: San Carlos, CA; Submission type: D; Filing date: 2026-10-02; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 45067885; Total Amount Sold: 15738155; Federal exemptions: 06b”
Sep 17, 2026SEC Form D ↗
CAD Therapeutics, Inc.SEC Form D Equity · Form D reports $4M sold of $10M offered
Source quote
  • Filed Oct 2, 2026 · SEC Form D ↗
    “Name of Issuer: CAD Therapeutics, Inc.; CIK: 2157566; Address: New York, NY; Submission type: D; Filing date: 2026-10-02; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity, Other (SERIES A COMMON STOCK); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4000000; Federal exemptions: 06b”
Sep 17, 2026SEC Form D ↗
Huxley MedicalSEC Form D Debt / note · Form D reports $11.02M sold of $11.7M offered
Source quote
  • Filed Sep 30, 2026 · SEC Form D ↗
    “Name of Issuer: Huxley Medical, Inc.; CIK: 1869701; Address: Atlanta, GA; Submission type: D; Filing date: 2026-09-30; Industry Group: Other Health Care; Date of First Sale: 2026-09-16; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 11700000; Total Amount Sold: 11019335; Federal exemptions: 06b”
Sep 16, 2026SEC Form D ↗
Jupiter BioMedical ResearchSEC Form D Equity · Form D reports $30K sold of $1M offered
Source quote
  • Filed Sep 21, 2026 · SEC Form D ↗
    “Name of Issuer: Jupiter Biomedical Research, Inc.; CIK: 1694280; Address: Palm Beach Gardens, FL; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-09-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 30000; Federal exemptions: 06b, 4a5”
Sep 15, 2026SEC Form D ↗
Toetal SolutionsSEC Form D Equity · Form D reports $50K sold of $250K offered
Source quote
  • Filed Sep 24, 2026 · SEC Form D ↗
    “Name of Issuer: Toetal Solutions, Inc.; CIK: 1888204; Address: Malvern, PA; Submission type: D; Filing date: 2026-09-24; Industry Group: Other Health Care; Date of First Sale: 2026-09-15; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (Security to be acquired upon exercise.); Business combination transaction: false; Total Offering Amount: 250000; Total Amount Sold: 50000; Federal exemptions: 06b”
Sep 15, 2026SEC Form D ↗
Dignify TherapeuticsSEC Form D Debt / note · Form D reports $800K sold of $3M offered
Source quote
  • Filed Sep 25, 2026 · SEC Form D ↗
    “Name of Issuer: Dignify Therapeutics, LLC; CIK: 1622906; Address: Research Triangle Park, NC; Submission type: D; Filing date: 2026-09-25; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-15; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 800000; Federal exemptions: 06b”
Sep 15, 2026SEC Form D ↗
GT BiopharmaSEC Form D Equity · Form D reports $7.75M sold of $38.96M offered
Source quote
  • Filed Sep 29, 2026 · SEC Form D ↗
    “Name of Issuer: GT Biopharma, Inc.; CIK: 109657; Address: San Francisco, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 38958054; Total Amount Sold: 7750000; Federal exemptions: 06b”
Sep 14, 2026SEC Form D ↗
Harvard Apparatus Regenerative TechnologySEC Form D Equity · Form D reports $2.84M sold of $3M offered
Source quote
  • Filed Sep 14, 2026 · SEC Form D ↗
    “Name of Issuer: Harvard Apparatus Regenerative Technology, Inc.; CIK: 1563665; Address: Holliston, MA; Submission type: D; Filing date: 2026-09-14; Industry Group: Biotechnology; Date of First Sale: 2026-09-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2838911; Federal exemptions: 06b”
Sep 11, 2026SEC Form D ↗
OpZiraSEC Form D Equity · Form D reports $2.02M sold of $5M offered
Source quote
  • Filed Sep 15, 2026 · SEC Form D ↗
    “Name of Issuer: OpZira, Inc.; CIK: 2124535; Address: Middletown, PA; Submission type: D; Filing date: 2026-09-15; Industry Group: Other Technology; Date of First Sale: 2026-09-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 2025000; Federal exemptions: 06b”
Sep 9, 2026SEC Form D ↗
Theia Imaging LLCSEC Form D SAFE · Form D reports $160K sold of $1M offered
Source quote
  • Filed Sep 17, 2026 · SEC Form D ↗
    “Name of Issuer: Theia Imaging LLC; CIK: 2155415; Address: Durham, NC; Submission type: D; Filing date: 2026-09-17; Industry Group: Other Health Care; Date of First Sale: 2026-09-09; Types of Securities Offered: Other (SAFE (Simple Agreement for Future Equity)); Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 160000; Federal exemptions: 06b”
Sep 9, 2026SEC Form D ↗
Caspian Therapeutics, Inc.SEC Form D Equity · Form D reports $50M sold
Source quote
  • Filed Sep 23, 2026 · SEC Form D ↗
    “Name of Issuer: Caspian Therapeutics, Inc.; CIK: 2156247; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-23; Industry Group: Biotechnology; Date of First Sale: 2026-09-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 50000000; Total Amount Sold: 50000000; Federal exemptions: 06b”
Sep 8, 2026SEC Form D ↗
EncisionSEC Form D Equity · Form D reports $80K sold
Source quote
  • Filed Sep 17, 2026 · SEC Form D ↗
    “Name of Issuer: ENCISION INC; CIK: 930775; Address: Boulder, CO; Submission type: D; Filing date: 2026-09-17; Industry Group: Other Health Care; Date of First Sale: 2026-09-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 80000; Total Amount Sold: 80000; Federal exemptions: 06b”
Sep 8, 2026SEC Form D ↗
Aqur BiosciencesSEC Form D Equity · Form D reports $1.5M sold
Source quote
  • Filed Sep 18, 2026 · SEC Form D ↗
    “Name of Issuer: Aqur Biosciences, Inc.; CIK: 2094075; Address: Westlake Village, CA; Submission type: D; Filing date: 2026-09-18; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1500000; Federal exemptions: 06b”
Sep 3, 2026SEC Form D ↗
seqWell, Inc.SEC Form D Equity · Form D reports $960K sold of $1M offered
Source quote
  • Filed Sep 10, 2026 · SEC Form D ↗
    “Name of Issuer: seqWell Inc.; CIK: 1679720; Address: Beverly, MA; Submission type: D; Filing date: 2026-09-10; Industry Group: Other Technology; Date of First Sale: 2026-09-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 960110; Federal exemptions: 06b”
Sep 1, 2026SEC Form D ↗
CoologicsSEC Form D SAFE · Form D reports $1M sold of $2.5M offered
Source quote
  • Filed Sep 10, 2026 · SEC Form D ↗
    “Name of Issuer: Coologics, Inc.; CIK: 2150705; Address: Grove City, OH; Submission type: D; Filing date: 2026-09-10; Industry Group: Other; Date of First Sale: 2026-09-01; Types of Securities Offered: Other (Simple Agreement for Future Equity (SAFE)); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1000000; Federal exemptions: 06b”
Sep 1, 2026SEC Form D ↗
Myris TherapeuticsSEC Form D Debt / note · Form D reports $500K sold of $4.5M offered
Source quote
  • Filed Oct 14, 2026 · SEC Form D ↗
    “Name of Issuer: Myris Therapeutics, Inc.; CIK: 1924725; Address: Sharpsburg, PA; Submission type: D; Filing date: 2026-10-14; Industry Group: Biotechnology; Date of First Sale: 2026-09-01; Types of Securities Offered: Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 4500000; Total Amount Sold: 500000; Federal exemptions: 06b”
Sep 1, 2026SEC Form D ↗
Intelligent Bio SolutionsSEC Form D Equity · Form D reports $4.98M sold
Source quote
  • Filed Sep 14, 2026 · SEC Form D ↗
    “Name of Issuer: INTELLIGENT BIO SOLUTIONS INC.; CIK: 1725430; Address: New York, NY; Submission type: D; Filing date: 2026-09-14; Industry Group: Other Health Care; Date of First Sale: 2026-08-31; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 4979631; Total Amount Sold: 4979631; Federal exemptions: 06b”
Aug 31, 2026SEC Form D ↗
3HelixSEC Form D Equity · Form D reports $7.84M sold of $10M offered
Source quote
  • Filed Sep 21, 2026 · SEC Form D ↗
    “Name of Issuer: 3Helix, Inc.; CIK: 2001622; Address: Salt Lake City, UT; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-08-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 7835028; Federal exemptions: 06b”
Aug 31, 2026SEC Form D ↗
Retham Technologies LLCSEC Form D Equity · Form D reports $1.06M sold of $1.5M offered
Source quote
  • Filed Sep 11, 2026 · SEC Form D ↗
    “Name of Issuer: Retham Technologies, Inc.; CIK: 2144681; Address: Wauwatosa, WI; Submission type: D; Filing date: 2026-09-11; Industry Group: Other; Date of First Sale: 2026-08-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1060000; Federal exemptions: 06b”
Aug 28, 2026SEC Form D ↗
Tempo Therapeutics IncSEC Form D Debt / note · Form D reports $14M sold of $14.5M offered
Source quote
  • Filed Sep 11, 2026 · SEC Form D ↗
    “Name of Issuer: Tempo Therapeutics, Inc.; CIK: 1813688; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-11; Industry Group: Biotechnology; Date of First Sale: 2026-08-27; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 14500000; Total Amount Sold: 14000000; Federal exemptions: 06b”
Aug 27, 2026SEC Form D ↗
AlzheonSEC Form D Equity · Form D reports $78.8M sold of $500M offered
Source quote
  • Filed Sep 10, 2026 · SEC Form D ↗
    “Name of Issuer: ALZHEON, INC.; CIK: 1582636; Address: Framingham, MA; Submission type: D; Filing date: 2026-09-10; Industry Group: Biotechnology; Date of First Sale: 2026-08-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 499999999; Total Amount Sold: 78797184; Federal exemptions: 06b”
Aug 26, 2026SEC Form D ↗
Cloverleaf Bio, Inc.SEC Form D Equity · Form D reports $14.8M sold of $29.6M offered
Source quote
  • Filed Sep 9, 2026 · SEC Form D ↗
    “Name of Issuer: Cloverleaf Bio, Inc.; CIK: 2153574; Address: New Haven, CT; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 29599977; Total Amount Sold: 14799988; Federal exemptions: 06b”
Aug 24, 2026SEC Form D ↗
Malcova Inc.SEC Form D Equity · Form D reports $1.21M sold of $2M offered
Source quote
  • Filed Sep 8, 2026 · SEC Form D ↗
    “Name of Issuer: Malcova, Inc; CIK: 2152940; Address: Newark, CA; Submission type: D; Filing date: 2026-09-08; Industry Group: Other Technology; Date of First Sale: 2026-08-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1214000; Federal exemptions: 06b”
Aug 24, 2026SEC Form D ↗
OrthobondSEC Form D Debt / note · Form D reports $8.35M sold of $10M offered
Source quote
  • Filed Sep 1, 2026 · SEC Form D ↗
    “Name of Issuer: Orthobond Corp; CIK: 1329147; Address: Monmouth Junction, NJ; Submission type: D; Filing date: 2026-09-01; Industry Group: Other Technology; Date of First Sale: 2026-08-24; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 8346000; Federal exemptions: 06b”
Aug 24, 2026SEC Form D ↗
Laurentide Therapeutics Inc.SEC Form D Equity · Form D reports $100K sold
Source quote
  • Filed Sep 28, 2026 · SEC Form D ↗
    “Name of Issuer: Laurentide Therapeutics Inc.; CIK: 2157396; Address: Atlanta, GA; Submission type: D; Filing date: 2026-09-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-20; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 100000; Total Amount Sold: 99999; Federal exemptions: 06b”
Aug 20, 2026SEC Form D ↗
Jupiter NeurosciencesSEC Form D Equity · Form D reports $775K sold
Source quote
  • Filed Sep 4, 2026 · SEC Form D ↗
    “Name of Issuer: JUPITER NEUROSCIENCES, INC.; CIK: 1679628; Address: Palm Beach Gardens, FL; Submission type: D; Filing date: 2026-09-04; Industry Group: Other Health Care; Date of First Sale: 2026-08-20; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 774787; Total Amount Sold: 774787; Federal exemptions: 06b”
Aug 20, 2026SEC Form D ↗
Avery TherapeuticsSEC Form D Equity · Form D reports $8.47M sold of $15.4M offered
Source quote
  • Filed Sep 21, 2026 · SEC Form D ↗
    “Name of Issuer: Avery Therapeutics, Inc.; CIK: 1708135; Address: Tucson, AZ; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-08-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15400000; Total Amount Sold: 8468859; Federal exemptions: 06b”
Aug 19, 2026SEC Form D ↗
Halia TherapeuticsSEC Form D Equity + debt/notes · Form D reports $3.49M sold of $20M offered
Source quote
  • Filed Aug 31, 2026 · SEC Form D ↗
    “Name of Issuer: Halia Therapeutics, Inc.; CIK: 1829255; Address: Lehi, UT; Submission type: D; Filing date: 2026-08-31; Industry Group: Biotechnology; Date of First Sale: 2026-08-17; Types of Securities Offered: Equity, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 3486474; Federal exemptions: 06b”
Aug 17, 2026SEC Form D ↗
Iambic TherapeuticsSEC Form D Debt / note · Form D reports $65.97M sold of $66.5M offered
Source quote
  • Filed Sep 9, 2026 · SEC Form D ↗
    “Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-14; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 66500000; Total Amount Sold: 65965000; Federal exemptions: 06b”
Aug 14, 2026SEC Form D ↗
Acuitive TechnologiesSEC Form D SAFE · Form D reports $1.88M sold of $3M offered
Source quote
  • Filed Sep 24, 2026 · SEC Form D ↗
    “Name of Issuer: Acuitive Technologies, Inc.; CIK: 1864239; Address: Allendale, NJ; Submission type: D; Filing date: 2026-09-24; Industry Group: Other Health Care; Date of First Sale: 2026-08-14; Types of Securities Offered: Other (Simple Agreements for Future Equity (SAFEs)); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1875000; Federal exemptions: 06b”
Aug 14, 2026SEC Form D ↗
Turn TherapeuticsSEC Form D Equity · Form D reports $1.65M sold (offering size open-ended)
Source quote
  • Filed Aug 26, 2026 · SEC Form D ↗
    “Name of Issuer: Turn Therapeutics Inc.; CIK: 2023016; Address: Westlake Village, CA; Submission type: D; Filing date: 2026-08-26; Industry Group: Biotechnology; Date of First Sale: 2026-08-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1650000; Federal exemptions: 06b”
Aug 14, 2026SEC Form D ↗
Thetis Pharmaceuticals LLCSEC Form D Debt / note · Form D reports $560K sold of $1M offered
Source quote
  • Filed Oct 13, 2026 · SEC Form D ↗
    “Name of Issuer: Thetis Pharmaceuticals LLC; CIK: 1528491; Address: Deep River, CT; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-13; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 560300; Federal exemptions: 06b”
Aug 13, 2026SEC Form D ↗
Noveome BiotherapeuticsSEC Form D Debt / note · Form D reports $6.75M sold of $15M offered
Source quote
  • Filed Aug 27, 2026 · SEC Form D ↗
    “Name of Issuer: Noveome Biotherapeutics, Inc.; CIK: 1478304; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-08-27; Industry Group: Biotechnology; Date of First Sale: 2026-08-12; Types of Securities Offered: Debt, Other (Convertible promissory notes); Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 6750503; Federal exemptions: 06b”
Aug 12, 2026SEC Form D ↗
Aptevo TherapeuticsSEC Form D Equity · Form D reports $3.47M sold
Source quote
  • Filed Aug 26, 2026 · SEC Form D ↗
    “Name of Issuer: Aptevo Therapeutics Inc.; CIK: 1671584; Address: Seattle, WA; Submission type: D; Filing date: 2026-08-26; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-12; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3472683; Total Amount Sold: 3472683; Federal exemptions: 06c”
Aug 12, 2026SEC Form D ↗
FemasysSEC Form D Equity · Form D reports $30M sold
Source quote
  • Filed Aug 20, 2026 · SEC Form D ↗
    “Name of Issuer: FEMASYS INC; CIK: 1339005; Address: Suwanee, GA; Submission type: D; Filing date: 2026-08-20; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 30000000; Federal exemptions: 06b”
Aug 10, 2026SEC Form D ↗
OS TherapiesSEC Form D Equity + debt/notes · Form D reports $5M sold of $10M offered
Source quote
  • Filed Aug 25, 2026 · SEC Form D ↗
    “Name of Issuer: OS Therapies Inc; CIK: 1795091; Address: Grasonville, MD; Submission type: D; Filing date: 2026-08-25; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 5000000; Federal exemptions: 06b”
Aug 10, 2026SEC Form D ↗
Superluminal MedicinesSEC Form D Equity · Form D reports $65.48M sold
Source quote
  • Filed Sep 3, 2026 · SEC Form D ↗
    “Name of Issuer: Superluminal Medicines, Inc.; CIK: 1989478; Address: Boston, MA; Submission type: D; Filing date: 2026-09-03; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 65480796; Total Amount Sold: 65480796; Federal exemptions: 06b”
Aug 10, 2026SEC Form D ↗
Auron TherapeuticsSEC Form D Debt / note · Form D reports $7.12M sold of $12M offered
Source quote
  • Filed Aug 13, 2026 · SEC Form D ↗
    “Name of Issuer: Auron Therapeutics, Inc.; CIK: 1746139; Address: Wellesley, MA; Submission type: D; Filing date: 2026-08-13; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 7118141; Federal exemptions: 06b”
Aug 10, 2026SEC Form D ↗
MalarVxSEC Form D Debt / note · Form D reports $125K sold of $2.5M offered
Source quote
  • Filed Aug 25, 2026 · SEC Form D ↗
    “Name of Issuer: MalarVx, Inc.; CIK: 1559688; Address: Seattle, WA; Submission type: D; Filing date: 2026-08-25; Industry Group: Biotechnology; Date of First Sale: 2026-08-08; Types of Securities Offered: Other (Promissory Note convertible into equity.); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 125000; Federal exemptions: 06b”
Aug 8, 2026SEC Form D ↗
Unravel BiosciencesSEC Form D Debt / note · Form D reports $4.1M sold of $4.5M offered
Source quote
  • Filed Aug 24, 2026 · SEC Form D ↗
    “Name of Issuer: Unravel Biosciences, Inc.; CIK: 1876967; Address: Medford, MA; Submission type: D; Filing date: 2026-08-24; Industry Group: Biotechnology; Date of First Sale: 2026-08-07; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 4500000; Total Amount Sold: 4100000; Federal exemptions: 06b”
Aug 7, 2026SEC Form D ↗
CardiosenseSEC Form D Equity + debt/notes · Form D reports $26.14M sold of $42.01M offered
Source quote
  • Filed Aug 24, 2026 · SEC Form D ↗
    “Name of Issuer: Cardiosense, Inc.; CIK: 1957335; Address: Chicago, IL; Submission type: D; Filing date: 2026-08-24; Industry Group: Other Health Care; Date of First Sale: 2026-08-07; Types of Securities Offered: Equity, Security to be acquired, Other (Convertible Promissory Notes have converted into equity in connection with this transaction); Business combination transaction: false; Total Offering Amount: 42012230; Total Amount Sold: 26137050; Federal exemptions: 06b”
Aug 7, 2026SEC Form D ↗
Aer TherapeuticsSEC Form D Debt / note · Form D reports $3M sold
Source quote
  • Filed Aug 19, 2026 · SEC Form D ↗
    “Name of Issuer: Aer Therapeutics, Inc.; CIK: 1959576; Address: Research Triangle Park, NC; Submission type: D; Filing date: 2026-08-19; Industry Group: Biotechnology; Date of First Sale: 2026-08-07; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b”
Aug 7, 2026SEC Form D ↗
Limber Prosthetics & Orthotics Inc. Filed as Limber Prosthetics, Inc.SEC Form D Equity · Form D reports $135K sold of $1.88M offered
Source quote
  • Filed Aug 18, 2026 · SEC Form D ↗
    “Name of Issuer: Limber Prosthetics, Inc.; CIK: 2072119; Address: San Diego, CA; Submission type: D; Filing date: 2026-08-18; Industry Group: Other Health Care; Date of First Sale: 2026-08-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1875000; Total Amount Sold: 135343; Federal exemptions: 06b”
Aug 7, 2026SEC Form D ↗
InSitu BiologicsSEC Form D Debt / note · Form D reports $1.25M sold of $3.38M offered
Source quote
  • Filed Aug 10, 2026 · amended Oct 14, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: InSitu Biologics, Inc.; CIK: 1723443; Address: Oakdale, MN; Submission type: D/A; Filing date: 2026-10-14; Industry Group: Biotechnology; Date of First Sale: 2026-08-04; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 3375000; Total Amount Sold: 1250000; Federal exemptions: 06b”
Aug 4, 2026SEC Form D/A ↗
Aegle TherapeuticsSEC Form D Equity · Form D reports $2.28M sold
Source quote
  • Filed Aug 28, 2026 · SEC Form D ↗
    “Name of Issuer: Aegle Therapeutics Corp; CIK: 1797825; Address: Woburn, MA; Submission type: D; Filing date: 2026-08-28; Industry Group: Biotechnology; Date of First Sale: 2026-08-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2277698; Total Amount Sold: 2277698; Federal exemptions: 06b”
Aug 4, 2026SEC Form D ↗
Hepion PharmaceuticalsSEC Form D Equity · Form D reports $3.06M sold
Source quote
  • Filed Aug 5, 2026 · SEC Form D ↗
    “Name of Issuer: Hepion Pharmaceuticals, Inc.; CIK: 1583771; Address: Red Bank, NJ; Submission type: D; Filing date: 2026-08-05; Industry Group: Biotechnology; Date of First Sale: 2026-07-31; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3055000; Total Amount Sold: 3055000; Federal exemptions: 06b”
Jul 31, 2026SEC Form D ↗
BiolibertySEC Form D Equity · Form D reports $2.95M sold
Source quote
  • Filed Aug 27, 2026 · SEC Form D ↗
    “Name of Issuer: Bioliberty Ltd; CIK: 2151818; Address: Edinburgh, United Kingdom; Submission type: D; Filing date: 2026-08-27; Industry Group: Other Technology; Date of First Sale: 2026-07-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2947097; Total Amount Sold: 2947097; Federal exemptions: 06b”
Jul 31, 2026SEC Form D ↗
Hyku BiosciencesSEC Form D Equity · Form D reports $8.61M sold
Source quote
  • Filed Aug 13, 2026 · SEC Form D ↗
    “Name of Issuer: HYKU BIOSCIENCES INC.; CIK: 1980518; Address: Concord, MA; Submission type: D; Filing date: 2026-08-13; Industry Group: Other; Date of First Sale: 2026-07-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 8612446; Total Amount Sold: 8612446; Federal exemptions: 06b”
Jul 30, 2026SEC Form D ↗
DalCor Pharmaceuticals Filed as DalCor Pharmaceuticals US, LLCSEC Form D Equity · Form D reports $6.96M sold
Source quote
  • Filed Aug 28, 2026 · SEC Form D ↗
    “Name of Issuer: DalCor Pharmaceuticals US, LLC; CIK: 1673368; Address: Sarasota, FL; Submission type: D; Filing date: 2026-08-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6958236; Total Amount Sold: 6958236; Federal exemptions: 06b”
Jul 30, 2026SEC Form D ↗
Trace BiosciencesSEC Form D Equity · Form D reports $8.33M sold of $16.23M offered
Source quote
  • Filed Aug 12, 2026 · SEC Form D ↗
    “Name of Issuer: Trace Biosciences Inc.; CIK: 2147501; Address: Beaverton, OR; Submission type: D; Filing date: 2026-08-12; Industry Group: Biotechnology; Date of First Sale: 2026-07-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 16234498; Total Amount Sold: 8334499; Federal exemptions: 06b”
Jul 28, 2026SEC Form D ↗
PleoPharmaSEC Form D Debt / note · Form D reports $5.5M sold of $15M offered
Source quote
  • Filed Aug 10, 2026 · SEC Form D ↗
    “Name of Issuer: PLEOPHARMA, INC.; CIK: 1801323; Address: Phoenixville, PA; Submission type: D; Filing date: 2026-08-10; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-28; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5500000; Federal exemptions: 06b”
Jul 28, 2026SEC Form D ↗
MedulocSEC Form D Equity · Form D reports $1.84M sold
Source quote
  • Filed Aug 6, 2026 · SEC Form D ↗
    “Name of Issuer: Meduloc, Inc.; CIK: 2014714; Address: Del Mar, CA; Submission type: D; Filing date: 2026-08-06; Industry Group: Other Health Care; Date of First Sale: 2026-07-24; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 1843000; Total Amount Sold: 1843000; Federal exemptions: 06b”
Jul 24, 2026SEC Form D ↗
oRF BiologicsSEC Form D Equity · Form D reports $1.73M sold of $2.5M offered
Source quote
  • Filed Jul 31, 2026 · SEC Form D ↗
    “Name of Issuer: ORF Biologics, Inc.; CIK: 2048350; Address: Tiffin, IA; Submission type: D; Filing date: 2026-07-31; Industry Group: Biotechnology; Date of First Sale: 2026-07-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1734220; Federal exemptions: 06b”
Jul 23, 2026SEC Form D ↗
NextPoint TherapeuticsSEC Form D Equity · Form D reports $33.73M sold of $48.73M offered
Source quote
  • Filed Jul 30, 2026 · SEC Form D ↗
    “Name of Issuer: NextPoint Therapeutics, Inc.; CIK: 1959209; Address: Cambridge, MA; Submission type: D; Filing date: 2026-07-30; Industry Group: Biotechnology; Date of First Sale: 2026-07-22; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 48729165; Total Amount Sold: 33728772; Federal exemptions: 06b”
Jul 22, 2026SEC Form D ↗
Integrated BiosciencesSEC Form D Equity · Form D reports $68.37M sold of $100M offered
Source quote
  • Filed Aug 5, 2026 · SEC Form D ↗
    “Name of Issuer: Integrated Biosciences, Inc.; CIK: 2148371; Address: Redwood City, CA; Submission type: D; Filing date: 2026-08-05; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 100000000; Total Amount Sold: 68374977; Federal exemptions: 06b”
Jul 21, 2026SEC Form D ↗
Jasper Therapeutics, Inc.SEC Form D Equity · Form D reports $132M sold
Source quote
  • Filed Aug 5, 2026 · SEC Form D ↗
    “Name of Issuer: Jasper Therapeutics, Inc.; CIK: 1788028; Address: Redwood City, CA; Submission type: D; Filing date: 2026-08-05; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 131999611; Total Amount Sold: 131999611; Federal exemptions: 06b”
Jul 21, 2026SEC Form D ↗
TheradaptiveSEC Form D Equity · Form D reports $36.16M sold of $77.93M offered
Source quote
  • Filed Aug 4, 2026 · SEC Form D ↗
    “Name of Issuer: Theradaptive, Inc.; CIK: 2148461; Address: Frederick, MD; Submission type: D; Filing date: 2026-08-04; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 77925166; Total Amount Sold: 36156177; Federal exemptions: 06b”
Jul 21, 2026SEC Form D ↗
Accipiter BiosciencesSEC Form D Equity · Form D reports $10.49M sold
Source quote
  • Filed Jul 28, 2026 · SEC Form D ↗
    “Name of Issuer: Accipiter Biosciences Inc.; CIK: 1973963; Address: Seattle, WA; Submission type: D; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10492778; Total Amount Sold: 10492778; Federal exemptions: 06b”
Jul 21, 2026SEC Form D ↗
InterAct TherapeuticsSEC Form D Debt / note · Form D reports $250K sold of $2M offered
Source quote
  • Filed Jul 21, 2026 · SEC Form D ↗
    “Name of Issuer: InterAct Therapeutics, Inc.; CIK: 2107143; Address: Dallas, TX; Submission type: D; Filing date: 2026-07-21; Industry Group: Other Health Care; Date of First Sale: 2026-07-20; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 250000; Federal exemptions: 06b”
Jul 20, 2026SEC Form D ↗
FluidForm Inc. Filed as FluidForm Bio, Inc.SEC Form D Equity · Form D reports $1.7M sold of $3M offered
Source quote
  • Filed Aug 27, 2026 · SEC Form D ↗
    “Name of Issuer: FluidForm Bio, Inc.; CIK: 2062460; Address: Waltham, MA; Submission type: D; Filing date: 2026-08-27; Industry Group: Biotechnology; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1703371; Federal exemptions: 06b”
Jul 16, 2026SEC Form D ↗
GeorgiamuneSEC Form D Equity · Form D reports $92.69M sold of $131.85M offered
Source quote
  • Filed Aug 17, 2026 · SEC Form D ↗
    “Name of Issuer: Georgiamune, Inc.; CIK: 2148230; Address: Gaithersburg, MD; Submission type: D; Filing date: 2026-08-17; Industry Group: Biotechnology; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity, Other (Series B Preferred Stock); Business combination transaction: false; Total Offering Amount: 131852011; Total Amount Sold: 92692709; Federal exemptions: 06b”
Jul 16, 2026SEC Form D ↗
Ratio TherapeuticsSEC Form D Equity · Form D reports $70M sold
Source quote
  • Filed Jul 31, 2026 · SEC Form D ↗
    “Name of Issuer: Ratio Therapeutics, Inc.; CIK: 2004792; Address: Boston, MA; Submission type: D; Filing date: 2026-07-31; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69999974; Total Amount Sold: 69999974; Federal exemptions: 06b”
Jul 16, 2026SEC Form D ↗
GenomenonSEC Form D Equity · Form D reports $6.03M sold of $10M offered
Source quote
  • Filed Jul 30, 2026 · SEC Form D ↗
    “Name of Issuer: Genomenon, Inc.; CIK: 1650557; Address: Ann Arbor, MI; Submission type: D; Filing date: 2026-07-30; Industry Group: Biotechnology; Date of First Sale: 2026-07-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 6025002; Federal exemptions: 06b”
Jul 15, 2026SEC Form D ↗
ALZpath, Inc.SEC Form D Equity · Form D reports $8.41M sold of $10.41M offered
Source quote
  • Filed Jul 21, 2026 · SEC Form D ↗
    “Name of Issuer: ALZpath, Inc.; CIK: 2145244; Address: Carlsbad, CA; Submission type: D; Filing date: 2026-07-21; Industry Group: Biotechnology; Date of First Sale: 2026-07-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10411219; Total Amount Sold: 8411219; Federal exemptions: 06b”
Jul 14, 2026SEC Form D ↗
SonavexSEC Form D Equity · Form D reports $3.1M sold of $15M offered
Source quote
  • Filed Jul 28, 2026 · SEC Form D ↗
    “Name of Issuer: Sonavex, Inc.; CIK: 1645892; Address: city not listed;DONNELL STREET, BALTIMORE, MARYLAND; Submission type: D; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2026-07-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 3102995; Federal exemptions: 06b”
Jul 13, 2026SEC Form D ↗
Cooler Heads Care Inc.SEC Form D Equity · Form D reports $3.27M sold of $6M offered
Source quote
  • Filed Jul 23, 2026 · SEC Form D ↗
    “Name of Issuer: COOLER HEADS CARE, INC.; CIK: 1972845; Address: San Diego, CA; Submission type: D; Filing date: 2026-07-23; Industry Group: Other Health Care; Date of First Sale: 2026-07-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5999928; Total Amount Sold: 3267467; Federal exemptions: 06b”
Jul 10, 2026SEC Form D ↗
Pelva Health CorporationSEC Form D SAFE · Form D reports $30K sold of $2M offered
Source quote
  • Filed Aug 7, 2026 · SEC Form D ↗
    “Name of Issuer: Pelva Health Corp; CIK: 2008160; Address: Edina, MN; Submission type: D; Filing date: 2026-08-07; Industry Group: Other Health Care; Date of First Sale: 2026-07-09; Types of Securities Offered: Other (SAFE instrument); Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 30000; Federal exemptions: 06b”
Jul 9, 2026SEC Form D ↗
TECLensSEC Form D Debt / note · Form D reports $5.23M sold of $10.23M offered
Source quote
  • Filed Jul 24, 2026 · SEC Form D ↗
    “Name of Issuer: TECLens, Inc.; CIK: 1708436; Address: Stamford, CT; Submission type: D; Filing date: 2026-07-24; Industry Group: Other Health Care; Date of First Sale: 2026-07-09; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10230000; Total Amount Sold: 5230000; Federal exemptions: 06b”
Jul 9, 2026SEC Form D ↗
TYBR HealthSEC Form D Equity · Form D reports $14.35M sold of $30M offered
Source quote
  • Filed Jul 22, 2026 · SEC Form D ↗
    “Name of Issuer: TYBR Health, Inc.; CIK: 1835188; Address: Houston, TX; Submission type: D; Filing date: 2026-07-22; Industry Group: Biotechnology; Date of First Sale: 2026-07-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 14354342; Federal exemptions: 06b”
Jul 9, 2026SEC Form D ↗
Silo PharmaSEC Form D Equity · Form D reports $4M sold
Source quote
  • Filed Jul 14, 2026 · SEC Form D ↗
    “Name of Issuer: Silo Pharma, Inc.; CIK: 1514183; Address: Sarasota, FL; Submission type: D; Filing date: 2026-07-14; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-09; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000015; Total Amount Sold: 4000015; Federal exemptions: 06b”
Jul 9, 2026SEC Form D ↗
Hexamer TherapeuticsSEC Form D Equity · Form D reports $500K sold of $2.5M offered
Source quote
  • Filed Sep 15, 2026 · SEC Form D ↗
    “Name of Issuer: Hexamer Therapeutics, Inc; CIK: 1797915; Address: Pullman, WA; Submission type: D; Filing date: 2026-09-15; Industry Group: Biotechnology; Date of First Sale: 2026-07-07; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 500000; Federal exemptions: 06b”
Jul 7, 2026SEC Form D ↗
LifewardSEC Form D Equity + debt/notes · Form D reports $11.16M sold (offering size open-ended)
Source quote
  • Filed Jul 8, 2026 · SEC Form D ↗
    “Name of Issuer: Lifeward Ltd.; CIK: 1607962; Address: Hudson, MA; Submission type: D; Filing date: 2026-07-08; Industry Group: Biotechnology; Date of First Sale: 2026-07-06; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 11160000; Federal exemptions: 06b”
Jul 6, 2026SEC Form D ↗
Shape Memory MedicalSEC Form D Debt / note · Form D reports $6.91M sold of $10M offered
Source quote
  • Filed Jul 16, 2026 · amended Jul 31, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Shape Memory Medical Inc.; CIK: 1630786; Address: San Jose, CA; Submission type: D/A; Filing date: 2026-07-31; Industry Group: Other Health Care; Date of First Sale: 2026-07-02; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 6912400; Federal exemptions: 06b”
Jul 2, 2026SEC Form D/A ↗
AmlogenyxSEC Form D Debt / note · Form D reports $10M sold of $20M offered
Source quote
  • Filed Jul 9, 2026 · SEC Form D ↗
    “Name of Issuer: Amlogenyx Inc.; CIK: 2031988; Address: Novato, CA; Submission type: D; Filing date: 2026-07-09; Industry Group: Biotechnology; Date of First Sale: 2026-07-01; Types of Securities Offered: Other (Convertible Promissory Notes and equity securities issuable upon conversion thereof); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 10000000; Federal exemptions: 06b”
Jul 1, 2026SEC Form D ↗
Merlin Biotech Inc.SEC Form D Debt / note · Form D reports $50K sold
Source quote
  • Filed Aug 11, 2026 · SEC Form D ↗
    “Name of Issuer: Merlin Biotech, Inc.; CIK: 2149714; Address: Doylestown, PA; Submission type: D; Filing date: 2026-08-11; Industry Group: Biotechnology; Date of First Sale: 2026-06-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 50000; Total Amount Sold: 50000; Federal exemptions: 06b”
Jun 30, 2026SEC Form D ↗
410 MedicalSEC Form D Equity · Form D reports $10.32M sold of $12M offered
Source quote
  • Filed Jul 15, 2026 · SEC Form D ↗
    “Name of Issuer: 410 Medical, Inc.; CIK: 1630050; Address: Durham, NC; Submission type: D; Filing date: 2026-07-15; Industry Group: Other Health Care; Date of First Sale: 2026-06-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 10323798; Federal exemptions: 06b”
Jun 30, 2026SEC Form D ↗
ImmunoVecSEC Form D Equity + debt/notes · Form D reports $12.71M sold of $15M offered
Source quote
  • Filed Jul 14, 2026 · SEC Form D ↗
    “Name of Issuer: ImmunoVec, Inc.; CIK: 1914272; Address: Los Angeles, CA; Submission type: D; Filing date: 2026-07-14; Industry Group: Other Technology; Date of First Sale: 2026-06-29; Types of Securities Offered: Equity, Security to be acquired, Other (Preferred Stock and Common Stock issuable upon conversion thereof. Total Offering Amount and Total Amount Sold include conversion of the previously issued convertible securities.); Business combination transaction: false; Total Offering Amount: 14999944; Total Amount Sold: 12705822; Federal exemptions: 06b”
Jun 29, 2026SEC Form D ↗
Vantis VascularSEC Form D Equity · Form D reports $18.64M sold of $21.5M offered
Source quote
  • Filed Jul 10, 2026 · SEC Form D ↗
    “Name of Issuer: Vantis Vascular, Inc.; CIK: 1761882; Address: San Jose, CA; Submission type: D; Filing date: 2026-07-10; Industry Group: Other; Date of First Sale: 2026-06-26; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 21500000; Total Amount Sold: 18639500; Federal exemptions: 06b”
Jun 26, 2026SEC Form D ↗
Cellular LogisticsSEC Form D Debt / note · Form D reports $50K sold of $100K offered
Source quote
  • Filed Jul 15, 2026 · SEC Form D ↗
    “Name of Issuer: Cellular Logistics, Inc.; CIK: 1688621; Address: Madison, WI; Submission type: D; Filing date: 2026-07-15; Industry Group: Biotechnology; Date of First Sale: 2026-06-25; Types of Securities Offered: Debt, Other (convertible promissory note); Business combination transaction: false; Total Offering Amount: 100000; Total Amount Sold: 50000; Federal exemptions: 06b”
Jun 25, 2026SEC Form D ↗
Akadeum Life SciencesSEC Form D Equity · Form D reports $2.13M sold of $3.43M offered
Source quote
  • Filed Jul 9, 2026 · SEC Form D ↗
    “Name of Issuer: AKADEUM LIFE SCIENCES, INC.; CIK: 1622872; Address: Ann Arbor, MI; Submission type: D; Filing date: 2026-07-09; Industry Group: Biotechnology; Date of First Sale: 2026-06-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3427230; Total Amount Sold: 2130557; Federal exemptions: 06b”
Jun 25, 2026SEC Form D ↗
InnSight TechnologySEC Form D Equity · Form D reports $1.35M sold of $3M offered
Source quote
  • Filed Jul 13, 2026 · SEC Form D ↗
    “Name of Issuer: InnSight Technology, Inc.; CIK: 1956287; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-07-13; Industry Group: Other Health Care; Date of First Sale: 2026-06-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1350000; Federal exemptions: 06b”
Jun 23, 2026SEC Form D ↗
Rapalogix HealthSEC Form D Equity · Form D reports $19.11M sold of $25M offered
Source quote
  • Filed Jun 26, 2026 · SEC Form D ↗
    “Name of Issuer: Rapalogix Health, Inc.; CIK: 2008372; Address: Carlsbad, CA; Submission type: D; Filing date: 2026-06-26; Industry Group: Biotechnology; Date of First Sale: 2026-06-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 24999999; Total Amount Sold: 19112746; Federal exemptions: 06b”
Jun 22, 2026SEC Form D ↗
Pneuma RespiratorySEC Form D Equity · Form D reports $3.57M sold (offering size open-ended)
Source quote
  • Filed Jul 1, 2026 · SEC Form D ↗
    “Name of Issuer: Pneuma Respiratory, Inc.; CIK: 1701794; Address: Boone, NC; Submission type: D; Filing date: 2026-07-01; Industry Group: Pharmaceuticals; Date of First Sale: 2026-06-18; Types of Securities Offered: Equity, Option/warrant, Other (Common Stock and Warrants to Purchase Common Stock); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 3570115; Federal exemptions: 06b”
Jun 18, 2026SEC Form D ↗
CYduct DiagnosticsSEC Form D Equity · Form D reports $1.96M sold
Source quote
  • Filed Jul 2, 2026 · SEC Form D ↗
    “Name of Issuer: CYduct Diagnostics, Inc.; CIK: 1388994; Address: Westport, CT; Submission type: D; Filing date: 2026-07-02; Industry Group: Biotechnology; Date of First Sale: 2026-06-15; Types of Securities Offered: Equity, Other (Common Stock); Business combination transaction: false; Total Offering Amount: 1961000; Total Amount Sold: 1961000; Federal exemptions: 06b”
Jun 15, 2026SEC Form D ↗
Qlaris BioSEC Form D Debt / note · Form D reports $3.95M sold
Source quote
  • Filed Jun 17, 2026 · SEC Form D ↗
    “Name of Issuer: Qlaris Bio, Inc.; CIK: 1786717; Address: Dedham, MA; Submission type: D; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2026-06-12; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 3946659; Total Amount Sold: 3946659; Federal exemptions: 06b”
Jun 12, 2026SEC Form D ↗
TETmedicalSEC Form D Equity · Form D reports $3.53M sold of $9.81M offered
Source quote
  • Filed Jun 24, 2026 · SEC Form D ↗
    “Name of Issuer: TETmedical, Inc.; CIK: 1980705; Address: Fair Haven, NJ; Submission type: D; Filing date: 2026-06-24; Industry Group: Biotechnology; Date of First Sale: 2026-06-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 9812108; Total Amount Sold: 3533611; Federal exemptions: 06b”
Jun 12, 2026SEC Form D ↗
NeOnc Technologies Filed as NEONC TECHNOLOGIES HOLDINGS, INC.SEC Form D Equity · Form D reports $5M sold
Source quote
  • Filed Jun 25, 2026 · SEC Form D ↗
    “Name of Issuer: NEONC TECHNOLOGIES HOLDINGS, INC.; CIK: 1979414; Address: Calabasas, CA; Submission type: D; Filing date: 2026-06-25; Industry Group: Biotechnology; Date of First Sale: 2026-06-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b”
Jun 10, 2026SEC Form D ↗
CND Life SciencesSEC Form D Debt / note · Form D reports $6.32M sold
Source quote
  • Filed Jun 16, 2026 · amended Aug 3, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: CND Life Sciences, Inc.; CIK: 1841099; Address: Scottsdale, AZ; Submission type: D/A; Filing date: 2026-08-03; Industry Group: Biotechnology; Date of First Sale: 2026-06-09; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 6316514; Total Amount Sold: 6316514; Federal exemptions: 06b”
Jun 9, 2026SEC Form D/A ↗
CeleCor TherapeuticsSEC Form D Equity · Form D reports $11.86M sold of $15M offered
Source quote
  • Filed Jul 9, 2026 · SEC Form D ↗
    “Name of Issuer: CeleCor Therapeutics, Inc.; CIK: 1705381; Address: Del Mar, CA; Submission type: D; Filing date: 2026-07-09; Industry Group: Pharmaceuticals; Date of First Sale: 2026-06-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 11856325; Federal exemptions: 06b”
Jun 9, 2026SEC Form D ↗
Reservoir NeuroscienceSEC Form D Equity · Form D reports $3M sold of $8M offered
Source quote
  • Filed Jun 17, 2026 · SEC Form D ↗
    “Name of Issuer: Reservoir Neuroscience, Inc.; CIK: 1878332; Address: San Francisco, CA; Submission type: D; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2026-06-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 2999999; Federal exemptions: 06b”
Jun 8, 2026SEC Form D ↗
CSA MedicalSEC Form D Equity · Form D reports $2.91M sold of $11.22M offered
Source quote
  • Filed Jul 23, 2026 · SEC Form D ↗
    “Name of Issuer: CSA Medical, Inc.; CIK: 1403000; Address: Lexington, MA; Submission type: D; Filing date: 2026-07-23; Industry Group: Other; Date of First Sale: 2026-06-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11217710; Total Amount Sold: 2908295; Federal exemptions: 06b”
Jun 8, 2026SEC Form D ↗
Aspira Women's HealthSEC Form D Equity · Form D reports $1.49M sold
Source quote
  • Filed Jun 22, 2026 · SEC Form D ↗
    “Name of Issuer: Aspira Women's Health Inc.; CIK: 926617; Address: Austin, TX; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2026-06-05; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1485000; Total Amount Sold: 1485000; Federal exemptions: 06b”
Jun 5, 2026SEC Form D ↗
EndoSoundSEC Form D Equity · Form D reports $250K sold of $5M offered
Source quote
  • Filed Jun 17, 2026 · SEC Form D ↗
    “Name of Issuer: EndoSound, Inc.; CIK: 1850978; Address: Portland, OR; Submission type: D; Filing date: 2026-06-17; Industry Group: Other Health Care; Date of First Sale: 2026-06-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 250000; Federal exemptions: 06b”
Jun 5, 2026SEC Form D ↗
NucleinSEC Form D Debt / note · Form D reports $9.25M sold of $16.11M offered
Source quote
  • Filed Jun 22, 2026 · amended Aug 14, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Nuclein, LLC; CIK: 1787352; Address: Austin, TX; Submission type: D/A; Filing date: 2026-08-14; Industry Group: Biotechnology; Date of First Sale: 2026-06-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 16114842; Total Amount Sold: 9253488; Federal exemptions: 06b”
Jun 4, 2026SEC Form D/A ↗
Tolerance BioSEC Form D Equity · Form D reports $15.1M sold (offering size open-ended)
Source quote
  • Filed Jun 18, 2026 · SEC Form D ↗
    “Name of Issuer: Tolerance Bio Inc.; CIK: 2075488; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-06-18; Industry Group: Biotechnology; Date of First Sale: 2026-06-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 15101584; Federal exemptions: 06b”
Jun 3, 2026SEC Form D ↗
Channel RoboticsSEC Form D Equity · Form D reports $4.72M sold
Source quote
  • Filed Jun 3, 2026 · SEC Form D ↗
    “Name of Issuer: CHANNEL ROBOTICS, INC.; CIK: 2045979; Address: Del Mar, CA; Submission type: D; Filing date: 2026-06-03; Industry Group: Other Health Care; Date of First Sale: 2026-06-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4718586; Total Amount Sold: 4718586; Federal exemptions: 06b”
Jun 2, 2026SEC Form D ↗
Thiogenesis Therapeutics, Inc.SEC Form D Equity · Form D reports $29K sold
Source quote
  • Filed Jun 9, 2026 · SEC Form D ↗
    “Name of Issuer: Thiogenesis Therapeutics, Corp.; CIK: 1877778; Address: Ontario, Canada; Submission type: D; Filing date: 2026-06-09; Industry Group: Biotechnology; Date of First Sale: 2026-06-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 28964; Total Amount Sold: 28964; Federal exemptions: 06b”
Jun 1, 2026SEC Form D ↗
ContralineSEC Form D Equity · Form D reports $55.8M sold of $115.93M offered
Source quote
  • Filed Jun 10, 2026 · SEC Form D ↗
    “Name of Issuer: Contraline, Inc.; CIK: 1818752; Address: Charlottesville, VA; Submission type: D; Filing date: 2026-06-10; Industry Group: Biotechnology; Date of First Sale: 2026-05-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 115929658; Total Amount Sold: 55804741; Federal exemptions: 06b”
May 29, 2026SEC Form D ↗
Human ContinuumSEC Form D Equity · Form D reports $722K sold
Source quote
  • Filed Jun 5, 2026 · SEC Form D ↗
    “Name of Issuer: Human Continuum Inc.; CIK: 2138781; Address: Jupiter, FL; Submission type: D; Filing date: 2026-06-05; Industry Group: Other; Date of First Sale: 2026-05-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 722500; Total Amount Sold: 722500; Federal exemptions: 06b”
May 29, 2026SEC Form D ↗
Medicenna Therapeutics, Inc.SEC Form D Equity · Form D reports $253K sold of $2.34M offered
Source quote
  • Filed Jul 6, 2026 · SEC Form D ↗
    “Name of Issuer: Medicenna Therapeutics Corp.; CIK: 1807983; Address: Ontario, Canada; Submission type: D; Filing date: 2026-07-06; Industry Group: Biotechnology; Date of First Sale: 2026-05-28; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (Each Unit is comprised of 1 common share and 1/2 of 1 common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional Share at an exercise price of CDN$0.65 per Share for a period of 3 years following May 28, 2026.); Business combination transaction: false; Total Offering Amount: 2343400; Total Amount Sold: 253458; Federal exemptions: 06b”
May 28, 2026SEC Form D ↗
Anodyne NanotechSEC Form D Equity · Form D reports $12.6M sold of $17.26M offered
Source quote
  • Filed Jun 11, 2026 · SEC Form D ↗
    “Name of Issuer: Anodyne Nanotech, Inc.; CIK: 1818572; Address: Boston, MA; Submission type: D; Filing date: 2026-06-11; Industry Group: Other Health Care; Date of First Sale: 2026-05-27; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 17259023; Total Amount Sold: 12597058; Federal exemptions: 06b”
May 27, 2026SEC Form D ↗
Spine BioPharmaSEC Form D Equity · Form D reports $385K sold of $8.5M offered
Source quote
  • Filed Jun 5, 2026 · SEC Form D ↗
    “Name of Issuer: Spine BioPharma, Inc.; CIK: 1852647; Address: New York, NY; Submission type: D; Filing date: 2026-06-05; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8500000; Total Amount Sold: 384798; Federal exemptions: 06b”
May 22, 2026SEC Form D ↗
Antlia Bioscience, Inc.SEC Form D Equity · Form D reports $6M sold of $20M offered
Source quote
  • Filed Jun 5, 2026 · SEC Form D ↗
    “Name of Issuer: Antlia Bioscience, Inc.; CIK: 1829522; Address: Encinitas, CA; Submission type: D; Filing date: 2026-06-05; Industry Group: Biotechnology; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 6000000; Federal exemptions: 06b”
May 22, 2026SEC Form D ↗
Optimeos Life Sciences, Inc.SEC Form D Debt / note · Form D reports $1M sold of $2M offered
Source quote
  • Filed Jun 3, 2026 · SEC Form D ↗
    “Name of Issuer: Optimeos Life Sciences, Inc.; CIK: 1819114; Address: Princeton, NJ; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-05-22; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1000000; Federal exemptions: 06b”
May 22, 2026SEC Form D ↗
MaxQ MedicalSEC Form D Equity · Form D reports $31.53M sold
Source quote
  • Filed Aug 19, 2026 · SEC Form D ↗
    “Name of Issuer: MaxQ Medical Inc.; CIK: 2027191; Address: Sunnyvale, CA; Submission type: D; Filing date: 2026-08-19; Industry Group: Manufacturing; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31529997; Total Amount Sold: 31529997; Federal exemptions: 06b, 4a5”
May 22, 2026SEC Form D ↗
Cerium PharmaceuticalsSEC Form D Equity · Form D reports $750K sold of $2.54M offered
Source quote
  • Filed Aug 6, 2026 · SEC Form D ↗
    “Name of Issuer: Cerium Pharmaceuticals, Inc.; CIK: 1677995; Address: Gaithersburg, MD; Submission type: D; Filing date: 2026-08-06; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2544000; Total Amount Sold: 750000; Federal exemptions: 06b”
May 22, 2026SEC Form D ↗
Infinant HealthSEC Form D Equity · Form D reports $39.25M sold of $118.23M offered
Source quote
  • Filed Jun 8, 2026 · SEC Form D ↗
    “Name of Issuer: Infinant Health, Inc.; CIK: 2139235; Address: Sacramento, CA; Submission type: D; Filing date: 2026-06-08; Industry Group: Other Health Care; Date of First Sale: 2026-05-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 118230513; Total Amount Sold: 39247552; Federal exemptions: 06b”
May 21, 2026SEC Form D ↗
HCW BiologicsSEC Form D Equity · Form D reports $4M sold
Source quote
  • Filed Jun 8, 2026 · SEC Form D ↗
    “Name of Issuer: HCW Biologics Inc.; CIK: 1828673; Address: Miramar, FL; Submission type: D; Filing date: 2026-06-08; Industry Group: Biotechnology; Date of First Sale: 2026-05-21; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b”
May 21, 2026SEC Form D ↗
Cognos TherapeuticsSEC Form D Debt / note · Form D reports $250K sold of $2M offered
Source quote
  • Filed Jul 2, 2026 · SEC Form D ↗
    “Name of Issuer: Cognos Therapeutics Inc; CIK: 1651490; Address: Inglewood, CA; Submission type: D; Filing date: 2026-07-02; Industry Group: Biotechnology; Date of First Sale: 2026-05-21; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 250000; Federal exemptions: 06b”
May 21, 2026SEC Form D ↗
Senti Biosciences Filed as Senti Biosciences Holdings, Inc.SEC Form D Debt / note · Form D reports $10M sold of $40M offered
Source quote
  • Filed Jun 4, 2026 · SEC Form D ↗
    “Name of Issuer: Senti Biosciences Holdings, Inc.; CIK: 1854270; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-04; Industry Group: Biotechnology; Date of First Sale: 2026-05-20; Types of Securities Offered: Debt, Other (Guarantee); Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 10000000; Federal exemptions: 06b”
May 20, 2026SEC Form D ↗
Biolexis TherapeuticsSEC Form D Debt / note · Form D reports $1.6M sold of $12M offered
Source quote
  • Filed Jun 3, 2026 · SEC Form D ↗
    “Name of Issuer: Biolexis Therapeutics Inc.; CIK: 1914060; Address: Lehi, UT; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-05-20; Types of Securities Offered: Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 1600000; Federal exemptions: 06b”
May 20, 2026SEC Form D ↗
ViCardia TherapeuticsSEC Form D Equity · Form D reports $700K sold
Source quote
  • Filed May 21, 2026 · SEC Form D ↗
    “Name of Issuer: ViCardia Therapeutics, Inc.; CIK: 2135564; Address: San Francisco, CA; Submission type: D; Filing date: 2026-05-21; Industry Group: Biotechnology; Date of First Sale: 2026-05-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 700000; Federal exemptions: 06b”
May 19, 2026SEC Form D ↗
Quince TherapeuticsSEC Form D Equity · Form D reports $114.72M sold of $186.42M offered
Source quote
  • Filed Jun 11, 2026 · SEC Form D ↗
    “Name of Issuer: Quince Therapeutics, Inc.; CIK: 1662774; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-11; Industry Group: Biotechnology; Date of First Sale: 2026-05-18; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 186422679; Total Amount Sold: 114720542; Federal exemptions: 06b”
May 18, 2026SEC Form D ↗
Portal BiotechnologiesSEC Form D Equity · Form D reports $9M sold
Source quote
  • Filed May 29, 2026 · SEC Form D ↗
    “Name of Issuer: Portal Biotechnologies, Inc.; CIK: 2049466; Address: Arlington, MA; Submission type: D; Filing date: 2026-05-29; Industry Group: Biotechnology; Date of First Sale: 2026-05-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8999999; Total Amount Sold: 8999999; Federal exemptions: 06b”
May 15, 2026SEC Form D ↗
MBQ PharmaSEC Form D Equity · Form D reports $991K sold (offering size open-ended)
Source quote
  • Filed Aug 14, 2026 · SEC Form D ↗
    “Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 991038; Federal exemptions: 06b”
May 15, 2026SEC Form D ↗
ImaginosticsSEC Form D SAFE · Form D reports $40K sold (offering size open-ended)
Source quote
  • Filed May 29, 2026 · SEC Form D ↗
    “Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-05-29; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer,typically preferred stock,upon the occurrence of specified triggering events including future financingroundS.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 40000; Federal exemptions: 06b”
May 14, 2026SEC Form D ↗
Reprise BiomedicalSEC Form D Equity · Form D reports $9.25M sold of $10M offered
Source quote
  • Filed May 21, 2026 · amended Jul 1, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Reprise Biomedical, Inc.; CIK: 1782236; Address: Plymouth, MN; Submission type: D/A; Filing date: 2026-07-01; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 9246100; Federal exemptions: 06b”
May 14, 2026SEC Form D/A ↗
Oncosynergy, Inc.SEC Form D Equity · Form D reports $6.61M sold of $8.21M offered
Source quote
  • Filed May 26, 2026 · SEC Form D ↗
    “Name of Issuer: ONCOSYNERGY, INC.; CIK: 1556747; Address: Stamford, CT; Submission type: D; Filing date: 2026-05-26; Industry Group: Biotechnology; Date of First Sale: 2026-05-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8208830; Total Amount Sold: 6608832; Federal exemptions: 06b”
May 11, 2026SEC Form D ↗
SentrimedSEC Form D Debt / note · Form D reports $250K sold of $1M offered
Source quote
  • Filed May 13, 2026 · SEC Form D ↗
    “Name of Issuer: Sentrimed, Inc.; CIK: 2014313; Address: Mullica Hill, NJ; Submission type: D; Filing date: 2026-05-13; Industry Group: Biotechnology; Date of First Sale: 2026-05-08; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 250000; Federal exemptions: 06b”
May 8, 2026SEC Form D ↗
GT Medical TechnologiesSEC Form D Equity · Form D reports $50.06M sold of $100.06M offered
Source quote
  • Filed Jul 22, 2026 · SEC Form D ↗
    “Name of Issuer: GT MEDICAL TECHNOLOGIES, INC.; CIK: 1723008; Address: Tempe, AZ; Submission type: D; Filing date: 2026-07-22; Industry Group: Other Health Care; Date of First Sale: 2026-05-08; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 100056698; Total Amount Sold: 50056676; Federal exemptions: 06b”
May 8, 2026SEC Form D ↗
Illuminare BiotechnologiesSEC Form D Equity · Form D reports $3.65M sold of $4M offered
Source quote
  • Filed Jun 4, 2026 · SEC Form D ↗
    “Name of Issuer: Illuminare Biotechnologies Inc; CIK: 1701523; Address: Brooklyn, NY; Submission type: D; Filing date: 2026-06-04; Industry Group: Biotechnology; Date of First Sale: 2026-05-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 3650000; Federal exemptions: 06b”
May 7, 2026SEC Form D ↗
Remedium BioSEC Form D Equity · Form D reports $1.5M sold of $10M offered
Source quote
  • Filed May 18, 2026 · SEC Form D ↗
    “Name of Issuer: Remedium Bio Inc.; CIK: 1892414; Address: Needham, MA; Submission type: D; Filing date: 2026-05-18; Industry Group: Biotechnology; Date of First Sale: 2026-05-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 1500000; Federal exemptions: 06b”
May 6, 2026SEC Form D ↗
Allyx Therapeutics Inc.SEC Form D Equity · Form D reports $26.43M sold of $30M offered
Source quote
  • Filed May 11, 2026 · SEC Form D ↗
    “Name of Issuer: Allyx Therapeutics, Inc.; CIK: 1865257; Address: New Haven, CT; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-05-04; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 29999999; Total Amount Sold: 26427730; Federal exemptions: 06b”
May 4, 2026SEC Form D ↗
CNS PharmaceuticalsSEC Form D Equity · Form D reports $22.52M sold
Source quote
  • Filed May 19, 2026 · SEC Form D ↗
    “Name of Issuer: CNS Pharmaceuticals, Inc.; CIK: 1729427; Address: Houston, TX; Submission type: D; Filing date: 2026-05-19; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-04; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 22525000; Total Amount Sold: 22525000; Federal exemptions: 06b”
May 4, 2026SEC Form D ↗
Miach OrthopaedicsSEC Form D Debt / note · Form D reports $6.5M sold
Source quote
  • Filed May 7, 2026 · SEC Form D ↗
    “Name of Issuer: Miach Orthopaedics Inc.; CIK: 1964453; Address: Westborough, MA; Submission type: D; Filing date: 2026-05-07; Industry Group: Other Health Care; Date of First Sale: 2026-05-01; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 6500000; Total Amount Sold: 6500000; Federal exemptions: 06b”
May 1, 2026SEC Form D ↗
Galaxy DiagnosticsSEC Form D Equity · Form D reports $3.02M sold of $5.7M offered
Source quote
  • Filed Jun 3, 2026 · SEC Form D ↗
    “Name of Issuer: Galaxy Diagnostics, Inc.; CIK: 1462444; Address: Durham, NC; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-05-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5699460; Total Amount Sold: 3019645; Federal exemptions: 06b”
May 1, 2026SEC Form D ↗
PROTECT3D Inc.SEC Form D Debt / note · Form D reports $845K sold of $1M offered
Source quote
  • Filed Jun 4, 2026 · SEC Form D ↗
    “Name of Issuer: Protect3d, Inc.; CIK: 1792316; Address: Durham, NC; Submission type: D; Filing date: 2026-06-04; Industry Group: Other Health Care; Date of First Sale: 2026-04-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 845000; Federal exemptions: 06b”
Apr 30, 2026SEC Form D ↗
Solius Filed as Solius Labs, Inc.SEC Form D Equity · Form D reports $3.5M sold of $17.91M offered
Source quote
  • Filed May 14, 2026 · SEC Form D ↗
    “Name of Issuer: Solius Labs, Inc.; CIK: 1537914; Address: Bainbridge Island, WA; Submission type: D; Filing date: 2026-05-14; Industry Group: Other Health Care; Date of First Sale: 2026-04-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 17911021; Total Amount Sold: 3500000; Federal exemptions: 06b”
Apr 29, 2026SEC Form D ↗
EyenukSEC Form D Equity · Form D reports $5.61M sold of $5.65M offered
Source quote
  • Filed Jun 22, 2026 · SEC Form D ↗
    “Name of Issuer: Eyenuk, Inc.; CIK: 1679996; Address: Woodland Hills, CA; Submission type: D; Filing date: 2026-06-22; Industry Group: Other Health Care; Date of First Sale: 2026-04-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5648246; Total Amount Sold: 5607046; Federal exemptions: 06b”
Apr 28, 2026SEC Form D ↗
Pagari Life ScienceSEC Form D Equity · Form D reports $97K sold of $300K offered
Source quote
  • Filed May 12, 2026 · SEC Form D ↗
    “Name of Issuer: Pagari Life Science Corp.; CIK: 1993125; Address: Bethalta, IL; Submission type: D; Filing date: 2026-05-12; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 97494; Federal exemptions: 06b”
Apr 28, 2026SEC Form D ↗
Perimeter Medical Imaging AISEC Form D Debt / note · Form D reports $4M sold
Source quote
  • Filed Jun 3, 2026 · amended Jun 18, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Perimeter Medical Imaging AI, Inc.; CIK: 1818286; Address: Ontario, Canada; Submission type: D/A; Filing date: 2026-06-18; Industry Group: Other Health Care; Date of First Sale: 2026-04-27; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b”
Apr 27, 2026SEC Form D/A ↗
CresilonSEC Form D Debt / note · Form D reports $29M sold
Source quote
  • Filed Apr 29, 2026 · amended Jun 26, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D/A; Filing date: 2026-06-26; Industry Group: Biotechnology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 29000000; Total Amount Sold: 28999199; Federal exemptions: 06c”
Apr 24, 2026SEC Form D/A ↗
ScitaraSEC Form D Debt / note · Form D reports $5M sold
Source quote
  • Filed Jun 18, 2026 · SEC Form D ↗
    “Name of Issuer: Scitara Corp; CIK: 1788003; Address: Marlborough, MA; Submission type: D; Filing date: 2026-06-18; Industry Group: Other Technology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b”
Apr 24, 2026SEC Form D ↗
Natsar Pharmaceuticals, Inc.SEC Form D Equity · Form D reports $4.22M sold (offering size open-ended)
Source quote
  • Filed May 8, 2026 · SEC Form D ↗
    “Name of Issuer: Natsar Pharmaceuticals, Inc.; CIK: 2134002; Address: Ellicott City, MD; Submission type: D; Filing date: 2026-05-08; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 4221000; Federal exemptions: 06b”
Apr 23, 2026SEC Form D ↗
Lighthouse PharmaceuticalsSEC Form D Equity · Form D reports $15.21M sold
Source quote
  • Filed May 7, 2026 · SEC Form D ↗
    “Name of Issuer: Lighthouse Pharmaceuticals, Inc.; CIK: 2133359; Address: Novato, CA; Submission type: D; Filing date: 2026-05-07; Industry Group: Other; Date of First Sale: 2026-04-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15206800; Total Amount Sold: 15206800; Federal exemptions: 06b”
Apr 22, 2026SEC Form D ↗
Verismo TherapeuticsSEC Form D Equity · Form D reports $28M sold
Source quote
  • Filed May 20, 2026 · SEC Form D ↗
    “Name of Issuer: Verismo Therapeutics, Inc.; CIK: 1855431; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-05-20; Industry Group: Other Health Care; Date of First Sale: 2026-04-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 28000000; Total Amount Sold: 28000000; Federal exemptions: 06b”
Apr 21, 2026SEC Form D ↗
Mitera BiosciencesSEC Form D SAFE · Form D reports $1.1M sold of $3M offered
Source quote
  • Filed May 6, 2026 · SEC Form D ↗
    “Name of Issuer: Mitera Biosciences Inc.; CIK: 2022224; Address: Bellevue, WA; Submission type: D; Filing date: 2026-05-06; Industry Group: Biotechnology; Date of First Sale: 2026-04-21; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1100000; Federal exemptions: 06b”
Apr 21, 2026SEC Form D ↗
Enveric BiosciencesSEC Form D Equity · Form D reports $5M sold
Source quote
  • Filed May 4, 2026 · SEC Form D ↗
    “Name of Issuer: Enveric Biosciences, Inc.; CIK: 890821; Address: Cambridge, MA; Submission type: D; Filing date: 2026-05-04; Industry Group: Biotechnology; Date of First Sale: 2026-04-17; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 5000002; Total Amount Sold: 5000002; Federal exemptions: 06b”
Apr 17, 2026SEC Form D ↗
CASI PharmaceuticalsSEC Form D Debt / note · Form D reports $5M sold
Source quote
  • Filed Apr 28, 2026 · SEC Form D ↗
    “Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-04-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-17; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b”
Apr 17, 2026SEC Form D ↗
Athos TherapeuticsSEC Form D Debt / note · Form D reports $10.28M sold of $20M offered
Source quote
  • Filed May 15, 2026 · SEC Form D ↗
    “Name of Issuer: Athos Therapeutics, Inc.; CIK: 1885079; Address: Torrance, CA; Submission type: D; Filing date: 2026-05-15; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-17; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 10282887; Federal exemptions: 06b”
Apr 17, 2026SEC Form D ↗
Preceptis MedicalSEC Form D Equity · Form D reports $2.56M sold of $6.9M offered
Source quote
  • Filed May 1, 2026 · SEC Form D ↗
    “Name of Issuer: Preceptis Medical, Inc.; CIK: 1537953; Address: Golden Valley, MN; Submission type: D; Filing date: 2026-05-01; Industry Group: Other Health Care; Date of First Sale: 2026-04-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6900000; Total Amount Sold: 2561370; Federal exemptions: 06b”
Apr 16, 2026SEC Form D ↗
Illexcor TherapeuticsSEC Form D Equity · Form D reports $13M sold of $69M offered
Source quote
  • Filed May 8, 2026 · SEC Form D ↗
    “Name of Issuer: Illexcor Therapeutics, Inc.; CIK: 2132799; Address: Henrico, VA; Submission type: D; Filing date: 2026-05-08; Industry Group: Biotechnology; Date of First Sale: 2026-04-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69000000; Total Amount Sold: 13000000; Federal exemptions: 06b”
Apr 15, 2026SEC Form D ↗
General OncologySEC Form D SAFE · Form D reports $4.81M sold
Source quote
  • Filed Apr 23, 2026 · SEC Form D ↗
    “Name of Issuer: General Oncology, Inc.; CIK: 1658021; Address: Newton, MA; Submission type: D; Filing date: 2026-04-23; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-15; Types of Securities Offered: Option/warrant, Other (Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.); Business combination transaction: false; Total Offering Amount: 4805299; Total Amount Sold: 4805299; Federal exemptions: 06b”
Apr 15, 2026SEC Form D ↗
PanGIA BiotechSEC Form D Debt / note · Form D reports $1.58M sold
Source quote
  • Filed May 11, 2026 · SEC Form D ↗
    “Name of Issuer: PANGIA BIOTECH, INC.; CIK: 2125789; Address: Delray Beach, FL; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-04-08; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1580000; Total Amount Sold: 1580000; Federal exemptions: 06c”
Apr 8, 2026SEC Form D ↗
TetrousSEC Form D Equity · Form D reports $1.74M sold of $4M offered
Source quote
  • Filed Apr 22, 2026 · SEC Form D ↗
    “Name of Issuer: Tetrous, Inc.; CIK: 2002357; Address: Sherman Oaks, CA; Submission type: D; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2026-04-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1741024; Federal exemptions: 06b”
Apr 8, 2026SEC Form D ↗
Click Therapeutics, Inc.SEC Form D Equity · Form D reports $50M sold
Source quote
  • Filed Oct 1, 2026 · SEC Form D ↗
    “Name of Issuer: Click Therapeutics, Inc.; CIK: 1623326; Address: New York, NY; Submission type: D; Filing date: 2026-10-01; Industry Group: Other Health Care; Date of First Sale: 2026-04-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 49999999; Total Amount Sold: 49999999; Federal exemptions: 06b”
Apr 7, 2026SEC Form D ↗
Bonum TherapeuticsSEC Form D Equity · Form D reports $26.91M sold of $32.3M offered
Source quote
  • Filed Apr 17, 2026 · SEC Form D ↗
    “Name of Issuer: Bonum Therapeutics, Inc.; CIK: 1898714; Address: Seattle, WA; Submission type: D; Filing date: 2026-04-17; Industry Group: Biotechnology; Date of First Sale: 2026-04-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 32301381; Total Amount Sold: 26907396; Federal exemptions: 06b”
Apr 3, 2026SEC Form D ↗
Bond BiosciencesSEC Form D Equity · Form D reports $7.61M sold of $15M offered
Source quote
  • Filed Apr 8, 2026 · amended Oct 5, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D/A; Filing date: 2026-10-05; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 7614879; Federal exemptions: 06b”
Apr 1, 2026SEC Form D/A ↗
CalyxoSEC Form D Equity · Form D reports $40.1M sold
Source quote
  • Filed Apr 16, 2026 · SEC Form D ↗
    “Name of Issuer: Calyxo, Inc.; CIK: 1668653; Address: Pleasanton, CA; Submission type: D; Filing date: 2026-04-16; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40099963; Total Amount Sold: 40099963; Federal exemptions: 06b”
Apr 1, 2026SEC Form D ↗
EnteroBiotixSEC Form D Equity · Form D reports $5.34M sold (offering size open-ended)
Source quote
  • Filed Apr 9, 2026 · SEC Form D ↗
    “Name of Issuer: EnteroBiotix LTD; CIK: 1946072; Address: Glasgow, United Kingdom; Submission type: D; Filing date: 2026-04-09; Industry Group: Biotechnology; Date of First Sale: 2026-03-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 5341593; Federal exemptions: 06b”
Mar 30, 2026SEC Form D ↗
Gilgamesh PharmaSEC Form D SAFE · Form D reports $2.25M sold of $15M offered
Source quote
  • Filed Mar 31, 2026 · SEC Form D ↗
    “Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-03-31; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-27; Types of Securities Offered: Option/warrant, Other (Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.); Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 2250000; Federal exemptions: 06b”
Mar 27, 2026SEC Form D ↗
Novel MicrodevicesSEC Form D Debt / note · Form D reports $1M sold of $8M offered
Source quote
  • Filed Apr 27, 2026 · SEC Form D ↗
    “Name of Issuer: Novel Microdevices, Inc.; CIK: 1837242; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-27; Industry Group: Other; Date of First Sale: 2026-03-27; Types of Securities Offered: Debt, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 1000000; Federal exemptions: 06b”
Mar 27, 2026SEC Form D ↗
TAS MedicalSEC Form D Equity · Form D reports $3.89M sold of $6.51M offered
Source quote
  • Filed Apr 10, 2026 · SEC Form D ↗
    “Name of Issuer: TAS Medical, Inc.; CIK: 1739794; Address: Windermere, FL; Submission type: D; Filing date: 2026-04-10; Industry Group: Other Technology; Date of First Sale: 2026-03-27; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6511056; Total Amount Sold: 3888800; Federal exemptions: 06b”
Mar 27, 2026SEC Form D ↗
OptimviaSEC Form D Equity · Form D reports $75K sold of $500K offered
Source quote
  • Filed Apr 8, 2026 · SEC Form D ↗
    “Name of Issuer: Optimvia, LLC; CIK: 1705874; Address: Cincinnati, OH; Submission type: D; Filing date: 2026-04-08; Industry Group: Other Health Care; Date of First Sale: 2026-03-26; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 75000; Federal exemptions: 06b”
Mar 26, 2026SEC Form D ↗
Alume Biosciences, Inc.SEC Form D SAFE · Form D reports $2.16M sold of $8M offered
Source quote
  • Filed Apr 6, 2026 · amended May 8, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-05-08; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 2160000; Federal exemptions: 06b”
Mar 24, 2026SEC Form D/A ↗
Myra EB SystemsSEC Form D Debt / note · Form D reports $10K sold of $2M offered
Source quote
  • Filed Apr 7, 2026 · SEC Form D ↗
    “Name of Issuer: Myra EB Systems LLC; CIK: 2125905; Address: Boxborough, MA; Submission type: D; Filing date: 2026-04-07; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 10000; Federal exemptions: 06b”
Mar 24, 2026SEC Form D ↗
Artelo BiosciencesSEC Form D Debt / note · Form D reports $315K sold
Source quote
  • Filed Mar 27, 2026 · SEC Form D ↗
    “Name of Issuer: ARTELO BIOSCIENCES, INC.; CIK: 1621221; Address: Solana Beach, CA; Submission type: D; Filing date: 2026-03-27; Industry Group: Biotechnology; Date of First Sale: 2026-03-20; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 315000; Total Amount Sold: 315000; Federal exemptions: 06b”
Mar 20, 2026SEC Form D ↗
Affinity BiosensorsSEC Form D SAFE · Form D reports $4.9M sold of $10M offered
Source quote
  • Filed Mar 23, 2026 · amended Oct 14, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D/A; Filing date: 2026-10-14; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4904771; Federal exemptions: 06b”
Mar 20, 2026SEC Form D/A ↗
Pearl Diagnostics, Inc.SEC Form D Equity · Form D reports $11.15M sold
Source quote
  • Filed Apr 21, 2026 · SEC Form D ↗
    “Name of Issuer: Pearl Diagnostics, Inc.; CIK: 1922830; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-21; Industry Group: Biotechnology; Date of First Sale: 2026-03-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11150000; Total Amount Sold: 11150000; Federal exemptions: 06b”
Mar 19, 2026SEC Form D ↗
SurgiBoxSEC Form D SAFE · Form D reports $486K sold of $3M offered
Source quote
  • Filed Sep 17, 2026 · SEC Form D ↗
    “Name of Issuer: SurgiBox Inc.; CIK: 1930227; Address: Cambridge, MA; Submission type: D; Filing date: 2026-09-17; Industry Group: Biotechnology; Date of First Sale: 2026-03-19; Types of Securities Offered: Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 486000; Federal exemptions: 06b”
Mar 19, 2026SEC Form D ↗
Waypoint OrthopedicsSEC Form D Debt / note · Form D reports $300K sold
Source quote
  • Filed Mar 19, 2026 · SEC Form D ↗
    “Name of Issuer: Waypoint Orthopedics, Inc.; CIK: 1828399; Address: Malvern, PA; Submission type: D; Filing date: 2026-03-19; Industry Group: Other Health Care; Date of First Sale: 2026-03-16; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 300000; Federal exemptions: 06b”
Mar 16, 2026SEC Form D ↗
Jana CareSEC Form D Equity · Form D reports $1.39M sold of $6M offered
Source quote
  • Filed Mar 26, 2026 · SEC Form D ↗
    “Name of Issuer: Jana Care, Inc.; CIK: 1696563; Address: Watertown, MA; Submission type: D; Filing date: 2026-03-26; Industry Group: Other Health Care; Date of First Sale: 2026-03-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5999995; Total Amount Sold: 1390635; Federal exemptions: 06b”
Mar 12, 2026SEC Form D ↗
ApnimedSEC Form D Equity · Form D reports $25M sold
Source quote
  • Filed Mar 27, 2026 · SEC Form D ↗
    “Name of Issuer: Apnimed, Inc.; CIK: 1745648; Address: Cambridge, MA; Submission type: D; Filing date: 2026-03-27; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 24999994; Total Amount Sold: 24999994; Federal exemptions: 06b”
Mar 11, 2026SEC Form D ↗
Numerion LabsSEC Form D Equity · Form D reports $19.79M sold of $35M offered
Source quote
  • Filed Mar 19, 2026 · SEC Form D ↗
    “Name of Issuer: Numerion Labs, Inc.; CIK: 1736153; Address: San Francisco, CA; Submission type: D; Filing date: 2026-03-19; Industry Group: Biotechnology; Date of First Sale: 2026-03-10; Types of Securities Offered: Equity, Other (Offer and sale of Series D Preferred Stock and Common Stock issuable upon conversion thereof. Certain outstanding shares of Common Stock were exchanged for shares of a specific series of Issuer's Preferred Stock for no consideration.); Business combination transaction: false; Total Offering Amount: 35000000; Total Amount Sold: 19794945; Federal exemptions: 06b”
Mar 10, 2026SEC Form D ↗
Biosolution DesignsSEC Form D Equity · Form D reports $705K sold of $1.5M offered
Source quote
  • Filed Mar 12, 2026 · SEC Form D ↗
    “Name of Issuer: BioSolution Designs, Inc.; CIK: 2110022; Address: Frederick, MD; Submission type: D; Filing date: 2026-03-12; Industry Group: Biotechnology; Date of First Sale: 2026-03-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 705000; Federal exemptions: 06b”
Mar 9, 2026SEC Form D ↗
Liquet MedicalSEC Form D Debt / note · Form D reports $75K sold of $1.5M offered
Source quote
  • Filed Mar 23, 2026 · SEC Form D ↗
    “Name of Issuer: Liquet Medical Inc.; CIK: 1887812; Address: Glen Allen, VA; Submission type: D; Filing date: 2026-03-23; Industry Group: Other Health Care; Date of First Sale: 2026-03-07; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 75000; Federal exemptions: 06b”
Mar 7, 2026SEC Form D ↗
Consano Bio, Inc.SEC Form D Equity · Form D reports $34.82M sold of $48.86M offered
Source quote
  • Filed Mar 20, 2026 · SEC Form D ↗
    “Name of Issuer: Consano Bio, Inc.; CIK: 1981285; Address: Burlington, MA; Submission type: D; Filing date: 2026-03-20; Industry Group: Biotechnology; Date of First Sale: 2026-03-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 48858795; Total Amount Sold: 34824466; Federal exemptions: 06b”
Mar 6, 2026SEC Form D ↗
BioLattice Ophthalmics, Inc. Filed as BioLattice Ophthalmics, Inc,SEC Form D Equity · Form D reports $575K sold of $2.5M offered
Source quote
  • Filed Mar 30, 2026 · SEC Form D ↗
    “Name of Issuer: BioLattice Ophthalmics, Inc,; CIK: 2125596; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-03-30; Industry Group: Biotechnology; Date of First Sale: 2026-03-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 575000; Federal exemptions: 06b”
Mar 6, 2026SEC Form D ↗
Marrow Access TechnologiesSEC Form D Equity + debt/notes · Form D reports $100K sold of $300K offered
Source quote
  • Filed Apr 9, 2026 · SEC Form D ↗
    “Name of Issuer: Marrow Access Technologies, Inc.; CIK: 1758381; Address: Eden Prairie, MN; Submission type: D; Filing date: 2026-04-09; Industry Group: Other Health Care; Date of First Sale: 2026-03-04; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 100000; Federal exemptions: 06b”
Mar 4, 2026SEC Form D ↗
Kala Pharmaceuticals, Inc. Filed as KALA BIO, Inc.SEC Form D Equity · Form D reports $1.75M sold
Source quote
  • Filed Mar 17, 2026 · SEC Form D ↗
    “Name of Issuer: KALA BIO, Inc.; CIK: 1479419; Address: Arlington, MA; Submission type: D; Filing date: 2026-03-17; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1753500; Total Amount Sold: 1753500; Federal exemptions: 06b”
Mar 3, 2026SEC Form D ↗
Inso Biosciences Inc.SEC Form D Debt / note · Form D reports $750K sold of $3M offered
Source quote
  • Filed Apr 10, 2026 · SEC Form D ↗
    “Name of Issuer: Inso Biosciences Inc.; CIK: 1906426; Address: Ithaca, NY; Submission type: D; Filing date: 2026-04-10; Industry Group: Biotechnology; Date of First Sale: 2026-03-03; Types of Securities Offered: Debt, Option/warrant, Security to be acquired, Other (Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be acquired upon such conversion.); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 750000; Federal exemptions: 06b”
Mar 3, 2026SEC Form D ↗
Inflammasome TherapeuticsSEC Form D Equity · Form D reports $13.16M sold
Source quote
  • Filed May 4, 2026 · SEC Form D ↗
    “Name of Issuer: Inflammasome Therapeutics, Inc.; CIK: 1989925; Address: Newton, MA; Submission type: D; Filing date: 2026-05-04; Industry Group: Biotechnology; Date of First Sale: 2026-02-27; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 13155645; Total Amount Sold: 13155645; Federal exemptions: 06b”
Feb 27, 2026SEC Form D ↗
ThrombolexSEC Form D Equity + debt/notes · Form D reports $32.77M sold of $51.1M offered
Source quote
  • Filed Mar 12, 2026 · SEC Form D ↗
    “Name of Issuer: Thrombolex, Inc.; CIK: 1703764; Address: Kingston, NJ; Submission type: D; Filing date: 2026-03-12; Industry Group: Other Health Care; Date of First Sale: 2026-02-26; Types of Securities Offered: Equity, Other (Includes Conversion of Outstanding Notes); Business combination transaction: false; Total Offering Amount: 51105000; Total Amount Sold: 32775000; Federal exemptions: 06b”
Feb 26, 2026SEC Form D ↗
Ramona Optics Inc.SEC Form D Equity · Form D reports $26.04M sold of $31.04M offered
Source quote
  • Filed Mar 12, 2026 · SEC Form D ↗
    “Name of Issuer: Ramona Optics, Inc.; CIK: 1841317; Address: Durham, NC; Submission type: D; Filing date: 2026-03-12; Industry Group: Biotechnology; Date of First Sale: 2026-02-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31037360; Total Amount Sold: 26037360; Federal exemptions: 06b”
Feb 25, 2026SEC Form D ↗
GeneCaptureSEC Form D Debt / note · Form D reports $50K sold of $3M offered
Source quote
  • Filed Feb 26, 2026 · SEC Form D ↗
    “Name of Issuer: GeneCapture, Inc.; CIK: 1559176; Address: Huntsville, AL; Submission type: D; Filing date: 2026-02-26; Industry Group: Other; Date of First Sale: 2026-02-25; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 50000; Federal exemptions: 06b”
Feb 25, 2026SEC Form D ↗
Levita Magnetics Filed as Levita Magnetics International Corp.SEC Form D Equity · Form D reports $30.71M sold of $57.71M offered
Source quote
  • Filed Apr 28, 2026 · SEC Form D ↗
    “Name of Issuer: Levita Magnetics International Corp.; CIK: 1911389; Address: Mountain View, CA; Submission type: D; Filing date: 2026-04-28; Industry Group: Other Health Care; Date of First Sale: 2026-02-24; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 57707603; Total Amount Sold: 30707603; Federal exemptions: 06b”
Feb 24, 2026SEC Form D ↗
Alphina TherapeuticsSEC Form D SAFE · Form D reports $154K sold of $10M offered
Source quote
  • Filed Mar 16, 2026 · SEC Form D ↗
    “Name of Issuer: Alphina Therapeutics, Inc.; CIK: 1882991; Address: New Haven, CT; Submission type: D; Filing date: 2026-03-16; Industry Group: Biotechnology; Date of First Sale: 2026-02-23; Types of Securities Offered: Option/warrant, Other (Simple Agreements for Future Equity (SAFEs)); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 153715; Federal exemptions: 06b”
Feb 23, 2026SEC Form D ↗
NuvairaSEC Form D SAFE · Form D reports $35.76M sold of $63.58M offered
Source quote
  • Filed Mar 4, 2026 · SEC Form D ↗
    “Name of Issuer: NUVAIRA, INC.; CIK: 1461990; Address: Minneapolis, MN; Submission type: D; Filing date: 2026-03-04; Industry Group: Other Health Care; Date of First Sale: 2026-02-20; Types of Securities Offered: Equity, Other (Conversion of SAFEs; Conversion of debt); Business combination transaction: false; Total Offering Amount: 63576279; Total Amount Sold: 35764878; Federal exemptions: 06b”
Feb 20, 2026SEC Form D ↗
Linnaeus TherapeuticsSEC Form D Equity · Form D reports $4.99M sold of $10M offered
Source quote
  • Filed Feb 27, 2026 · amended Apr 2, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-04-02; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4992000; Federal exemptions: 06b”
Feb 17, 2026SEC Form D/A ↗
Slate MedicinesSEC Form D Equity · Form D reports $10M sold of $130M offered
Source quote
  • Filed Mar 11, 2026 · SEC Form D ↗
    “Name of Issuer: Slate Medicines, Inc.; CIK: 2117806; Address: Boston, MA; Submission type: D; Filing date: 2026-03-11; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 130000000; Total Amount Sold: 9999992; Federal exemptions: 06b”
Feb 17, 2026SEC Form D ↗
Virtuoso SurgicalSEC Form D Equity · Form D reports $2.9M sold of $10M offered
Source quote
  • Filed May 11, 2026 · SEC Form D ↗
    “Name of Issuer: Virtuoso Surgical, Inc.; CIK: 1742075; Address: Nashville, TN; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-02-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2900000; Federal exemptions: 06b”
Feb 15, 2026SEC Form D ↗
TetraScienceSEC Form D Equity · Form D reports $15M sold
Source quote
  • Filed Feb 27, 2026 · SEC Form D ↗
    “Name of Issuer: TetraScience, Inc.; CIK: 1855742; Address: Boston, MA; Submission type: D; Filing date: 2026-02-27; Industry Group: Other; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 14999985; Total Amount Sold: 14999985; Federal exemptions: 06b”
Feb 13, 2026SEC Form D ↗
Altesa BioSciencesSEC Form D Equity · Form D reports $75M sold
Source quote
  • Filed Feb 23, 2026 · SEC Form D ↗
    “Name of Issuer: Altesa BioSciences, Inc.; CIK: 1960618; Address: College Park, GA; Submission type: D; Filing date: 2026-02-23; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 74999986; Total Amount Sold: 74999986; Federal exemptions: 06b”
Feb 13, 2026SEC Form D ↗
Ancilia BiosciencesSEC Form D Equity · Form D reports $10.08M sold
Source quote
  • Filed Apr 6, 2026 · SEC Form D ↗
    “Name of Issuer: Ancilia Biosciences, Inc.; CIK: 1975776; Address: New York, NY; Submission type: D; Filing date: 2026-04-06; Industry Group: Other; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10076464; Total Amount Sold: 10076464; Federal exemptions: 06b”
Feb 13, 2026SEC Form D ↗
Eldec PharmaceuticalsSEC Form D Debt / note · Form D reports $200K sold of $1.5M offered
Source quote
  • Filed Feb 12, 2026 · SEC Form D ↗
    “Name of Issuer: Eldec Pharmaceuticals, Inc.; CIK: 2110508; Address: Chapel Hill, NC; Submission type: D; Filing date: 2026-02-12; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-11; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 200000; Federal exemptions: 06b”
Feb 11, 2026SEC Form D ↗
Aatru MedicalSEC Form D Debt / note · Form D reports $700K sold of $2M offered
Source quote
  • Filed Feb 18, 2026 · amended Aug 11, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Aatru Medical LLC; CIK: 1709493; Address: Cleveland, OH; Submission type: D/A; Filing date: 2026-08-11; Industry Group: Other Health Care; Date of First Sale: 2026-02-10; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 700000; Federal exemptions: 06b”
Feb 10, 2026SEC Form D/A ↗
ILIAD BiotechnologiesSEC Form D Equity · Form D reports $115.54M sold
Source quote
  • Filed Feb 20, 2026 · SEC Form D ↗
    “Name of Issuer: ILIAD BIOTECHNOLOGIES, INC.; CIK: 2112659; Address: Weston, FL; Submission type: D; Filing date: 2026-02-20; Industry Group: Biotechnology; Date of First Sale: 2026-02-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 115540057; Total Amount Sold: 115540057; Federal exemptions: 06b”
Feb 5, 2026SEC Form D ↗
TelesairSEC Form D Equity · Form D reports $2.96M sold of $6M offered
Source quote
  • Filed Mar 18, 2026 · SEC Form D ↗
    “Name of Issuer: Telesair, Inc.; CIK: 1964253; Address: Irvine, CA; Submission type: D; Filing date: 2026-03-18; Industry Group: Other Technology; Date of First Sale: 2026-02-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6000000; Total Amount Sold: 2955791; Federal exemptions: 06b”
Feb 4, 2026SEC Form D ↗
PAVmed Inc.SEC Form D Equity · Form D reports $30M sold of $60M offered
Source quote
  • Filed Feb 17, 2026 · SEC Form D ↗
    “Name of Issuer: PAVmed Inc.; CIK: 1624326; Address: New York, NY; Submission type: D; Filing date: 2026-02-17; Industry Group: Other Health Care; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 30000000; Federal exemptions: 06b”
Feb 3, 2026SEC Form D ↗
PraeventixSEC Form D Equity · Form D reports $5.6M sold
Source quote
  • Filed Feb 13, 2026 · amended Sep 10, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Praeventix, Inc.; CIK: 1952974; Address: Exton, PA; Submission type: D/A; Filing date: 2026-09-10; Industry Group: Biotechnology; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5601950; Total Amount Sold: 5601950; Federal exemptions: 06b”
Feb 3, 2026SEC Form D/A ↗
Lexicon PharmaceuticalsSEC Form D Equity · Form D reports $55.67M sold of $59.15M offered
Source quote
  • Filed Feb 17, 2026 · SEC Form D ↗
    “Name of Issuer: LEXICON PHARMACEUTICALS, INC.; CIK: 1062822; Address: The Woodlands, TX; Submission type: D; Filing date: 2026-02-17; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-02; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 59150000; Total Amount Sold: 55668255; Federal exemptions: 06b”
Feb 2, 2026SEC Form D ↗
NexEos Diagnostics, Inc.SEC Form D Equity · Form D reports $3M sold
Source quote
  • Filed Feb 17, 2026 · SEC Form D ↗
    “Name of Issuer: NexEos Diagnostics, Inc.; CIK: 1783828; Address: Chester Springs, PA; Submission type: D; Filing date: 2026-02-17; Industry Group: Other Health Care; Date of First Sale: 2026-02-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b”
Feb 2, 2026SEC Form D ↗
CognixionSEC Form D Debt / note · Form D reports $4.05M sold
Source quote
  • Filed Feb 3, 2026 · SEC Form D ↗
    “Name of Issuer: Cognixion Corp; CIK: 1749036; Address: Santa Barbara, CA; Submission type: D; Filing date: 2026-02-03; Industry Group: Other; Date of First Sale: 2026-01-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 4050000; Total Amount Sold: 4050000; Federal exemptions: 06b”
Jan 30, 2026SEC Form D ↗
Trellis BioscienceSEC Form D Equity · Form D reports $6.09M sold (offering size open-ended)
Source quote
  • Filed May 15, 2026 · SEC Form D ↗
    “Name of Issuer: Trellis Bioscience, Inc.; CIK: 1162015; Address: Redwood City, CA; Submission type: D; Filing date: 2026-05-15; Industry Group: Biotechnology; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity, Other (Series C Interests); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 6093000; Federal exemptions: 06b”
Jan 30, 2026SEC Form D ↗
Allinaire TherapeuticsSEC Form D Equity · Form D reports $700K sold
Source quote
  • Filed Apr 14, 2026 · SEC Form D ↗
    “Name of Issuer: Allinaire Therapeutics Inc.; CIK: 2113399; Address: Cleveland, OH; Submission type: D; Filing date: 2026-04-14; Industry Group: Other; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 700000; Federal exemptions: 06b”
Jan 30, 2026SEC Form D ↗
GeniPhysSEC Form D Equity · Form D reports $3M sold of $5.55M offered
Source quote
  • Filed Feb 13, 2026 · SEC Form D ↗
    “Name of Issuer: GeniPhys, Inc.; CIK: 1955873; Address: Indianapolis, IN; Submission type: D; Filing date: 2026-02-13; Industry Group: Other Health Care; Date of First Sale: 2026-01-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5550000; Total Amount Sold: 2999910; Federal exemptions: 06b”
Jan 29, 2026SEC Form D ↗
Mirum PharmaceuticalsSEC Form D Equity · Form D reports $68.48M sold
Source quote
  • Filed Jan 29, 2026 · SEC Form D ↗
    “Name of Issuer: Mirum Pharmaceuticals, Inc.; CIK: 1759425; Address: Foster City, CA; Submission type: D; Filing date: 2026-01-29; Industry Group: Biotechnology; Date of First Sale: 2026-01-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 68480000; Total Amount Sold: 68480000; Federal exemptions: 06c”
Jan 23, 2026SEC Form D ↗
ImmunoMet TherapeuticsSEC Form D Equity · Form D reports $842K sold of $10M offered
Source quote
  • Filed Feb 5, 2026 · SEC Form D ↗
    “Name of Issuer: Immunomet Therapeutics, Inc.; CIK: 2109829; Address: Houston, TX; Submission type: D; Filing date: 2026-02-05; Industry Group: Biotechnology; Date of First Sale: 2026-01-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 842211; Federal exemptions: 06b”
Jan 21, 2026SEC Form D ↗
Ruskid LLCSEC Form D Equity · Form D reports $1.37M sold of $2M offered
Source quote
  • Filed Feb 13, 2026 · SEC Form D ↗
    “Name of Issuer: RUSKID LLC; CIK: 2110722; Address: Rancho Santa FE, CA; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: 2026-01-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1370000; Federal exemptions: 06b”
Jan 16, 2026SEC Form D ↗
AirNexis TherapeuticsSEC Form D Equity · Form D reports $62M sold of $200M offered
Source quote
  • Filed Mar 9, 2026 · SEC Form D ↗
    “Name of Issuer: AirNexis Therapeutics, Inc.; CIK: 2116194; Address: Palo Alto, CA; Submission type: D; Filing date: 2026-03-09; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 200000000; Total Amount Sold: 62000000; Federal exemptions: 06b”
Jan 9, 2026SEC Form D ↗
MultiValent BiotherapiesSEC Form D Equity + debt/notes · Form D reports $10.01M sold (offering size open-ended)
Source quote
  • Filed Mar 2, 2026 · SEC Form D ↗
    “Name of Issuer: MultiValent Biotherapies, Inc.; CIK: 2107846; Address: Los Altos, CA; Submission type: D; Filing date: 2026-03-02; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 10012500; Federal exemptions: 06b”
Jan 9, 2026SEC Form D ↗
Spheryx, Inc.SEC Form D Equity · Form D reports $500K sold of $2.7M offered
Source quote
  • Filed Jan 22, 2026 · SEC Form D ↗
    “Name of Issuer: Spheryx, Inc.; CIK: 1630562; Address: New York, NY; Submission type: D; Filing date: 2026-01-22; Industry Group: Other; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2700000; Total Amount Sold: 500400; Federal exemptions: 06b”
Jan 9, 2026SEC Form D ↗
TwoStep TherapeuticsSEC Form D Equity · Form D reports $21.11M sold of $62.21M offered
Source quote
  • Filed Jan 20, 2026 · SEC Form D ↗
    “Name of Issuer: TwoStep Therapeutics, Inc.; CIK: 2015273; Address: San Carlos, CA; Submission type: D; Filing date: 2026-01-20; Industry Group: Other; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 62209510; Total Amount Sold: 21109518; Federal exemptions: 06b”
Jan 9, 2026SEC Form D ↗
Caldera TherapeuticsSEC Form D Equity · Form D reports $37.5M sold
Source quote
  • Filed Jan 21, 2026 · SEC Form D ↗
    “Name of Issuer: Caldera Therapeutics, Inc.; CIK: 2069936; Address: Cambridge, MA; Submission type: D; Filing date: 2026-01-21; Industry Group: Biotechnology; Date of First Sale: 2026-01-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 37500000; Total Amount Sold: 37500000; Federal exemptions: 06b”
Jan 8, 2026SEC Form D ↗
Entact BioSEC Form D Equity · Form D reports $10M sold
Source quote
  • Filed Jun 3, 2026 · SEC Form D ↗
    “Name of Issuer: Entact Bio, Inc.; CIK: 2008244; Address: Watertown, MA; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-01-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 9999997; Total Amount Sold: 9999997; Federal exemptions: 06b”
Jan 8, 2026SEC Form D ↗
PrognomiQSEC Form D Equity · Form D reports $11.87M sold
Source quote
  • Filed Jan 16, 2026 · SEC Form D ↗
    “Name of Issuer: PrognomIQ, Inc.; CIK: 2034700; Address: San Mateo, CA; Submission type: D; Filing date: 2026-01-16; Industry Group: Other Health Care; Date of First Sale: 2026-01-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11872784; Total Amount Sold: 11872784; Federal exemptions: 06b”
Jan 2, 2026SEC Form D ↗
Omega OphthalmicsSEC Form D Equity · Form D reports $320K sold of $9.6M offered
Source quote
  • Filed Jan 15, 2026 · SEC Form D ↗
    “Name of Issuer: Omega Ophthalmics LLC; CIK: 1937862; Address: Versailles, KY; Submission type: D; Filing date: 2026-01-15; Industry Group: Other; Date of First Sale: 2026-01-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 9600000; Total Amount Sold: 320000; Federal exemptions: 06b”
Jan 2, 2026SEC Form D ↗
Holobiome, Inc.SEC Form D SAFE · Form D reports $10M sold
Source quote
  • Filed Jul 22, 2026 · SEC Form D ↗
    “Name of Issuer: Holobiome, Inc.; CIK: 1763027; Address: Boston, MA; Submission type: D; Filing date: 2026-07-22; Industry Group: Biotechnology; Date of First Sale: 2025-12-24; Types of Securities Offered: Other (Simple Agreement for Future Equity (SAFES)); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 10000000; Federal exemptions: 06b”
Dec 24, 2025SEC Form D ↗
Phenomix SciencesSEC Form D Equity · Form D reports $2.5M sold of $5M offered
Source quote
  • Filed Dec 29, 2025 · SEC Form D ↗
    “Name of Issuer: Phenomix Sciences, Inc.; CIK: 1966746; Address: Menlo Park, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Other Health Care; Date of First Sale: 2025-12-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000004; Total Amount Sold: 2500002; Federal exemptions: 06b”
Dec 23, 2025SEC Form D ↗
QureatorSEC Form D Equity · Form D reports $6.68M sold of $6.88M offered
Source quote
  • Filed Mar 6, 2026 · SEC Form D ↗
    “Name of Issuer: Qureator, Inc.; CIK: 2109274; Address: San Diego, CA; Submission type: D; Filing date: 2026-03-06; Industry Group: Biotechnology; Date of First Sale: 2025-12-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6881746; Total Amount Sold: 6680994; Federal exemptions: 06b”
Dec 23, 2025SEC Form D ↗
CellanomeSEC Form D Equity · Form D reports $75.93M sold
Source quote
  • Filed Jun 22, 2026 · SEC Form D ↗
    “Name of Issuer: Cellanome, Inc.; CIK: 1886462; Address: Foster City, CA; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2025-12-23; Types of Securities Offered: Equity, Other (Series C Preferred Stock); Business combination transaction: false; Total Offering Amount: 75930476; Total Amount Sold: 75930476; Federal exemptions: 06b”
Dec 23, 2025SEC Form D ↗
Adaptin BioSEC Form D Equity · Form D reports $1.91M sold of $4M offered
Source quote
  • Filed Jan 5, 2026 · amended Jun 22, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: ADAPTIN BIO, INC.; CIK: 1938571; Address: Charlotte, NC; Submission type: D/A; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2025-12-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1912000; Federal exemptions: 06b”
Dec 22, 2025SEC Form D/A ↗
Slam BioTherapeuticsSEC Form D Debt / note · Form D reports $1M sold of $4M offered
Source quote
  • Filed Dec 29, 2025 · SEC Form D ↗
    “Name of Issuer: SLAM BioTherapeutics, Inc.; CIK: 1983523; Address: Westlake Village, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-12-19; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1000000; Federal exemptions: 06b”
Dec 19, 2025SEC Form D ↗
Riverain TechnologiesSEC Form D Equity · Form D reports $8.25M sold
Source quote
  • Filed Jan 26, 2026 · SEC Form D ↗
    “Name of Issuer: Riverain Technologies, Inc.; CIK: 2107191; Address: Miamisburg, OH; Submission type: D; Filing date: 2026-01-26; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8250000; Total Amount Sold: 8250000; Federal exemptions: 06b”
Dec 19, 2025SEC Form D ↗
RICOVR Healthcare Inc.SEC Form D Equity · Form D reports $550K sold of $1.5M offered
Source quote
  • Filed Jan 20, 2026 · SEC Form D ↗
    “Name of Issuer: Ricovr Healthcare Inc.; CIK: 1800521; Address: Princeton, NJ; Submission type: D; Filing date: 2026-01-20; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 550000; Federal exemptions: 06b”
Dec 19, 2025SEC Form D ↗
Spiro MedicalSEC Form D Equity · Form D reports $37.1M sold of $69.1M offered
Source quote
  • Filed Jan 5, 2026 · SEC Form D ↗
    “Name of Issuer: Spiro Medical Inc.; CIK: 1996433; Address: Belleair Bluffs, FL; Submission type: D; Filing date: 2026-01-05; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69095598; Total Amount Sold: 37095655; Federal exemptions: 06b”
Dec 19, 2025SEC Form D ↗
Axena HealthSEC Form D Equity + debt/notes · Form D reports $15.05M sold (offering size open-ended)
Source quote
  • Filed Apr 14, 2026 · SEC Form D ↗
    “Name of Issuer: Axena Health, Inc.; CIK: 1988865; Address: Auburndale, MA; Submission type: D; Filing date: 2026-04-14; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (Convertibles); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 15046942; Federal exemptions: 06b”
Dec 19, 2025SEC Form D ↗
GenialisSEC Form D Debt / note · Form D reports $700K sold of $3M offered
Source quote
  • Filed Dec 31, 2025 · SEC Form D ↗
    “Name of Issuer: Genialis, Inc.; CIK: 1948756; Address: Boston, MA; Submission type: D; Filing date: 2025-12-31; Industry Group: Biotechnology; Date of First Sale: 2025-12-17; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 700000; Federal exemptions: 06b”
Dec 17, 2025SEC Form D ↗
Healionics CorporationSEC Form D Equity · Form D reports $1.96M sold of $20M offered
Source quote
  • Filed Dec 31, 2025 · SEC Form D ↗
    “Name of Issuer: Healionics CORP; CIK: 1413969; Address: Seattle, WA; Submission type: D; Filing date: 2025-12-31; Industry Group: Other; Date of First Sale: 2025-12-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 1964221; Federal exemptions: 06b”
Dec 16, 2025SEC Form D ↗
DMC Biotechnologies, Inc.SEC Form D Equity + debt/notes · Form D reports $1.41M sold of $2.5M offered
Source quote
  • Filed Dec 30, 2025 · SEC Form D ↗
    “Name of Issuer: DMC Biotechnologies, Inc.; CIK: 1728411; Address: Boulder, CO; Submission type: D; Filing date: 2025-12-30; Industry Group: Biotechnology; Date of First Sale: 2025-12-16; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired, Other (Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1414267; Federal exemptions: 06b”
Dec 16, 2025SEC Form D ↗
Nocion TherapeuticsSEC Form D Equity · Form D reports $23M sold
Source quote
  • Filed Mar 13, 2026 · SEC Form D ↗
    “Name of Issuer: Nocion Therapeutics, Inc.; CIK: 1841279; Address: Watertown, MA; Submission type: D; Filing date: 2026-03-13; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 22999999; Total Amount Sold: 22999999; Federal exemptions: 06b”
Dec 15, 2025SEC Form D ↗
GlycologixSEC Form D Equity + debt/notes · Form D reports $800K sold of $1M offered
Source quote
  • Filed Dec 29, 2025 · SEC Form D ↗
    “Name of Issuer: Glycologix, Inc.; CIK: 1903671; Address: Beverly, MA; Submission type: D; Filing date: 2025-12-29; Industry Group: Other Technology; Date of First Sale: 2025-12-12; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 800000; Federal exemptions: 06b”
Dec 12, 2025SEC Form D ↗
OXOS MedicalSEC Form D Equity · Form D reports $10.71M sold of $28.21M offered
Source quote
  • Filed Dec 19, 2025 · SEC Form D ↗
    “Name of Issuer: OXOS MEDICAL, INC.; CIK: 1694304; Address: Atlanta, GA; Submission type: D; Filing date: 2025-12-19; Industry Group: Other Technology; Date of First Sale: 2025-12-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 28207000; Total Amount Sold: 10706990; Federal exemptions: 06b”
Dec 12, 2025SEC Form D ↗
Nacuity PharmaceuticalsSEC Form D Equity + debt/notes · Form D reports $8.39M sold of $30M offered
Source quote
  • Filed Dec 30, 2025 · SEC Form D ↗
    “Name of Issuer: Nacuity Pharmaceuticals, Inc.; CIK: 1690279; Address: Fort Worth, TX; Submission type: D; Filing date: 2025-12-30; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-11; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired, Other (Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant Conversion); Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 8393350; Federal exemptions: 06b”
Dec 11, 2025SEC Form D ↗
Aprea TherapeuticsSEC Form D Equity · Form D reports $3.06M sold of $5.78M offered
Source quote
  • Filed Dec 29, 2025 · SEC Form D ↗
    “Name of Issuer: Aprea Therapeutics, Inc.; CIK: 1781983; Address: Doylestown, PA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-12-10; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5783766; Total Amount Sold: 3055822; Federal exemptions: 06b”
Dec 10, 2025SEC Form D ↗
Mediar TherapeuticsSEC Form D Equity · Form D reports $37.85M sold of $75.7M offered
Source quote
  • Filed Dec 23, 2025 · SEC Form D ↗
    “Name of Issuer: Mediar Therapeutics, Inc.; CIK: 1766784; Address: Boston, MA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 75699630; Total Amount Sold: 37849815; Federal exemptions: 06b”
Dec 10, 2025SEC Form D ↗
VogenxSEC Form D Debt / note · Form D reports $750K sold of $5M offered
Source quote
  • Filed Jan 7, 2026 · SEC Form D ↗
    “Name of Issuer: Vogenx, Inc.; CIK: 1903784; Address: Raleigh, NC; Submission type: D; Filing date: 2026-01-07; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-10; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 750000; Federal exemptions: 06b”
Dec 10, 2025SEC Form D ↗
Aethlon Medical, Inc.SEC Form D Equity · Form D reports $2.15M sold
Source quote
  • Filed Dec 23, 2025 · SEC Form D ↗
    “Name of Issuer: AETHLON MEDICAL INC; CIK: 882291; Address: San Diego, CA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-08; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2153700; Total Amount Sold: 2153700; Federal exemptions: 06b”
Dec 8, 2025SEC Form D ↗
Innovaprep LLCSEC Form D Debt / note · Form D reports $100K sold of $1M offered
Source quote
  • Filed Dec 17, 2025 · SEC Form D ↗
    “Name of Issuer: INNOVAPREP INC.; CIK: 1753878; Address: Drexel, MO; Submission type: D; Filing date: 2025-12-17; Industry Group: Biotechnology; Date of First Sale: 2025-12-05; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 100000; Federal exemptions: 06b”
Dec 5, 2025SEC Form D ↗
OrthoPreserveSEC Form D Debt / note · Form D reports $157K sold of $2M offered
Source quote
  • Filed Dec 23, 2025 · SEC Form D ↗
    “Name of Issuer: OrthoPreserve, Inc.; CIK: 2034639; Address: Henrico, VA; Submission type: D; Filing date: 2025-12-23; Industry Group: Other Health Care; Date of First Sale: 2025-12-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 157000; Federal exemptions: 06b”
Dec 4, 2025SEC Form D ↗
Amphix Bio, Inc.SEC Form D Equity · Form D reports $10.3M sold of $12.5M offered
Source quote
  • Filed Dec 19, 2025 · SEC Form D ↗
    “Name of Issuer: Amphix Bio, Inc.; CIK: 2101704; Address: Chicago, IL; Submission type: D; Filing date: 2025-12-19; Industry Group: Biotechnology; Date of First Sale: 2025-12-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 10300000; Federal exemptions: 06b”
Dec 4, 2025SEC Form D ↗
Oncotelic TherapeuticsSEC Form D Equity + debt/notes · Form D reports $275K sold of $12.5M offered
Source quote
  • Filed Dec 11, 2025 · SEC Form D ↗
    “Name of Issuer: Oncotelic Therapeutics, Inc.; CIK: 908259; Address: Agoura Hills, CA; Submission type: D; Filing date: 2025-12-11; Industry Group: Biotechnology; Date of First Sale: 2025-12-04; Types of Securities Offered: Equity, Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 275000; Federal exemptions: 06b”
Dec 4, 2025SEC Form D ↗
Kazia Therapeutics Limited Filed as KAZIA THERAPEUTICS LTDSEC Form D Equity · Form D reports $55.25M sold
Source quote
  • Filed Dec 18, 2025 · SEC Form D ↗
    “Name of Issuer: KAZIA THERAPEUTICS LTD; CIK: 1075880; Address: Sydney Nsw, Australia; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 55251088; Total Amount Sold: 55251088; Federal exemptions: 06b”
Dec 3, 2025SEC Form D ↗
DELFI DiagnosticsSEC Form D Debt / note · Form D reports $34.33M sold of $60M offered
Source quote
  • Filed Dec 18, 2025 · SEC Form D ↗
    “Name of Issuer: Delfi Diagnostics, Inc.; CIK: 1783735; Address: Palo Alto, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 34333315; Federal exemptions: 06b”
Dec 1, 2025SEC Form D ↗
NovilyticSEC Form D Equity · Form D reports $531K sold of $1M offered
Source quote
  • Filed Dec 15, 2025 · SEC Form D ↗
    “Name of Issuer: Novilytic, LLC; CIK: 1850261; Address: West Lafayette, IN; Submission type: D; Filing date: 2025-12-15; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 530800; Federal exemptions: 06b”
Dec 1, 2025SEC Form D ↗
Telos BiotechSEC Form D Equity · Form D reports $725K sold of $2.25M offered
Source quote
  • Filed Dec 12, 2025 · SEC Form D ↗
    “Name of Issuer: Telos Biotech Inc.; CIK: 1815708; Address: Dallas, TX; Submission type: D; Filing date: 2025-12-12; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2250000; Total Amount Sold: 724999; Federal exemptions: 06b”
Dec 1, 2025SEC Form D ↗
Minnesota Medical TechnologiesSEC Form D Equity · Form D reports $8.28M sold of $17M offered
Source quote
  • Filed Dec 10, 2025 · SEC Form D ↗
    “Name of Issuer: Minnesota Medical Technologies Corp; CIK: 1736524; Address: Stewartville, MN; Submission type: D; Filing date: 2025-12-10; Industry Group: Other Health Care; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 16999964; Total Amount Sold: 8279547; Federal exemptions: 06b”
Dec 1, 2025SEC Form D ↗
Zeo ScientifixSEC Form D Equity · Form D reports $500K sold of $5M offered
Source quote
  • Filed Dec 5, 2025 · SEC Form D ↗
    “Name of Issuer: Zeo ScientifiX, Inc.; CIK: 1557376; Address: Davie, FL; Submission type: D; Filing date: 2025-12-05; Industry Group: Biotechnology; Date of First Sale: 2025-11-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 500000; Federal exemptions: 06b”
Nov 30, 2025SEC Form D ↗
TRIANA Biomedicines, Inc.SEC Form D Equity · Form D reports $120.06M sold
Source quote
  • Filed Dec 4, 2025 · SEC Form D ↗
    “Name of Issuer: Triana Biomedicines, Inc.; CIK: 1815337; Address: Lexington, MA; Submission type: D; Filing date: 2025-12-04; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120061960; Total Amount Sold: 120061960; Federal exemptions: 06b”
Nov 26, 2025SEC Form D ↗
Life Biosciences Inc.SEC Form D Equity · Form D reports $31M sold
Source quote
  • Filed Apr 24, 2026 · SEC Form D ↗
    “Name of Issuer: Life Biosciences LLC; CIK: 1751806; Address: Boston, MA; Submission type: D; Filing date: 2026-04-24; Industry Group: Other; Date of First Sale: 2025-11-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31000002; Total Amount Sold: 31000002; Federal exemptions: 06b”
Nov 25, 2025SEC Form D ↗
Prana Therapies, Inc.SEC Form D Equity · Form D reports $40.23M sold
Source quote
  • Filed Aug 10, 2026 · SEC Form D ↗
    “Name of Issuer: Prana Therapies, Inc.; CIK: 2029240; Address: Encinitas, CA; Submission type: D; Filing date: 2026-08-10; Industry Group: Biotechnology; Date of First Sale: 2025-11-25; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 40226932; Total Amount Sold: 40226932; Federal exemptions: 06b”
Nov 25, 2025SEC Form D ↗
MindImmune TherapeuticsSEC Form D Equity · Form D reports $15.22M sold of $17.01M offered
Source quote
  • Filed Dec 5, 2025 · amended Mar 5, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: MindImmune Therapeutics, Inc.; CIK: 1792522; Address: Kingston, RI; Submission type: D/A; Filing date: 2026-03-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-24; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 17014485; Total Amount Sold: 15218343; Federal exemptions: 06b”
Nov 24, 2025SEC Form D/A ↗
NextStep Robotics Inc.SEC Form D SAFE · Form D reports $1M sold of $3M offered
Source quote
  • Filed Apr 9, 2026 · SEC Form D ↗
    “Name of Issuer: NEXTSTEP ROBOTICS, INC.; CIK: 1729819; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-09; Industry Group: Other Technology; Date of First Sale: 2025-11-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (SIMPLE AGREEMENT FOR FUTURE EQUITY); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1000000; Federal exemptions: 06b”
Nov 24, 2025SEC Form D ↗
Paulex BioSEC Form D Equity · Form D reports $18.52M sold of $22.5M offered
Source quote
  • Filed Dec 18, 2025 · SEC Form D ↗
    “Name of Issuer: Paulex Bio Inc.; CIK: 2071082; Address: LA Jolla, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 22500000; Total Amount Sold: 18516040; Federal exemptions: 06c”
Nov 21, 2025SEC Form D ↗
Relation TherapeuticsSEC Form D Debt / note · Form D reports $36.17M sold
Source quote
  • Filed Dec 9, 2025 · SEC Form D ↗
    “Name of Issuer: Relation Therapeutics Inc.; CIK: 1876828; Address: Miami Beach, FL; Submission type: D; Filing date: 2025-12-09; Industry Group: Biotechnology; Date of First Sale: 2025-11-21; Types of Securities Offered: Debt, Security to be acquired, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 36175000; Total Amount Sold: 36175000; Federal exemptions: 06b”
Nov 21, 2025SEC Form D ↗
A-Synaptic Pharma Filed as A-SYNAPTIC CORP.SEC Form D Equity · Form D reports $533K sold of $2M offered
Source quote
  • Filed Dec 4, 2025 · SEC Form D ↗
    “Name of Issuer: A-SYNAPTIC CORP.; CIK: 1913553; Address: Ontario, Canada; Submission type: D; Filing date: 2025-12-04; Industry Group: Other; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 533100; Federal exemptions: 06b”
Nov 21, 2025SEC Form D ↗
Armonica Technologies, Inc.SEC Form D Equity · Form D reports $4.21M sold of $5.71M offered
Source quote
  • Filed Dec 8, 2025 · SEC Form D ↗
    “Name of Issuer: Armonica Technologies, Inc.; CIK: 1714729; Address: Albuquerque, NM; Submission type: D; Filing date: 2025-12-08; Industry Group: Biotechnology; Date of First Sale: 2025-11-20; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5714702; Total Amount Sold: 4214700; Federal exemptions: 06b”
Nov 20, 2025SEC Form D ↗
Nature's ToolboxSEC Form D Equity · Form D reports $10.37M sold of $15M offered
Source quote
  • Filed Dec 23, 2025 · amended Feb 4, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Nature's Toolbox, Inc.; CIK: 1798793; Address: Rio Rancho, NM; Submission type: D/A; Filing date: 2026-02-04; Industry Group: Biotechnology; Date of First Sale: 2025-11-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15001975; Total Amount Sold: 10365162; Federal exemptions: 06b”
Nov 19, 2025SEC Form D/A ↗
Aeovian PharmaceuticalsSEC Form D Equity · Form D reports $55M sold
Source quote
  • Filed Dec 22, 2025 · SEC Form D ↗
    “Name of Issuer: Aeovian Pharmaceuticals, Inc.; CIK: 1710088; Address: Berkeley, CA; Submission type: D; Filing date: 2025-12-22; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 54999996; Total Amount Sold: 54999996; Federal exemptions: 06b”
Nov 18, 2025SEC Form D ↗
Okami MedicalSEC Form D Equity · Form D reports $28.94M sold of $46.73M offered
Source quote
  • Filed Dec 1, 2025 · SEC Form D ↗
    “Name of Issuer: Okami Medical, Inc.; CIK: 1675564; Address: Aliso Viejo, CA; Submission type: D; Filing date: 2025-12-01; Industry Group: Other Technology; Date of First Sale: 2025-11-18; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 46735000; Total Amount Sold: 28936718; Federal exemptions: 06b”
Nov 18, 2025SEC Form D ↗
BTB TherapeuticsSEC Form D Equity · Form D reports $8.9M sold of $10.4M offered
Source quote
  • Filed Dec 1, 2025 · amended Aug 12, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: BTB Therapeutics, Inc.; CIK: 2055053; Address: Escondido, CA; Submission type: D/A; Filing date: 2026-08-12; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10402704; Total Amount Sold: 8902204; Federal exemptions: 06b”
Nov 14, 2025SEC Form D/A ↗
Allurion TechnologiesSEC Form D Equity · Form D reports $5M sold
Source quote
  • Filed Nov 26, 2025 · SEC Form D ↗
    “Name of Issuer: ALLURION TECHNOLOGIES, INC.; CIK: 1964979; Address: Natick, MA; Submission type: D; Filing date: 2025-11-26; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b”
Nov 14, 2025SEC Form D ↗
Ablative SolutionsSEC Form D Equity · Form D reports $10.41M sold of $45M offered
Source quote
  • Filed Nov 26, 2025 · SEC Form D ↗
    “Name of Issuer: Ablative Solutions, Inc.; CIK: 1535723; Address: Wakefield, MA; Submission type: D; Filing date: 2025-11-26; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 45000000; Total Amount Sold: 10407500; Federal exemptions: 06b”
Nov 14, 2025SEC Form D ↗
Repair BiotechnologiesSEC Form D Equity · Form D reports $5.26M sold of $11M offered
Source quote
  • Filed Nov 25, 2025 · SEC Form D ↗
    “Name of Issuer: Repair Biotechnologies, Inc.; CIK: 1750699; Address: Syracuse, NY; Submission type: D; Filing date: 2025-11-25; Industry Group: Biotechnology; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11000000; Total Amount Sold: 5258906; Federal exemptions: 06b”
Nov 14, 2025SEC Form D ↗
Solve TherapeuticsSEC Form D Equity · Form D reports $48.21M sold of $120.54M offered
Source quote
  • Filed Nov 25, 2025 · SEC Form D ↗
    “Name of Issuer: Solve Therapeutics, Inc.; CIK: 1905252; Address: Belmont, CA; Submission type: D; Filing date: 2025-11-25; Industry Group: Biotechnology; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120535618; Total Amount Sold: 48214232; Federal exemptions: 06b”
Nov 14, 2025SEC Form D ↗
Enrich BiosystemsSEC Form D Debt / note · Form D reports $1.45M sold of $1.5M offered
Source quote
  • Filed Nov 26, 2025 · SEC Form D ↗
    “Name of Issuer: ENRICH BIOSYSTEMS INC.; CIK: 1931770; Address: Branford, CT; Submission type: D; Filing date: 2025-11-26; Industry Group: Biotechnology; Date of First Sale: 2025-11-13; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1450000; Federal exemptions: 06b”
Nov 13, 2025SEC Form D ↗
Akura MedicalSEC Form D Equity · Form D reports $51.45M sold of $72M offered
Source quote
  • Filed Dec 3, 2025 · SEC Form D ↗
    “Name of Issuer: Akura Medical, Inc.; CIK: 1902758; Address: Campbell, CA; Submission type: D; Filing date: 2025-12-03; Industry Group: Other Health Care; Date of First Sale: 2025-11-12; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 71999999; Total Amount Sold: 51449999; Federal exemptions: 06b”
Nov 12, 2025SEC Form D ↗
NanoViricidesSEC Form D Equity · Form D reports $6M sold
Source quote
  • Filed Feb 25, 2026 · SEC Form D ↗
    “Name of Issuer: NANOVIRICIDES, INC.; CIK: 1379006; Address: Shelton, CT; Submission type: D; Filing date: 2026-02-25; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6000000; Total Amount Sold: 6000000; Federal exemptions: 06b”
Nov 12, 2025SEC Form D ↗
Ophthalmic Therapeutic InnovationSEC Form D Equity · Form D reports $100K sold of $300K offered
Source quote
  • Filed Dec 2, 2025 · SEC Form D ↗
    “Name of Issuer: Ophthalmic Therapeutic Innovation LLC; CIK: 2098204; Address: Watertown, MA; Submission type: D; Filing date: 2025-12-02; Industry Group: Biotechnology; Date of First Sale: 2025-11-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 100000; Federal exemptions: 06b”
Nov 8, 2025SEC Form D ↗
VahatiCorSEC Form D Equity · Form D reports $21.18M sold of $32.38M offered
Source quote
  • Filed Dec 4, 2025 · SEC Form D ↗
    “Name of Issuer: VahatiCor, Inc.; CIK: 2042118; Address: Santa Clara, CA; Submission type: D; Filing date: 2025-12-04; Industry Group: Other Health Care; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 32383479; Total Amount Sold: 21183479; Federal exemptions: 06b”
Nov 7, 2025SEC Form D ↗
SpineologySEC Form D Equity · Form D reports $12.64M sold of $14.08M offered
Source quote
  • Filed Nov 19, 2025 · amended Jun 17, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: SPINEOLOGY INC; CIK: 1165842; Address: St. Paul, MN; Submission type: D/A; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 14079337; Total Amount Sold: 12641849; Federal exemptions: 06b”
Nov 7, 2025SEC Form D/A ↗
Atrility MedicalSEC Form D Debt / note · Form D reports $1M sold of $2M offered
Source quote
  • Filed Feb 5, 2026 · SEC Form D ↗
    “Name of Issuer: Atrility Medical, Inc.; CIK: 1734892; Address: Madison, WI; Submission type: D; Filing date: 2026-02-05; Industry Group: Other Health Care; Date of First Sale: 2025-11-07; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1000000; Federal exemptions: 06b”
Nov 7, 2025SEC Form D ↗
Pelthos TherapeuticsSEC Form D Debt / note · Form D reports $18M sold
Source quote
  • Filed Nov 19, 2025 · SEC Form D ↗
    “Name of Issuer: Pelthos Therapeutics Inc.; CIK: 1919246; Address: Durham, NC; Submission type: D; Filing date: 2025-11-19; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-06; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Senior secured convertible notes, which are convertible into shares of the Company's common stock, par value $0.0001 per share.); Business combination transaction: false; Total Offering Amount: 18000000; Total Amount Sold: 18000000; Federal exemptions: 06b”
Nov 6, 2025SEC Form D ↗
MedicovestorSEC Form D SAFE · Form D reports $3.16M sold of $4.06M offered
Source quote
  • Filed Dec 5, 2025 · SEC Form D ↗
    “Name of Issuer: Medicovestor, Inc.; CIK: 2099357; Address: New York, NY; Submission type: D; Filing date: 2025-12-05; Industry Group: Biotechnology; Date of First Sale: 2025-11-05; Types of Securities Offered: Equity, Other (Simple Agreements for Future Equity); Business combination transaction: false; Total Offering Amount: 4064834; Total Amount Sold: 3164834; Federal exemptions: 06b”
Nov 5, 2025SEC Form D ↗
VST BioSEC Form D Equity · Form D reports $31.89M sold
Source quote
  • Filed Nov 18, 2025 · amended Apr 24, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: VST BIO Corp; CIK: 2093250; Address: San Diego, CA; Submission type: D/A; Filing date: 2026-04-24; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31888146; Total Amount Sold: 31888146; Federal exemptions: 06b”
Nov 5, 2025SEC Form D/A ↗
LifeLens TechnologiesSEC Form D Equity · Form D reports $21.1M sold of $40M offered
Source quote
  • Filed Nov 17, 2025 · amended Sep 8, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: LifeLens Technologies, Inc.; CIK: 1782780; Address: Ivyland, PA; Submission type: D/A; Filing date: 2026-09-08; Industry Group: Other Technology; Date of First Sale: 2025-11-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 21104217; Federal exemptions: 06b”
Nov 4, 2025SEC Form D/A ↗
Invea TherapeuticsSEC Form D Equity · Form D reports $120K sold
Source quote
  • Filed Dec 10, 2025 · SEC Form D ↗
    “Name of Issuer: Invea Therapeutics, Inc; CIK: 1906425; Address: Guilford, CT; Submission type: D; Filing date: 2025-12-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 120250; Total Amount Sold: 120250; Federal exemptions: 06b”
Oct 31, 2025SEC Form D ↗
Levee MedicalSEC Form D Debt / note · Form D reports $12.5M sold
Source quote
  • Filed Nov 12, 2025 · amended May 5, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Levee Medical, Inc.; CIK: 1877814; Address: Durham, NC; Submission type: D/A; Filing date: 2026-05-05; Industry Group: Other Health Care; Date of First Sale: 2025-10-31; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 12500000; Federal exemptions: 06b”
Oct 31, 2025SEC Form D/A ↗
EpalexSEC Form D Equity · Form D reports $1.2M sold of $3.2M offered
Source quote
  • Filed Nov 10, 2025 · SEC Form D ↗
    “Name of Issuer: EPALEX Corp; CIK: 1755010; Address: Mountain View, CA; Submission type: D; Filing date: 2025-11-10; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3199991; Total Amount Sold: 1200000; Federal exemptions: 06b”
Oct 31, 2025SEC Form D ↗
Gut-Brain-Axis Therapeutics Inc.SEC Form D Equity · Form D reports $1.97M sold of $20M offered
Source quote
  • Filed Nov 6, 2025 · SEC Form D ↗
    “Name of Issuer: Gut-Brain-Axis Therapeutics Inc.; CIK: 1996678; Address: Tempe, AZ; Submission type: D; Filing date: 2025-11-06; Industry Group: Biotechnology; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 1965000; Federal exemptions: 06c”
Oct 31, 2025SEC Form D ↗
Elixirgen TherapeuticsSEC Form D Debt / note · Form D reports $4M sold
Source quote
  • Filed Nov 13, 2025 · SEC Form D ↗
    “Name of Issuer: ELIXIRGEN THERAPEUTICS, INC.; CIK: 1744333; Address: Baltimore, MD; Submission type: D; Filing date: 2025-11-13; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b”
Oct 30, 2025SEC Form D ↗
Saluda MedicalSEC Form D Equity · Form D reports $30M sold
Source quote
  • Filed Nov 12, 2025 · SEC Form D ↗
    “Name of Issuer: Saluda Medical, Inc.; CIK: 1973574; Address: Bloomington, MN; Submission type: D; Filing date: 2025-11-12; Industry Group: Other Health Care; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 29999995; Total Amount Sold: 29999995; Federal exemptions: 06b”
Oct 30, 2025SEC Form D ↗
Model MedicinesSEC Form D Equity · Form D reports $3.26M sold of $5M offered
Source quote
  • Filed Nov 14, 2025 · SEC Form D ↗
    “Name of Issuer: Model Medicines, Inc.; CIK: 1892786; Address: San Deigo, CA; Submission type: D; Filing date: 2025-11-14; Industry Group: Other; Date of First Sale: 2025-10-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 3260000; Federal exemptions: 06b”
Oct 29, 2025SEC Form D ↗
TearSolutionsSEC Form D Equity · Form D reports $517K sold
Source quote
  • Filed Nov 10, 2025 · SEC Form D ↗
    “Name of Issuer: TearSolutions, Inc.; CIK: 1611687; Address: Charlottesville, VA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 517000; Total Amount Sold: 517000; Federal exemptions: 06b”
Oct 29, 2025SEC Form D ↗
CoRegenSEC Form D Equity · Form D reports $13.5M sold
Source quote
  • Filed Feb 26, 2026 · SEC Form D ↗
    “Name of Issuer: CoRegen, Inc.; CIK: 2012886; Address: Houston, TX; Submission type: D; Filing date: 2026-02-26; Industry Group: Biotechnology; Date of First Sale: 2025-10-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 13500000; Total Amount Sold: 13500000; Federal exemptions: 06b”
Oct 28, 2025SEC Form D ↗
TuHURA Biosciences Filed as TuHURA Biosciences, Inc./NVSEC Form D Equity · Form D reports $1.5M sold of $3M offered
Source quote
  • Filed Nov 10, 2025 · SEC Form D ↗
    “Name of Issuer: TuHURA Biosciences, Inc./NV; CIK: 1498382; Address: Tampa, FL; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-27; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1500000; Federal exemptions: 06b”
Oct 27, 2025SEC Form D ↗
CelularitySEC Form D Equity · Form D reports $2M sold of $6.67M offered
Source quote
  • Filed Nov 3, 2025 · SEC Form D ↗
    “Name of Issuer: Celularity Inc; CIK: 1752828; Address: Florham Park, NJ; Submission type: D; Filing date: 2025-11-03; Industry Group: Biotechnology; Date of First Sale: 2025-10-24; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6666667; Total Amount Sold: 2000000; Federal exemptions: 06c”
Oct 24, 2025SEC Form D ↗
Rani Therapeutics Filed as Rani Therapeutics Holdings, Inc.SEC Form D Equity · Form D reports $60.26M sold
Source quote
  • Filed Nov 10, 2025 · SEC Form D ↗
    “Name of Issuer: Rani Therapeutics Holdings, Inc.; CIK: 1856725; Address: San Jose, CA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-23; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 60255052; Total Amount Sold: 60255052; Federal exemptions: 06b”
Oct 23, 2025SEC Form D ↗
Antigenix TherapeuticsSEC Form D Equity · Form D reports $3.36M sold of $8.36M offered
Source quote
  • Filed Oct 24, 2025 · SEC Form D ↗
    “Name of Issuer: Antigenix Therapeutics, Inc.; CIK: 2073993; Address: Princeton, NJ; Submission type: D; Filing date: 2025-10-24; Industry Group: Other Health Care; Date of First Sale: 2025-10-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8363695; Total Amount Sold: 3363695; Federal exemptions: 06b”
Oct 22, 2025SEC Form D ↗
GEn1E LifesciencesSEC Form D Equity · Form D reports $5.52M sold of $11.89M offered
Source quote
  • Filed Dec 29, 2025 · SEC Form D ↗
    “Name of Issuer: GEN1E LIFESCIENCES INC.; CIK: 1752886; Address: Palo Alto, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11887377; Total Amount Sold: 5520803; Federal exemptions: 06b”
Oct 21, 2025SEC Form D ↗
Alto Neuroscience, Inc.SEC Form D Equity · Form D reports $50M sold
Source quote
  • Filed Oct 27, 2025 · SEC Form D ↗
    “Name of Issuer: Alto Neuroscience, Inc.; CIK: 1999480; Address: Mountain View, CA; Submission type: D; Filing date: 2025-10-27; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 49999533; Total Amount Sold: 49999533; Federal exemptions: 06b”
Oct 21, 2025SEC Form D ↗
XDemicsSEC Form D Equity · Form D reports $7.4M sold
Source quote
  • Filed Feb 6, 2026 · SEC Form D ↗
    “Name of Issuer: XDemics Corp; CIK: 2026725; Address: San Rafael, CA; Submission type: D; Filing date: 2026-02-06; Industry Group: Biotechnology; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 7399999; Total Amount Sold: 7399999; Federal exemptions: 06b”
Oct 21, 2025SEC Form D ↗
Osteal TherapeuticsSEC Form D Equity · Form D reports $15.6M sold of $26.7M offered · filed Nov 5, 2025
Source quote
  • Filed Nov 5, 2025 · SEC Form D ↗
    “Name of Issuer: Osteal Therapeutics, Inc.; CIK: 1735936; Address: Dallas, TX; Submission type: D; Filing date: 2025-11-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 26702156; Total Amount Sold: 15602151; Federal exemptions: 06b”
Oct 17, 2025SEC Form D ↗
Andson BiotechSEC Form D Equity · Form D reports $4.74M sold of $5M offered · filed Oct 22, 2025
Source quote
  • Filed Oct 22, 2025 · SEC Form D ↗
    “Name of Issuer: Andson Biotech Inc.; CIK: 2017131; Address: Atlanta, GA; Submission type: D; Filing date: 2025-10-22; Industry Group: Biotechnology; Date of First Sale: 2025-10-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 4735000; Federal exemptions: 06b”
Oct 17, 2025SEC Form D ↗
Vesteck, Inc.SEC Form D Equity · Form D reports $354K sold of $500K offered · filed Oct 30, 2025
Source quote
  • Filed Oct 30, 2025 · SEC Form D ↗
    “Name of Issuer: VESTECK, INC.; CIK: 1882165; Address: Carlsbad, CA; Submission type: D; Filing date: 2025-10-30; Industry Group: Other Technology; Date of First Sale: 2025-10-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 353578; Federal exemptions: 06b”
Oct 16, 2025SEC Form D ↗
Luminary TherapeuticsSEC Form D Equity · Form D reports $1.41M sold of $12.39M offered · filed Nov 5, 2025
Source quote
  • Filed Nov 5, 2025 · SEC Form D ↗
    “Name of Issuer: Luminary Therapeutics, Inc.; CIK: 1793860; Address: Minneapolis, MN; Submission type: D; Filing date: 2025-11-05; Industry Group: Biotechnology; Date of First Sale: 2025-10-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12388157; Total Amount Sold: 1406112; Federal exemptions: 06b”
Oct 14, 2025SEC Form D ↗
SFC FluidicsSEC Form D Equity · Form D reports $250K sold of $650K offered · filed Oct 24, 2025
Source quote
  • Filed Oct 24, 2025 · SEC Form D ↗
    “Name of Issuer: SFC FLUIDICS INC.; CIK: 1352226; Address: Fayetteville, AR; Submission type: D; Filing date: 2025-10-24; Industry Group: Other; Date of First Sale: 2025-10-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 650000; Total Amount Sold: 250000; Federal exemptions: 06b”
Oct 13, 2025SEC Form D ↗
ENDRA Life SciencesSEC Form D Equity · Form D reports $14.4M sold · filed Oct 24, 2025
Source quote
  • Filed Oct 24, 2025 · SEC Form D ↗
    “Name of Issuer: ENDRA Life Sciences Inc.; CIK: 1681682; Address: Ann Arbor, MI; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-10-10; Types of Securities Offered: Equity, Other (Prefunded and Common Warrants to purchase shares of Common Stock); Business combination transaction: false; Total Offering Amount: 14402880; Total Amount Sold: 14402880; Federal exemptions: 06c”
Oct 10, 2025SEC Form D ↗
MarvelBiomeSEC Form D Equity · Form D reports $39.56M sold of $52.5M offered · filed Oct 22, 2025
Source quote
  • Filed Oct 22, 2025 · SEC Form D ↗
    “Name of Issuer: MarvelBiome, Inc.; CIK: 1815665; Address: Woburn, MA; Submission type: D; Filing date: 2025-10-22; Industry Group: Biotechnology; Date of First Sale: 2025-10-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 52503006; Total Amount Sold: 39561794; Federal exemptions: 06b”
Oct 10, 2025SEC Form D ↗
EyconisSEC Form D Equity · Form D reports $25M sold of $89.75M offered · filed Oct 22, 2025
Source quote
  • Filed Oct 22, 2025 · SEC Form D ↗
    “Name of Issuer: Eyconis, Inc.; CIK: 2010730; Address: Redwood City, CA; Submission type: D; Filing date: 2025-10-22; Industry Group: Other; Date of First Sale: 2025-10-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 89750003; Total Amount Sold: 24999996; Federal exemptions: 06b”
Oct 8, 2025SEC Form D ↗
Cleveland DiagnosticsSEC Form D Equity · Form D reports $14.42M sold · filed Oct 20, 2025
Source quote
  • Filed Oct 20, 2025 · SEC Form D ↗
    “Name of Issuer: Cleveland Diagnostics, Inc.; CIK: 1637038; Address: Cleveland, OH; Submission type: D; Filing date: 2025-10-20; Industry Group: Biotechnology; Date of First Sale: 2025-10-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 14421653; Total Amount Sold: 14421653; Federal exemptions: 06b”
Oct 7, 2025SEC Form D ↗
Blue Marlin TherapeuticsSEC Form D Equity · Form D reports $100K sold (offering size open-ended) · filed Oct 21, 2025
Source quote
  • Filed Oct 21, 2025 · SEC Form D ↗
    “Name of Issuer: Blue Marlin Therapeutics, Inc.; CIK: 2092364; Address: Charlottesville, VA; Submission type: D; Filing date: 2025-10-21; Industry Group: Biotechnology; Date of First Sale: 2025-10-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 100000; Federal exemptions: 06b”
Oct 6, 2025SEC Form D ↗
Ironfist TherapeuticsSEC Form D Equity · Form D reports $2K sold of $2K offered · filed Oct 20, 2025
Source quote
  • Filed Oct 20, 2025 · SEC Form D ↗
    “Name of Issuer: Ironfist Therapeutics, Inc.; CIK: 2091572; Address: Campbell, CA; Submission type: D; Filing date: 2025-10-20; Industry Group: Other Technology; Date of First Sale: 2025-10-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1800; Total Amount Sold: 1750; Federal exemptions: 06b”
Oct 4, 2025SEC Form D ↗
Moat Biotechnology CorporationSEC Form D Equity · Form D reports $26K sold of $15.59M offered · filed Oct 20, 2025
Source quote
  • Filed Oct 20, 2025 · SEC Form D ↗
    “Name of Issuer: MOAT BIOTECHNOLOGY Corp; CIK: 1944095; Address: Oklahoma City, OK; Submission type: D; Filing date: 2025-10-20; Industry Group: Biotechnology; Date of First Sale: 2025-10-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15593738; Total Amount Sold: 26400; Federal exemptions: 06b”
Oct 3, 2025SEC Form D ↗
Mercury BioSEC Form D Equity · Form D reports $2.38M sold of $7.95M offered · filed Oct 24, 2025
Source quote
  • Filed Oct 24, 2025 · SEC Form D ↗
    “Name of Issuer: Mercury Bio, Inc.; CIK: 1952927; Address: Santa FE, NM; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-09-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 7954094; Total Amount Sold: 2376107; Federal exemptions: 06b”
Sep 30, 2025SEC Form D ↗
Spiral TherapeuticsSEC Form D Equity · Form D reports $27.09M sold · filed Apr 16, 2026
Source quote
  • Filed Apr 16, 2026 · SEC Form D ↗
    “Name of Issuer: Spiral Therapeutics Inc; CIK: 1761906; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-04-16; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 27089842; Total Amount Sold: 27089839; Federal exemptions: 06b”
Sep 30, 2025SEC Form D ↗
Corner TherapeuticsSEC Form D Debt / note · Form D reports $16.75M sold · filed Oct 20, 2025
Source quote
  • Filed Oct 20, 2025 · SEC Form D ↗
    “Name of Issuer: Corner Therapeutics, Inc.; CIK: 2019875; Address: Watertown, MA; Submission type: D; Filing date: 2025-10-20; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-26; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 16754446; Total Amount Sold: 16754446; Federal exemptions: 06b”
Sep 26, 2025SEC Form D ↗
inSoma Bio, Inc.SEC Form D SAFE · Form D reports $2.69M sold of $4M offered · filed Oct 20, 2025
Source quote
  • Filed Oct 20, 2025 · amended Jan 22, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: inSoma Bio, Inc.; CIK: 1814250; Address: Durham, NC; Submission type: D/A; Filing date: 2026-01-22; Industry Group: Biotechnology; Date of First Sale: 2025-09-24; Types of Securities Offered: Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 2689372; Federal exemptions: 06b”
Sep 24, 2025SEC Form D/A ↗
Nirrin Technologies Inc.SEC Form D Equity · Form D reports $6.7M sold of $9.71M offered · filed Jun 15, 2026
Source quote
  • Filed Jun 15, 2026 · SEC Form D ↗
    “Name of Issuer: Nirrin Technologies, Inc.; CIK: 1889145; Address: Billerica, MA; Submission type: D; Filing date: 2026-06-15; Industry Group: Biotechnology; Date of First Sale: 2025-09-23; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 9711196; Total Amount Sold: 6699781; Federal exemptions: 06b”
Sep 23, 2025SEC Form D ↗
Carolina MolecularSEC Form D Equity · Form D reports $1.12M sold of $1.7M offered · filed Nov 13, 2025
Source quote
  • Filed Nov 13, 2025 · SEC Form D ↗
    “Name of Issuer: Carolina Molecular Inc.; CIK: 2096691; Address: Morrisville, NC; Submission type: D; Filing date: 2025-11-13; Industry Group: Biotechnology; Date of First Sale: 2025-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1700000; Total Amount Sold: 1125000; Federal exemptions: 06b”
Sep 17, 2025SEC Form D ↗
ABLi Therapeutics, Inc.SEC Form D Equity · Form D reports $1M sold · filed Jan 13, 2026
Source quote
  • Filed Jan 13, 2026 · SEC Form D ↗
    “Name of Issuer: ABLi Therapeutics, Inc.; CIK: 2104142; Address: Atlanta, GA; Submission type: D; Filing date: 2026-01-13; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 1000000; Federal exemptions: 06b”
Sep 15, 2025SEC Form D ↗
Epibone, Inc.SEC Form D Equity · Form D reports $4.29M sold of $4.3M offered · filed Oct 24, 2025
Source quote
  • Filed Oct 24, 2025 · SEC Form D ↗
    “Name of Issuer: EpiBone, Inc.; CIK: 1798436; Address: New York, NY; Submission type: D; Filing date: 2025-10-24; Industry Group: Other; Date of First Sale: 2025-09-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4300506; Total Amount Sold: 4287429; Federal exemptions: 06b”
Sep 2, 2025SEC Form D ↗
Protein Dynamic SolutionsSEC Form D Equity · Form D reports $1.77M sold (offering size open-ended) · filed Nov 7, 2025
Source quote
  • Filed Nov 7, 2025 · SEC Form D ↗
    “Name of Issuer: Protein Dynamic Solutions, Inc.; CIK: 1780775; Address: Wilmington, DE; Submission type: D; Filing date: 2025-11-07; Industry Group: Biotechnology; Date of First Sale: 2025-08-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1772369; Federal exemptions: 06b”
Aug 13, 2025SEC Form D ↗
Aethl BioSEC Form D SAFE · Form D reports $1.64M sold of $5M offered · filed Apr 17, 2026
Source quote
  • Filed Apr 17, 2026 · SEC Form D ↗
    “Name of Issuer: Aethl Bio, Inc.; CIK: 2116929; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-04-17; Industry Group: Biotechnology; Date of First Sale: 2025-07-14; Types of Securities Offered: Security to be acquired, Other (Simple Agreement for Future Equity (SAFE)); Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 1635000; Federal exemptions: 06b”
Jul 14, 2025SEC Form D ↗
Dualitas TherapeuticsSEC Form D Equity · Form D reports $32.6M sold of $66.6M offered · filed Nov 18, 2025
Source quote
  • Filed Nov 18, 2025 · SEC Form D ↗
    “Name of Issuer: Dualitas Therapeutics, Inc.; CIK: 2091994; Address: South San Francisco, CA; Submission type: D; Filing date: 2025-11-18; Industry Group: Biotechnology; Date of First Sale: 2025-07-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 66599990; Total Amount Sold: 32599997; Federal exemptions: 06b”
Jul 7, 2025SEC Form D ↗
InstyllaSEC Form D Equity · Form D reports $34.78M sold of $35.03M offered · filed Oct 23, 2025
Source quote
  • Filed Oct 23, 2025 · amended Jul 28, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Instylla, Inc.; CIK: 1708696; Address: Bedford, MA; Submission type: D/A; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2025-07-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 35034025; Total Amount Sold: 34783984; Federal exemptions: 06b”
Jul 7, 2025SEC Form D/A ↗
Odyssey Therapeutics (2) Filed as Odyssey Therapeutics, Inc.SEC Form D Equity · Form D reports $214.03M sold · filed Dec 4, 2025
Source quote
  • Filed Dec 4, 2025 · SEC Form D ↗
    “Name of Issuer: Odyssey Therapeutics, Inc.; CIK: 1882782; Address: Boston, MA; Submission type: D; Filing date: 2025-12-04; Industry Group: Biotechnology; Date of First Sale: 2025-06-16; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 214025200; Total Amount Sold: 214025200; Federal exemptions: 06b”
Jun 16, 2025SEC Form D ↗
Strand TherapeuticsSEC Form D Equity · Form D reports $108.1M sold of $120.1M offered · filed Mar 17, 2026
Source quote
  • Filed Mar 17, 2026 · SEC Form D ↗
    “Name of Issuer: Strand Therapeutics Inc.; CIK: 1778475; Address: Boston, MA; Submission type: D; Filing date: 2026-03-17; Industry Group: Biotechnology; Date of First Sale: 2025-05-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120099940; Total Amount Sold: 108099927; Federal exemptions: 06b”
May 23, 2025SEC Form D ↗
Strategikon PharmaSEC Form D Debt / note · Form D reports $2.29M sold of $3M offered · filed Nov 21, 2025
Source quote
  • Filed Nov 21, 2025 · SEC Form D ↗
    “Name of Issuer: Strategikon Pharma, Inc.; CIK: 1722200; Address: San Francisco, CA; Submission type: D; Filing date: 2025-11-21; Industry Group: Other Technology; Date of First Sale: 2025-05-08; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2291885; Federal exemptions: 06b”
May 8, 2025SEC Form D ↗
Eliaz TherapeuticsSEC Form D SAFE · Form D reports $850K sold · filed Oct 24, 2025
Source quote
  • Filed Oct 24, 2025 · SEC Form D ↗
    “Name of Issuer: Eliaz Therapeutics Inc.; CIK: 2042609; Address: Santa Rosa, CA; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-03-28; Types of Securities Offered: Other (SAFEs); Business combination transaction: false; Total Offering Amount: 850000; Total Amount Sold: 850000; Federal exemptions: 06b”
Mar 28, 2025SEC Form D ↗
Bot ImageSEC Form D Equity + debt/notes · Form D reports $280K sold of $1M offered · filed Oct 20, 2025
Source quote
  • Filed Oct 20, 2025 · SEC Form D ↗
    “Name of Issuer: Bot Image, Inc.; CIK: 1778258; Address: Omaha, NE; Submission type: D; Filing date: 2025-10-20; Industry Group: Other; Date of First Sale: 2025-01-08; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 280000; Federal exemptions: 06b”
Jan 8, 2025SEC Form D ↗
Immorta BioSEC Form D Equity · Form D reports $613K sold of $5M offered · filed Oct 16, 2026
Source quote
  • Filed Oct 16, 2026 · SEC Form D ↗
    “Name of Issuer: Immorta Bio, Inc.; CIK: 2102665; Address: Miami Beach, FL; Submission type: D; Filing date: 2026-10-16; Industry Group: Biotechnology; Date of First Sale: 2024-11-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 612503; Federal exemptions: 06c”
Nov 5, 2024SEC Form D ↗
ProEncia BiotechnologySEC Form D Equity + debt/notes · Form D reports $1.51M sold of $2M offered · filed Aug 26, 2026
Source quote
  • Filed Aug 26, 2026 · SEC Form D ↗
    “Name of Issuer: ProEncia Biotechnology Inc.; CIK: 2103044; Address: Woodbury, MN; Submission type: D; Filing date: 2026-08-26; Industry Group: Biotechnology; Date of First Sale: 2024-10-04; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1510000; Federal exemptions: 06b”
Oct 4, 2024SEC Form D ↗
Jabez BiosciencesSEC Form D Equity · Form D reports $31K sold (offering size open-ended) · filed Mar 26, 2026
Source quote
  • Filed Mar 26, 2026 · SEC Form D ↗
    “Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2026-03-26; Industry Group: Biotechnology; Date of First Sale: 2024-06-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 31200; Federal exemptions: 06b”
Jun 11, 2024SEC Form D ↗
NOK TherapeuticsSEC Form D Equity · Form D reports $3K sold · filed Mar 26, 2026
Source quote
  • Filed Mar 26, 2026 · amended May 1, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2026-05-01; Industry Group: Biotechnology; Date of First Sale: 2024-06-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3200; Total Amount Sold: 3200; Federal exemptions: 06b”
Jun 11, 2024SEC Form D/A ↗
Kaida BioPharmaSEC Form D Equity · Form D reports $1.6M sold of $4.1M offered · filed Jan 21, 2026
Source quote
  • Filed Jan 21, 2026 · amended Sep 1, 2026 · SEC Form D/A ↗ · original Form D ↗
    “Name of Issuer: Kaida BioPharma Inc.; CIK: 1973954; Address: Fort Lauderdale, FL; Submission type: D/A; Filing date: 2026-09-01; Industry Group: Biotechnology; Date of First Sale: 2023-10-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4100507; Total Amount Sold: 1600507; Federal exemptions: 06b”
Oct 24, 2023SEC Form D/A ↗
ElidahSEC Form D Equity · Form D reports $2.02M sold of $2.5M offered · filed Apr 6, 2026
Source quote
  • Filed Apr 6, 2026 · SEC Form D ↗
    “Name of Issuer: Elidah, Inc.; CIK: 2113916; Address: Newtown, CT; Submission type: D; Filing date: 2026-04-06; Industry Group: Manufacturing; Date of First Sale: 2023-06-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 2018000; Federal exemptions: 06b”
Jun 2, 2023SEC Form D ↗

Data checked Oct 21, 2026. SEC Form D raises and NIH awards · All dated changes.

Feedback